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In general, CD8+ T lymphocytes respond to a single class I MHC/peptide 
complex, a phenomenon known as “MHC self-restriction”.  We previously reported that 
CD8+ CTLs from C57BL/6 mice were restricted to both H-2Kb and H-2Db when 
responding to the horse cyt c-derived peptide, p41-49.  In Part I of this dissertation, we 
examine structural features of H-2Kb/cyt c and H-2Db/cyt c complexes responsible for 
dual recognition.  B6.H-4.1c, a representative cloned CTL, was induced by similar 
concentrations of native peptide added to either H-2Kb- or H-2Db-expressing targets.  
Furthermore, the dissociation rates for both H-2Kb/cyt c and H-2Db/cyt c were 
comparable, but the optimal concentration of native peptide significantly increased for 
both H-2Kb/cyt c and H-2Db/cyt c in peptide competition assays.  Based on computer-
generated models, we proposed that the Pro44-Gly45 sequence was critical for B6.H-4.1c 
recognition and therefore constructed single Ala substitution analogues of cyt c, 
designated p41-49/44A and p41-49/45A.  Although p41-49/44A binds as well to H-2Kb 
and H-2Db as the native peptide, B6.H-4.1c recognition was abrogated.  The H-2Kb/p41-
49/45A and H-2Db/p41-49/45A complexes were lysed, but required significantly higher 
peptide concentrations than the native peptide.  Molecular models for cyt c, p41-49/44A 
and p41-49/45A demonstrated that disrupting the Pro44-Gly45 sequence altered peptide 
configuration and inhibited B6.H-4.1c recognition.  Nonspecific immunosuppressive 
agents are critical in clinical transplantation success, but cause generalized T cell 
inhibition and leave patients susceptible to elevated rates of infection and malignancy.  In 
part II of this dissertation, we propose that removing allospecific CTLs that selectively 
expand in vitro will abrogate the alloreactive response.  We show that five CD8+ 
Vβ families in bm19 anti-C57BL/6 cultures proliferate, but cytolytic analysis implicates 
only Vβ9+ and Vβ12+ CTLs as responders against H-2Kb-expressing targets.  Removal of 
both Vβ9/12+ alloreactive CTLs did not affect the response to Kb-restricted antigens, nor 
to unrelated H-2d alloantigens.  Depletion of both Vβ9/12+ families significantly 
prolonged B6 allograft survival in bm19 mice.  In addition, bm19 mice mounted a cell-
mediated response against L. monocytogenes despite removing Vβ9/12+ CTLs.  These 
studies demonstrate the synergistic effect of two Vβ families on alloreactivity and 
confirm that depletion of allograft-specific Vβ+ CTLs prolong graft survival without 
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 The cell-mediated immune response relies heavily on the ability of cytotoxic T 
lymphocytes (CTL) to recognize and eliminate antigen-presenting cells (APC) bearing 
foreign antigens.  CTLs can respond to antigenic peptides presented by “self“ class I 
major histocompatibility complex (MHC) molecules, denoted antigen-specific 
recognition, and to genetically disparate class I MHC/peptide complexes, denoted 
allospecific recognition.  Antigen-specific recognition requires internal processing of 
foreign proteins, usually into 8-10 amino acid (AA) sequences, that are subsequently 
bound to the class I MHC molecule and presented on the cell surface (i.e., intracellular 
pathogens).  Allospecific recognition traditionally refers to the CTL response against 
target cells that present foreign, or disparate, class I MHC molecules on their surface (i.e., 
transplanted tissues).  In general, CTLs express the cluster of differentiation (CD) co-
receptor, CD8, and interact, via the T cell receptor (TCR), with class I MHC/peptide 
complexes.  Understanding the interactions of both antigen- and allospecific CTLs with 
the APC is essential to the future development of peptide-based vaccines and/or 
immunomodulatory monoclonal antibody (mAb) therapies. 
The following sections will provide a brief review of the current knowledge 
pertaining to the class I MHC molecule, antigen processing and presentation, and the 
interactions of the MHC/peptide/TCR trimolecular complex, as well as the history of 
transplant research and the direct and indirect pathways of allograft rejection. 
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The Class I MHC 
 The mouse MHC molecule is encoded by the H-2 MHC gene complex and is 
located on the short arm of chromosome 17, while the human leukocyte antigen (HLA) 
molecule is encoded by the HLA gene complex and is located on the short arm of 
chromosome 6.  Although the mouse H-2 complex was discovered first, the human HLA 
sequence was the first to be determined, in part due to the progress of the Human 
Genome Project (1,2).  In humans, the class I HLA genes (distal to the centromere) and 
class II genes (proximal to the centromere) are separated by the class III region (Figure 
1).  The mouse class I H-2 genes are arranged within K (proximal to the centromere) and 
D-L (distal to the centromere) regions and separated by class II and III genes (Figure 1).   
For the purpose of this dissertation, we will focus on the murine class I H-2 genes. 
The class I H-2 region is further subdivided into five gene regions [H2-K, -D, -Q, -T, and 
-M] and encode the class Ia molecules, H-2K, H-2D and H-2L, and the nonclassical class 
Ib molecules, Qa-1, Qa-2, Qb-1, Q10, TL, M3 and CD1d (3,4).  There are approximately 
30 functional murine class I genes, but this number does vary among mouse haplotypes 
(5).  The H-2 Ia molecules are highly polymorphic, expressed ubiquitously and present 
antigenic peptides to CD8+ CTLs, while Ib molecules are moderately polymorphic, 
expressed in various different tissue types and present antigens to both TCR αβ- and γδ-
bearing effector cells (4). 
Class I MHC molecules (Figure 2) are expressed on the cell surface of virtually 
all nucleated cells and are composed of a 45 kD heavy chain and a 12 kD noncovalently 
associated light chain, denoted β2-microglobulin (β2m) (6).  The heavy chain is a 
glycosylated transmembrane protein with both intracellular and extracellular components.  
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The extracellular portion consists of three domains (α1, α2, and α3) that contain 
approximately 90 AA each.  The amino terminal domains (α1 and α2) form the peptide-
binding groove, consisting of eight strands of antiparallel β-pleated sheets that support 
two α helices aligned in an antiparallel orientation.  The membrane proximal domain (α3) 
forms an “immunoglobulin-like” molecule, with folded regions similar to the Fc portion 
of immunoglobulin (Ig) molecules, which support the α1 and α2 domains (7).  The 
extracellular components are anchored to the cell surface by a 23 AA hydrophobic 
transmembrane region (8).  The intracellular portion is composed of 37 AA, most of 
which are hydrophilic.  The β2m molecule is encoded by the B2m gene, located on 
chromosome 2, and contains approximately 99AA (9).  This 12 kD light chain is an 
“immunoglobulin-like” non-glycosylated protein that associates noncovalently with the 
class I MHC heavy chain, assisting the α3 domain in supporting the peptide-binding 
groove (10-12).  The formation of a stable class I MHC/β2m complex is required for 
peptide binding in the lumen of the endoplasmic reticulum (ER). 
 
Class I MHC Antigen Processing and Presentation 
 The primary source of antigenic peptides that bind to the class I MHC molecule 
are derived from newly synthesized proteins in the cytosol (13-15).  Unfolded proteins 
and polypeptides within the cytosol are modified, by covalently linking the cofactor 
ubiquitin, before they can be degraded by the protease, proteasome (16) (Figure 3).  The 
proteasome is a multifactorial protease that contains both catalytic subunits and 
proteolytic activities that can be activated by interferon-γ (IFN-γ) and PA28 (17).  
Proteasomes degrade proteins to oligopeptides, ranging from 4 to 20 AA residues, and 
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are responsible for generating the C-terminus of antigenic peptides.  The N-terminus is 
subsequently modified and, in some cases, extended by a second set of proteases, termed 
endopeptidases and aminopeptidases (18). 
 The bulk of oligopeptides generated by the proteasome are further degraded into 
AAs by the endopeptidases and aminopeptidases, but a fraction of these peptides are 
translocated into the lumen of the ER by the transported associated with antigen 
processing (TAP) (13).  TAP is composed of two subunits, TAP1 and TAP2, encoded 
within the class II MHC region.  TAP is a member of the ATP-binding cassette (ABC) 
family of transporters and requires ATP for its transport activity.  Peptides, ranging from 
8 to 13 residues, bind to TAP, inducing a conformational change in the TAP/peptide 
complex.  This conformational change induces ATP hydrolysis, pore opening and the 
release of the peptide into the lumen of the ER (14). 
 Several studies involving TAP-deficient cells have demonstrated that TAP is the 
major supplier of peptides to the ER lumen (19-21).  TAP-deficient cells fail to assemble 
class I MHC/peptide complexes in the ER and therefore have severe defects in the 
surface expression of MHC molecules (22,23). 
 Newly synthesized class I MHC heavy chains (α1, α2 and α3) in the ER lumen 
bind to the 88 kD membrane-bound chaperone protein, calnexin.  Calnexin induces a 
partially folded configuration in the MHC molecule that allows noncovalent binding of 
the β2m molecule.  After β2m association, calnexin is replaced with a second chaperone, 
denoted calreticulin, and the MHC/β2m /calreticulin complex moves to and associates 
with TAP, tapasin and the ER-resident protein, ERp57 (24,25).  This large protein 
complex is called the class I MHC peptide-loading complex.   
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The N-terminus of tapasin interacts with the α2 and α3 domains of the class I 
heavy chains, while the C-terminus of tapasin binds to TAP (24,26,27).  Tapasin is 
encoded in the class II MHC region and is involved in MHC peptide loading.  Like TAP-
deficient cells, tapasin-deficient cells express few cell surface class I molecules and 
exhibit defective antigen presentation (25,28,29).  Cresswell and coworkers (30) have 
demonstrated that the addition of soluble tapasin proteins to tapasin-deficient cells 
increases the stability of the TAP, enhances peptide transport capacity and restores stable 
MHC/peptide surface expression. 
 The ER-resident protein, ERp57, is covalently linked to tapasin by a 
disulfide bond and facilitates the complete oxidation of the class I heavy chains.  
Mutations in the tapasin molecule that prevent ERp57/tapasin interactions not only 
abrogate MHC oxidation, but also inhibit peptide loading (31).  Thus, the formation of 
the complete class I MHC peptide-loading complex is required to maintain efficient 
peptide loading. 
Class I MHC/β2m complexes are released from the class I MHC peptide-loading 
complex after peptide translocation into the ER by TAP.  The incorporation of peptide 
into the peptide-binding groove induces the release of the MHC/peptide complex from 
the class I MHC peptide-loading complex, but the MHC/peptide complex re-associates 





The αβ TCR Structure and TCR/MHC/Peptide Interactions 
 Immunoprecipitation of the TCR from T cell clones revealed an 85,000 to 90,000 
molecular weight (MW) disulfide-bonded heterodimer structure that consists of two 
45,0000 to 50,000 MW glycosylated subunits, termed α and β (33).  The α polypeptide 
gene segment contains a leader (L), variable (V), joining (J) and constant (C) region, 
while the β heterodimer contains all of α polypeptide regions plus an additional diversity 
(D) region distal to the V region and proximal to the J region.  Thus, the α chain forms by 
a single in-frame rearrangement (V-J) and the β chain requires two successive 
rearrangements (V-D-J) before joining the C region (34,35).  The αβ TCR consists of an 
N-terminal V region (distal to the cell surface) and a C-terminal C region (membrane 
bound).  Homologous to Ig complementary-determining regions (CDR), the αβ TCR 
displays three CDR regions that protrude from the distal ends of both the Vβ and Vα 
domains that contact the MHC/peptide complex (36-39).  CDR1 and CDR2 are encoded 
within the V region and CDR3 results from V-J rearrangements in the α chain and the V-
D-J rearrangements in the β chain (40). 
 Initial attempts, by this lab in collaboration with Nathenson, to determine the 
interactions between the TCR and MHC/peptide complex analyzed a large panel of 
alloreactive CTLs for their reactivity on a diverse group of H-2Kb mutant cell lines (41).  
These studies revealed that the TCR was aligned over the distal surface of the                
H-2Kb/peptide complex, parallel to the β-pleated sheet of the α1 and α2 domains.  
Similarly, Janeway and others reported that the TCR Vα domain made contact with the 
 
 8
peptide N-terminus while the Vβ domain made contact with the C-terminus on the class II 
MHC/peptide complex (42). 
By determining the x-ray crystal structure of the 2C TCR/H-2Kb/dEV8 
trimolecular complex, Garcia and coworkers initially described the TCR/MHC/peptide 
interaction between the T cell clone, 2C, and the H-2Kb/dEV8 complex (37).  This group 
demonstrated that the 2C Vα CDR1 and CDR2 domains are positioned over the              
N-terminus of the dEV8 peptide, while the Vβ CDR1 and CDR2 domains are positioned 
over the C-terminus of dEV8.  Interestingly, the Vα and Vβ CDR3 domain associates with 
the central portion of the peptide, directly between the α helices of H-2Kb (37).  Several 
other investigators have since described similar results for human (36) and unrelated 
murine TCR/MHC/peptide crystal structures (38,39).  Thus, the major peptide residues 
that interact with the diverse CDR3 domain can be predicted, with some degree of 
confidence, to lie within the central peptide region.  This observation is important since it 
may prove particular useful in the development of peptide-based vaccines or in antigenic 
mimicry. 
 
A Brief History of Transplant Research 
 The earliest tissue transplantation recorded, believed to be performed as early as 
700 B.C., was by a Hindu surgeon who used a flap of skin from the patient’s forehead to 
cover and repair the patient’s amputated nose (Woodruff, 1960).  By the late 1800s skin 
grafting became an accepted practice, but the transplantation of internal organs was not 
successful until vascular anastomosis techniques were developed in the 1900s.  Carrel 
reported the first allotransplantation (in 1908) of both kidneys in a series of nine cats, in 
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which urine output was maintained for up to 25 days but ultimately resulted in the death 
of all nine cats (Carrel, 1908 p98).  The first human renal transplantation was reported by 
a Russian surgeon in 1936, but its success was hindered by mismatched blood types and 
resulted in minimal renal function before the patient’s death (Woodruff, 1960).  Almost 
two decades later, in 1952, the first successful renal transplant was performed between 
identical twins (43).  Currently, transplanted organs include the: cornea, kidney, liver, 
heart, lung, pancreatic islet cells and hematopoietic cells. 
 After extensively studying tumor engraftment in inbred mice strains, Clarence 
Little determined that transplantation immunology is governed by the “five laws of 
transplantation”  (Little, 1924; p75). 
1. Transplants within inbred strains will succeed. 
2. Transplants between inbred strains will fail. 
3. Transplants from a member of an inbred parental strain to an F1 offspring will 
succeed but those in the reverse direction will fail. 
4. Transplants from F2 and all subsequent generations to F1 animals will succeed. 
5. Transplants from inbred parental strains to the F2 generation will usually, but not 
always, fail. 
 
Although these “laws” appear confusing, the basic principle is that the graft recipient will 
reject any transplanted tissue that expresses a tissue antigen (now known to be the MHC) 
that is not expressed by the recipient. 
 Currently, the prevention of transplantation rejection requires that the recipient 
receive exogenous combinations of immunosuppressive agents, such as cyclosporine, 
tacrolimus, sirolimus, rapamycin, mycophenolate, azathioprine and steroids.  These 
nonspecific immunosuppressive agents can be used to inhibit lymphocyte gene 
transcription (i.e., cyclosporine), cytokine signaling (i.e., rapamycin), or nucleotide 
synthesis (i.e., mycophenolate).  More specifically, cyclosporine binds to and blocks the 
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phosphatase activity of calcineurin, the intracellular signaling protein essential for IL-2 
transcription (44).  In a separate manner, tacrolimus, a macrolide, binds to the 
intracellular FK506-binding protein and the tacrolimus/FK506 complex in turn 
inactivates calcineurin.  Sirolimus is a macrocyclic triene antibiotic that is structurally 
similar to FK506 and thus, by binding to calcineurin, interrupts IL-2 synthesis (45).  
Rapamycin also associates with FK506, but does not affect calcineurin, instead it blocks 
T cell proliferation by inhibiting the signaling transduction of IL-2 (45).  The active 
metabolite of mycophenolate mofetil, mycophenolic acid, inhibits purine synthesis, but 
this immunosuppressive agent is sparingly used since it has been shown to cause 
significant leukopenia (46).  Likewise, azathioprine, an analogue of 6-mercaptopurine, is 
a purine synthesis inhibitor and thus blocks cellular division.  T cell proliferation and 
cytokine gene transcription are disrupted by the use of corticosteroids (46). 
 Several experimental immunosuppressive agents are considered potential adjuncts 
to traditional exogenous therapies.  Brinkmann and coworkers have demonstrated that the 
administration of FTY720 reduces the total number of circulating lymphocytes, increases 
lymphocyte homing to lymphoid tissues (lymph nodes and Peyer’s patches) and prevents 
the entry of lymphocytes into the tissue graft (47,48).  Other experimental drugs of 
interest include 15-deoxysperqualin, which prevents T and B cells differentiation into 
effector cells, and leflunomide, which prevents lymphocyte proliferation by inhibiting 
pyrimidine synthesis and tyrosine kinase activation.   
The use of antibodies (Ab) specific for recipient T cells, the IL-2 receptor (IL-
2R), and a variety of transplant rejection markers have recently been implicated as a 
potential adjunct to traditional immunosuppressive agents.  The immunomodulating 
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agent, OKT3 is a mouse-derived mAb directed against the human form of the CD3 region 
and has been used successfully to reverse acute rejection episodes when added to 
traditional immunosuppressive agents (49).  Campath-1H is a humanized mAb directed 
against the CD52 antigen, a marker present on >95% of circulating lymphocytes, and 
causes the reduction of the total number of circulating T cells, B cells, NK cells and 
monocytes.  Several immunomodulator agents are directed against the IL-2R α chain 
(CD25), and have been shown to reduce allograft refection in renal transplant recipients 
by 49% six months after transplantation (50,51). 
The transplantation of organs is now a relatively common occurrence in the 
United States, with approximately 10,000 kidney transplants performed each year.  
Patient survival 1 year after renal transplantation is better than 90% and kidney function 
at 1 year exceeds 85% (52).  Unfortunately, the conditional half-life of renal transplants 
(the number of years at which half of transplanted kidneys are rejected compared to those 
functioning at one year) remains at less than 10 years.  The 1 year survival of hepatic 
transplantation is approximately 75%, probably due to the finding that this organ is 
resistant to Ab-mediated rejection (53,54).  Heart and lung transplantations are relatively 
new arrivals to clinical transplantation, but have been highly successful, with 1 year 
survival rates that exceed 80%.  These patients, however, exhibit organ specific 
complications, with cardiac patients developing atherosclerotic disease and lung patients 
developing bronchiolitis obliterans, as manifestations of chronic rejection.  Pancreas and 
islet cell transplantations have demonstrated a success rate of approximately 80% when 
patients receive sirolimus, tacrolimus and anti-IL-2R (55).  The current success rates are 
dependent on the lifelong use of immunosuppressive agents and increase the risk of 
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infection and cancer development.  Therefore, to prevent these complications and 
increase patient quality of life it is important that other, more specific, 
immunosuppressive agents are researched and developed in the future. 
 
Direct versus Indirect Allorecognition 
 The immunological response of the recipient immune system to donor MHC 
molecules is the primary hindrance to the success of allo-transplantation (56,57).  The 
recognition of allogeneic MHC molecules on the transplanted graft elicits a strong 
alloreactive reaction, resulting in the destruction of donor cells and hence graft rejection.  
Class I allorecognition is traditionally considered to be the recognition of foreign 
MHC/peptide complexes presented on the cell surface of donor cells by CD8+ CTLs of 
the recipient’s immune system (direct allorecognition).  An alternative mechanism was, 
however, suggested in 1982 by Lechler and Batchelor in which the donor transplant 
MHC molecules were processed and presented as peptides by recipient APCs (indirect 
allorecognition) (58).  Since then, several investigators have furthered this proposal in 
human, mouse and rat models (59-64).  Thus, allorecognition can occur via two 
pathways, the direct and the indirect allorecognition pathways.  The alloreactive CTLs 
that utilize the direct pathway are characterized by a high precursor frequency (>90%) 
and a diverse TCR specificity, while CTLs that utilize the indirect pathway recognize 
processed forms of donor antigens associated with recipient MHC molecules and can be 
defined by a limited Vβ gene usage and CTLs that are directed against a single peptide 
determinant presented by the donor MHC (59,65,66).  Interestingly, it has been suggested 
that although the use of nonspecific immunosuppressive agents is capable of inhibiting 
 
 13
the acute rejection phase of direct recognition, these agents are not able to prevent 
chronic rejection by indirect allorecognition (67,68).  These observations suggest that 
acute allograft rejection is the result of direct allorecognition and that chronic rejection is 
the consequence of indirect allorecognition. 
 
Dissertation Overview 
 This dissertation examines two related areas of immunology: i) antigen-specific 
recognition of a single peptide, horse cytochrome c (cyt c) p41-49, in the context of two 
separate class I MHC molecules, H-2Kb and H-2Db, and ii) allospecific recognition of the 
parental strain, C57BL/6, class I MHC/peptide complex by the H-2Kbm19 mutant mouse.  
In Chapter 2, we propose that the dual recognition of H-2Kb/cyt c p41-49 and        H-
2Db/cyt c p41-49 complexes by a group of CTLs, represented by Clone B6.H-4.1c 
requires comparable MHC/peptide comformations.  Clone B6.H-4.1c was induced by in 
vitro priming with a tryptic digest of denatured cyt c and has previously been shown to 
respond to both H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes (69).  This 
chapter defines the minimal cyt c p41-49 peptide concentration required for recognition 
by Clone B6.H-4.1c and demonstrates that cyt c p41-49 binds to and stabilizes both       
H-2Kb and H-2Db molecules.  Furthermore, peptide competition experiments show that 
Clone B6.H-4.1c dual-restricted recognition of H-2Kb/cyt c p41-49 and H-2Db/cyt c   
p41-49 complexes are comparable.  This chapter also includes computer-generated 
molecular models to evaluate potential peptide residues involved in interacting with the 
TCR of Clone B6.H-4.1c.  In Chapter 3, we propose that the Pro44-Gly45 induced type II 
β bend is the critical peptide sequence involved in Clone B6.H-4.1c recognition of        
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H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.  This chapter utilizes horse cyt c 
analogues, constructed by single Ala substitutions at peptide positions p4 (Pro44 → Ala) 
and p5 (Gly45 → Ala), designated p41-49/44A and p41-49/45A, to evaluate H-2Kb and 
H-2Db stabilization and cytolytic activity of Clone B6.H-4.1c.  This chapter also uses 
computer-generated models of the native cyt c p41-49, and analogues p41-49/44A and 
p41-49/45A to demonstrate alterations in the Pro44-Gly45 type II β bend influence the 
distribution of peptide R-group surface availability, that disrupt interactions with the TCR 
of Clone B6.H-4.1c. 
In addition to identifying crucial components of the antigen-specific response of 
Clone B6.H-4.1c, this dissertation also addresses the critical features of allospecific 
recognition for closely related H-2Kb mutant strains.  In Chapter 4, we propose that 
alloreactive CTLs from the B6.H-2bm19 (bm19) (70) will undergo selective expansion 
following in vitro stimulation with irradiated C57BL/6 (B6) splenocytes (71), and that the 
removal of these bm19 anti-B6 splenocytes will abrogate the alloreactive response.  This 
chapter demonstrates that bm19 anti-B6 mixed lymphocyte cultures (MLC) preferentially 
express TCR Vβ+ families and that the depletion of specific bm19 Vβ+ CTLs abrogates  
H-2Kb-expressing target cell cytolysis.  In addition, Chapter 4 shows that the depletion of 
H-2Kb-specific CTLs does not inhibit unrelated allospecific or antigen-specific 
recognition.  In Chapter 5, we propose that the in vivo depletion of H-2Kb-specific CTLs 
(described in Chapter 4) will inhibit bm19 rejection of B6 skin allografts.  This chapter 
characterizes the prolonged survival of B6 skin allografts when TCR Vβ T cells are 
selectively removed from bm19 mice.  The ability of bm19 Vβ- mice to mount a T-cell 
mediated response is also evaluated in this chapter. 
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FIGURES AND FIGURE LEGENDS 
 
Fig. 1 Comparative genetic maps of the human (HLA) and mouse (H-2) gene 
complexes. 
 
The human HLA complex (chromosome 6) is shown on the top, with the mouse H-2 
complex (chromosome 17) below.  MHC-I, MHC-II and MHC-III regions are 
represented below the short arm of the chromosome.  This map is not complete nor drawn 









Fig. 2 Model of the class I MHC molecule (H-2Kb). 
 
Side-view of the H-2Kb class I MHC molecule, demonstrating the three extracellular 
domains of the α heavy chain (purple) and the β2m (red).  The peptide binding groove, 
















Fig. 3 Class I MHC peptide processing and presentation. 
 
Newly synthesized proteins are degraded into 4 to 20 AA peptides by the proteasome and 
further modified by aminopeptidases in the cytosol.  These peptides are subsequently 
bound by TAP and transported into the lumen of the ER.  Immediately after synthesis, 
class I MHC heavy chains bind with the chaperone, calnexin, in the ER lumen.  The 
binding of β2m to the MHC heavy chain facilitates the release of calnexin and the 
association of the MHC/β2m with calreticulin.  The class I heterodimer joins the class I 
peptide-loading complex - TAP, tapasin and Erp57 - and binds an 8-10 AA peptide.  
After peptide incorporation, the MHC/β2m/peptide complex re-associates with calnexin 
prior to being transported to the Golgi apparatus and finally arrives on the cell surface. 
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Antigen recognition by CD8+ CTLs occurs in response to a small peptide tightly 
bound to a single "self" class I MHC molecule.  We reported previously, however, that 
CD8+ CTLs from C57BL/6 mice are restricted to both H-2Kb and H-2Db class I 
molecules in their response to the horse cyt c-derived peptide, p41-49.  In this study, we 
examine the structural features of H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes 
responsible for this dual recognition.  A representative cloned CTL, designated Clone 
B6.H-4.1c, is induced by similar concentrations of peptide added to either H-2Kb- or     
H-2Db-expressing targets, demonstrating comparable recognition of both MHC/peptide 
complexes.  To determine the stability of H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 
complexes, we conducted peptide competition and RMA-S stabilization experiments.  
Displacement of horse cyt c p41-49 with a competitor peptide MI B chain p7-15, also 
shown to bind to H-2Kb and H-2Db, significantly increases the optimal concentration of 
the horse cyt c p41-49 required for lysis of either H-2Kb- or H-2Db-expressing targets by 
Clone B6.H-4.1c.  The dissociation rates for both H-2Kb/cyt c p41-49 and H-2Db/cyt c 
p41-49 complexes are also comparable, reaching a steady state at 60 minutes in both 
cases.  Computer-generated models of both complexes indicate that the bound peptide 
configurations display a prominent upward bulge with similar surface accessibility, due 
to the presence of Pro44-Gly45.  Thus, the Pro44-Gly45 dipeptide sequence may be critical 





One of the basic tenets of immunology that governs our understanding of antigen 
recognition by CD8+ cytotoxic T lymphocytes (CTL) is "self MHC restriction".  A self 
major histocompatibility complex (MHC)-restricted CD8+ CTL responds to a short 
peptide of 8 - 10 amino acid residues, presented in the context of a single self class I 
MHC molecule (1-5). In recent years, however, several studies in both human and murine 
systems (6-14) have demonstrated that a single peptide can be presented efficiently to 
CTLs by multiple class I MHC molecules.  Johnson and coworkers (8) showed that the 
nonamer peptide, p584-592, from the human immunodeficiency virus-1 (HIV-1) 
envelope glycoprotein (gp41), binds to and stabilizes two human class I MHC molecules, 
HLA-B14 and HLA-B8.  Both complexes are efficiently recognized by distinct CTL 
clones derived from different HIV-1 seropositive individuals (8).  Also, Ploegh and 
coworkers (6) showed that the Sendai virus nucleoprotein-derived peptide (SEV), SEV-9, 
binds to H-2Kb and H-2Db murine class I MHC molecules and is recognized efficiently 
by both H-2Kb- and H-2Db-restricted CTLs.  Similarly, we have observed that the mouse 
insulin I B chain p7-15 peptide (MI B chain p7-15) can bind to both H-2Kb and H-2Db 
and can elicit either H-2Kb- or H-2Db-restricted CTLs, respectively (12). 
To better understand the basis for CTL induction by peptide antigens derived 
from relatively simple proteins, we established a model system in our laboratory to 
examine the induction of CTLs specific for cytochrome c (cyt c)-derived peptide 
antigens.  We previously reported that a CTL response, induced by in vitro priming with 
a tryptic digest of denatured horse cyt c (15), is specific for the horse cytochrome c-
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derived nonamer peptide p41-49 and is restricted to both H-2Kb and H-2Db.  Clone  
B6.H-4.1c is representative of the CTL population and its response is dual-restricted to 
both   H-2Kb and H-2Db. 
We considered that the appearance of such dual class I H-2b-restricted CTLs 
might result from the in vitro priming approach used in their induction.  To address this 
possibility, we induced horse cyt c-specific CTLs by in vivo priming with either the horse 
cyt c tryptic digest or the cyt c p41-49 peptide alone.  In both instances we obtained CTLs 
with the identical peptide specificity and dual restriction characteristics as originally 
reported for the in vitro-derived CTLs (unpublished observations).  Similarly, Pease and 
coworkers (16) found that an H-2Ld-allospecific CTL, Clone 2C, recognizes the self 
peptide, dEV-8, presented by both the self class I molecule H-2Kb and its closely related 
mutant, H-2Kbm3 (16-19).  Furthermore, this cloned CTL line also responds to a peptide 
derived from 2-oxoglutarate dehydrogenase, designated p2Ca, in the context of both     
H-2Kb and H-2Ld (16).  
To determine how a T cell receptor (TCR) interacts with the distal surface of the 
MHC/peptide complex, we (in collaboration with Nathenson and coworkers) analyzed a 
large number of alloreactive CTLs for their reactivity on a diverse panel of H-2Kb mutant 
cell lines (20).  The results of this study revealed that the TCR is aligned over the distal 
surface of the peptide/Kb complex, parallel to the β-pleated sheets of the α1 and α2 
domains.  Janeway and coworkers (21) also reported that the TCR specific for a class II 
MHC/peptide complex is oriented in a similar manner, with its variable α (Vα) domain 
aligned over the amino terminus of the bound peptide and the TCR Vβ domain aligned 
over its carboxyl terminus. 
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Further insight into the structural relationships that underlie the interactions 
among the MHC class I molecule, the bound peptide and the TCR in this trimolecular 
complex has been revealed by resolution of the three-dimensional x-ray crystallographic 
structures for the trimolecular complex (22-26).  These x-ray crystal structures confirmed 
that the TCR Vα domain is aligned with the peptide amino terminus and the TCR Vβ 
domain with the peptide carboxyl terminus (23-25). 
Three distinct TCR complementarity-determining regions (CDR), designated 
CDR1, CDR2, and CDR3, are formed by the interaction of the TCR Vα and Vβ domains.  
These TCR hypervariable regions make direct contact with MHC and peptide residues at 
the distal surface of the MHC/peptide complex.  Bjorkman and coworkers (22,26) 
showed that the relatively invariant CDR1 and CDR2 regions contact the conserved 
residues on the class I MHC α helices, and the highly diverse sequences of the CDR3 
region interact directly with the bound peptide.  This interaction of the CDR3 region with 
bound peptide was verified both by direct TCR mutagenesis studies (27-30) and by direct 
binding of MHC/peptide tetramers to TCRs expressed on transfected cell lines (31). 
In this study we employ RMA-S stabilization assays (32,33) and peptide 
competition experiments (34,35) to show that the horse cyt c p41-49 peptide binds 
efficiently to both H-2Kb and H-2Db class I MHC molecules.  We also demonstrate that 
both H-2Kb and H-2Db-restricted responses of CTL Clone B6.H-4.1c to cyt c p41-49 
require similar peptide concentrations.  This indicates that the peptide-specific response 
in the context of H-2Kb is equivalent to the H-2Db-restricted response. 
To understand the structural basis for this anomalous CTL response, we utilized 
the coordinates obtained from previously published x-ray crystallography studies for     
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H-2Kb (36,37) and H-2Db (38) to generate H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 
complexes.  These computer-generated molecular models were used to address the 
following questions: (i) How does the horse cyt c-derived peptide p41-49 bind efficiently 
to both H-2Kb and H-2Db class I MHC molecules? and (ii) How does Clone B6.H-4.1c 
respond efficiently to the two complexes, H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49? 
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MATERIALS AND METHODS 
 
Animals  
Female C57BL/6 (B6) mice used in this study were obtained from this laboratory's 
breeding colony at West Virginia University Health Sciences Center Vivarium.  The B6 
colony was established in 1987 and has been maintained since then at the West Virginia 
University Health Sciences Center Vivarium.  All mice used in this study were between 8 
and 12 weeks of age. 
 
Target cell lines  
Transfected cell lines were derived from the thymidine kinase-negative L cell (H-2k) 
fibroblast line designated LMTK- and grown as adherent cultures in RPMI-1640 media 
supplemented with 10% FCS, 100 mM HEPES, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine (RP-10), as previously described (15). All 
transfected cell lines, which include L + Kb and L + Db (as well as the LMTK- cell line), 
were kindly provided by Drs. S. G. Nathenson and R. Zeff.  Appropriate H-2b class I cell 
surface expression was verified by flow cytometry in our laboratory (data not shown). 
 
Synthesis of peptides  
Drs. J. W. Yewdell and J. R. Bennink, generously provided the peptides, horse cyt c   
p41-49 [G-Q-A-P-G-F-T-Y-T] and MI B chain p7-15 [C-G-P-H-L-V-E-A-L].  Peptides 
were synthesized by fMoc chemistry using an automated peptide synthesizer (9050 
MilliGen PepSynthesizer), as previously described (39).  Amino acid composition and 
purity was determined by HPLC tracing (Waters 600E) and the Pico Tag Amino Acid 
 
 39
Analysis System (Waters).  Lyophilized peptides were solubilized in sterile 1X PBS at 
appropriate stock concentrations.  For the purpose of peptide competition assays, we have 
utilized horse cyt c p41-49 as the target peptide, and MI B chain p7-15 as the competitor 
peptide. 
 
RMA-S stabilization assays   
Peptide-induced stabilization of RMA-S cells has been described previously (32,33).  
Briefly, the B6-derived, transporter associated with antigen processing (TAP)-deficient, 
murine cell line RMA-S (40,41) was grown initially in RP-10 media in a humidified 
incubator at 37oC with 7% CO2.  RMA-S cells (2.5 X 106) were transferred to 30oC in 7% 
CO2 for 18-20 h to induce stable cell surface expression H-2Kb and H-2Db class I 
molecules.  Cells were then washed twice with 1X PBS, containing 2% FCS and 0.01% 
sodium azide (PBS-2%), and incubated with 10 µM peptide (horse cyt c p41-49 or MI B 
chain p7-15) for one hour.  Peptide-pulsed RMA-S cells were washed twice with PBS-
2% to remove excess peptide, resuspended in RP-10 media, and incubated in a 
humidified incubator at 37oC, 7% CO2.  RMA-S cells (5 X 105) were incubated with PE-
conjugated anti-H-2Kb or anti-H-2Db monoclonal antibodies (mAbs) and analyzed by 
flow cytometry at 0, 30, 60, 120 and 180 min.  
 
Antibodies and flow cytometry 
Phycoerythin (PE)-conjugated anti-H-2Kb (42) and anti-H-2Db (43) mAbs were 
purchased from Caltag Laboratories® (Burlingame, CA).  Peptide-pulsed RMA-S cells (5 
X 105) were incubated for 45 min on ice with 20 µl of mAb (1:20) and washed twice with 
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PBS-2%.  RMA-S cells (1 X 105) were analyzed for fluorescence intensity using a 
FACScan flow cytometer (Becton Dickinson, Mountain View, CA).  The mean channel 
fluorescence (MCF) indicates the mean channel number of fluorescence, detected from 
10,000 gated cells.  The fluorescence index was calculated, as previously determined 
(35), using the following formula: 
 
(MCF in the presence of peptide) - (MCF in the absence of peptide) 
_________________________________________________________________________________ 
(MCF in the absence of peptide) 
 
CTL Clone B6.H-4.1c   
The CTL Clone B6.H-4.1c was maintained in long-term culture as previously described 
(15).  Briefly, 4 X 105 Clone B6.H-4.1c cells were incubated in a 24-well flat-bottom 
plate with 5 X 106 irradiated (2000 rads) B6 spleen cells plus 2 µM horse cyt c p41-49 
suspended in RP-10 media.  Clone B6.H-4.1c CTLs were analyzed for lytic reactivity on 
day five and subsequently restimulated on day 7 of culture. 
 
51Cr-release assay   
The lytic activity of Clone B6.H-4.1c was determined by a standard in vitro 4-h 51Cr-
release assay (44).  Briefly, 1 X 106 target cells were incubated in 50 µl RP-10 media plus 
100 µCi sodium chromate 51 (51Cr; New England Nuclear, Boston, MA) per 1 X 106 
cells for 60 min at 37oC 7% CO2.  After 51Cr labeling, target cells were washed with 1X 
HBSS and resuspended in 10 ml RP-10.  Following an additional 30 min incubation in a 
37oC water bath, target cells were washed in 1X HBSS and resuspended in RP-10 media 
at a final concentration of 2 X 105 cells/ml.  Target cells were added (50 µl/well) to 96-
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well round-bottom microtiter plates.  Exogenous peptides to be tested were added in a 
volume of 50 µl/well at a final concentration of 2 µM and incubated for 20 min at 37oC, 
7% CO2.  Clone B6.H-4.1c effector cells were added in a volume of 100 µl/well with the 
following effector-to-target ratios: 30:1, 10:1, 3:1 and 1:1.  Assay plates were incubated 4 
h at 37oC, 7% CO2 then centrifuged for 7 min at 1200 rpm.  Supernatants (100 µl) were 
collected from each well and transferred to 6 X 50 mm tubes for determination of total 
51Cr counts on an LKB Clinigamma Model 1272 counter (LKB Instruments, Finland).  
The "percent specific lysis" was determined as follows: 
experimental cpm - spontaneous cpm 
% Specific Lysis =  _____________________________________________    X 100 
         maximum  - spontaneous cpm 
 
In all experiments, the spontaneous release values of targets in the absence of CTL 
effectors was routinely <10% of maximum lysis, as determined by addition of Triton X-
100 detergent to target cells.  
 
Minimum peptide concentration determination   
Final volume peptide concentrations ranging from 2 pM to 2 µM of horse cyt c p41-49 
were added to 51Cr-labeled target cells and incubated for 20 min at 37oC, 7% CO2.  Clone 
B6.H-4.1c effector CTLs were added in 100 µl/well at a constant effector-to-target (E:T) 
ratio of 3:1.  Assay plates were incubated for 4-h at 37oC, 7% CO2 and centrifuged for 7 
min at 1200 rpm; 100 µl supernatant was collected from each well and added to 6 x 50 
mm tubes for counting.  Minimum peptide concentrations were determined as the peptide 





Peptide competition inhibition assays   
Peptide competition inhibition assays were conducted as described previously (34,35).  
Briefly, a constant 10 µM concentration of competitor peptide (MI B chain p7-15) was 
added to the same wells containing target peptide (horse cyt c p41-49), with 
concentrations ranging from 2 pM to 2 µM.  Both target and competitor peptides were 
added to 51Cr-labeled target cells and incubated for 20 min at 37oC, 7% CO2.  Clone 
B6.H-4.1c effector CTLs were added at a constant E:T ratio of 3:1.  Assay plates were 
incubated for 4-h at 37oC, 7% CO2 centrifuged for 7 min at 1200 rpm.  A volume of 100 
µl supernatant was collected from each well and added to 6 x 50 mm tubes for counting.  
The percent inhibition was determined by a students' t-test analysis of the difference in 
target peptide concentration required to yield 30% lysis at an E:T ratio of 3:1 in the 
presence and absence of competitor peptide. 
 
Molecular modeling   
Computer modeling was used to examine the similarities and differences in the binding 
of horse cyt c p41-49 to both class I molecules and to better understand how the Clone 
B6.H-4.1c TCR might interact with the surface of both complexes.  Horse cyt c p41-49 
was introduced into the antigen-binding cleft of both H-2Kb and H-2Db molecular 
structures using a Silicon Graphics UNIX-based computer with QUANTA/CHARMm 
software designed by Molecular Simulations, Inc.  The coordinates for x-ray crystal 
structures, H-2Kb complexed with the SEV-9 p324-332 peptide [F-A-P-G-N-Y-P-A-L] 
(36,37) and H-2Db complexed with the influenza A p366-374 peptide                        
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[A-S-N-E-N-M-E-T-M] (38), were obtained from the Brookhaven Protein Data Bank 
(PDB) (1vab and 1hoc, respectively).  QUANTA/CHARMm software was used to 
introduce the horse cyt c p41-49 sequence into the H-2Kb and H-2Db x-ray crystal 
structures by replacing single amino acid residues.  Each amino acid replacement was 
followed by 50 cycles of regularization at the steepest descent (45) and 200 cycles of the 
adopted basis set Newton-Raphson (ABNR) method (46).  The peptide sequence was 
regularized after each amino acid residue replacement to reduce unfavorable bonds and 
angles.  To find the minimum energy configuration, the completed MHC/peptide 
complex was then subjected to 100 cycles of CHARMm energy minimization, using the 
ABNR method.  
 
Statistical analysis   
All statistics in this study were performed by a paired, one-tailed Student's t-test.  






We previously reported that B6-derived, horse cyt c-specific CTL effectors 
(represented in this study by CTL Clone B6.H-4.1c) can be induced by in vitro priming 
with syngeneic spleen cells coated with a tryptic digest of horse cyt c (15).   These CTLs 
are dual-restricted in their recognition of horse cyt c p41-49, in that they are activated by 
and respond to this peptide in the context of both H-2Kb and H-2Db class I molecules.  In 
the present study we describe the structural characteristics that provide the basis for this 
unique reactivity.  More specifically, we address the following questions:  (i) How does 
horse cyt c p41-49 [G-Q-A-P-G-F-T-Y-T] bind efficiently to the peptide-binding clefts of 
both H-2Kb and H-2Db class I molecules? and (ii) How does CTL Clone B6.H-4.1c 
respond efficiently to both H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes? 
 
Horse cyt c p41-49, as the target peptide for Clone B6.H-4.1c, contain a single dominant 
anchor residue for binding to H-2Kb and a strong anchor residue for binding to H-2Db   
To identify the important peptide anchor residues for horse cyt c p41-49 binding 
in the clefts of H-2Kb and H-2Db, we examined the peptide sequence for the appropriate 
consensus peptide-binding motifs as described previously by Rammensee and coworkers 
(47).  In addition, we evaluated the MI B chain p7-15 peptide sequence                        
[C-G-P-H-L-V-E-A-L], which also binds to both H-2Kb and H-2Db, (12) for the presence 
of anchor residues based on these peptide motifs for H-2Kb and H-2Db binding (47).  We 
previously determined that MI B chain p7-15 is the target antigen for H-2Kb-restricted, in 
vitro-derived CTLs, represented by Clone B6.MI-10.5.4 (12).  We later isolated a second 
CTL clone from in vivo-primed B6 mice, designated Clone B6.MI-9c2, which responded 
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to MI B chain p7-15 in the context of H-2Db (data not shown).  Thus, clearly the MI B 
chain p7-15 peptide can bind efficiently to both H-2Kb and H-2Db class I MHC 
molecules.  On this basis, we used MI B chain p7-15 as a competitor peptide in 
competitive inhibition studies to compare the responsiveness of Clone B6.H-4.1c to the 
H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.   
To identify potential anchor residues, we searched both peptide sequences for 
dominant, strong, or weak anchor residues generally implicated in anchoring peptides to 
the H-2Kb and H-2Db clefts (47).  Table I and Table II indicate those amino acids from 
horse cyt c p41-49 and MI B chain p7-15 that correspond to the peptide-binding motifs 
(47).  These residues are highlighted in bold type for both H-2Kb (Table I) and H-2Db 
(Table II) binding.  As indicated in Table I, horse cyt c p41-49 contains the dominant 
anchor, Phe46, at peptide position p6 of the H-2Kb-binding motif as well as two weak 
anchor residues, Pro44 and Thr47, at peptide positions p4 and p7, respectively.  In 
addition, MI B chain p7-15 contains the H-2Kb-binding motif dominant anchor Leu15 at 
peptide position p9, and a single weak anchor residue Glu13 at peptide position p7 (Table 
I).   
The H-2Db-binding motif, shown in Table II, reveals that both peptides display a 
single strong anchor residue as well as three weak anchor residues for binding to H-2Db.  
The horse cyt c p41-49 peptide contains the strong anchor residue, Phe46, at peptide 
position p6 and three weak anchor residues, Gln42, Thr47 and Tyr48, at peptide positions 
p2, p7 and p8, respectively.  The peptide, MI B chain p7-15, has a strong anchor residue, 
Pro9, at peptide position p3 plus three weak anchor residues, Val12, Glu13 and Leu15, at 
peptide positions p6, p7, and p9, respectively.  Thus both peptides contain a single 
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dominant anchor residue for binding to H-2Kb and a single strong anchor residue for 
binding to H-2Db.  These findings suggest that the peptide-binding affinity for horse cyt c 
p41-49 and MI B chain p7-15 is similar for the H-2Kb and H-2Db class I molecules.  
Thus, MI B chain p7-15 could function as a competitor peptide for binding to both H-2Kb 
and H-2Db. 
 
Optimum peptide concentrations are comparable for H-2Kb- and H-2Db-restricted 
recognition of horse cyt c p41-49 by Clone B6.H-4.1c  
An important question concerns whether Clone B6.H-4.1c responds similarly to 
horse cyt c p41-49 in the context of H-2Kb and H-2Db.  To address this question, we 
determined the optimum concentrations of horse cyt c p41-49 peptide needed to lyse 
51Cr-labeled L + Kb and L + Db target cells pulsed with concentrations of horse cyt c  
p41-49 ranging from 2 pM to 2 µM by Clone B6.H-4.1c.  The results in Figure 1 and 
Table III, using Clone B6.H-4.1c at a constant effector-to-target (E:T) ratio of 3:1, show 
that the optimum horse cyt c p41-49 concentration that yields 30% lysis is ~4 nM for    
H-2Kb and ~2 nM for H-2Db.  Thus Clone B6.H-4.1c recognizes and lyses both Kb- and 
Db-expressing peptide-pulsed targets with similar efficiency. 
 
MI B chain p7-15 inhibits the response of Clone B6.H-4.1c to both H-2Kb/cyt c p41-49 
and H-2Db/cyt c p41-49 complexes   
As noted previously, MI B chain p7-15 and horse cyt c p41-49 are similar in their 
expression of dominant and strong anchor residues for both H-2Kb and H-2Db peptide-
binding motifs.  On this basis we used MI B chain p7-15 in peptide competition 
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experiments to compare the relative binding affinities of horse cyt c p41-49 for H-2Kb 
and H-2Db class I molecules.  As shown in Figure 2 and Table III, for both H-2Kb and  
H-2Db class I molecules, the addition of the MI B chain p7-15 competitor peptide results 
in a significant increase in the concentration of horse cyt c p41-49 target peptide required 
to yield 30% lysis by Clone B6.H-4.1c.  The addition of 10 µM MI B chain p7-15 causes 
a >30-fold increase and a >100-fold increase, respectively, in the concentration of horse 
cyt c p41-49 required for 30% lysis of L + Kb and L + Db targets by Clone B6.H-4.1c 
(Table III).  Thus MI B chain p7-15 likely binds more efficiently to H-2Db than to H-2Kb.  
To confirm this conclusion, we performed RMA-S stabilization experiments, in 
which horse cyt c p41-49 and MI B chain p7-15 were added separately to RMA-S cells, 
to determine the levels of H-2Kb or H-2Db expression induced by each peptide.  We 
show, in Figure 3, that horse cyt c p41-49 binds efficiently to both class I H-2b molecules.  
Horse cyt c p41-49 and MI B chain p7-15 presented in the context of H-2Kb reach a 
steady state at 60 min, demonstrating that the stability of these MHC/peptide complexes 
are similar.  The peptide, MI B chain p7-15, however, appears to stabilize H-2Db more 
readily than horse cyt c p41-49 since H-2Db/MI p7-15 complexes reach a steady state at 
120 min and H-2Db/cyt c p41-49 complexes reach a steady state at 60 min.  The lag time 
of approximately 60 min in H-2Db/MI p7-15 dissociation may account for the >100-fold 
increase in horse cyt c p41-49 required for efficient Clone B6.H-4.1c recognition of      
H-2Db/cyt c p41-49 complexes as demonstrated by peptide competition analysis. 
The differences seen between the peptide competition assays, which measure 
MHC/peptide/TCR interactions, and RMA-S studies, which measure MHC expression, 
may be explained by the nature of the experiments themselves.  On the one hand, peptide 
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competition experiments incorporate a degree of sensitivity based on possible differences 
in both peptide binding to the class I MHC cleft as well as Clone B6.H-4.1c TCR 
interaction with the distal surface of H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 
complexes.  The RMA-S stabilization studies, however, are based solely on differences in 
the binding of horse cyt c p41-49 and MI B chain p7-15 in the clefts of H-2Kb and         
H-2Db, which alter the stability of the MHC/peptide complexes.  In either case, both 
peptides clearly bind very efficiently to both H-2Kb and H-2Db class I molecules and with 
similar kinetics. 
 
Molecular models predict the interaction of the Clone B6.H-4.1c TCR with H-2Kb/cyt c 
p41-49 and H-2Db/cyt c p41-49 complexes  
To determine the putative preferred binding configurations for horse cyt c p41-49 
in the H-2Kb and H-2Db peptide-binding clefts, we developed computer-generated 
molecular models of the horse cyt c p41-49 peptide bound in the clefts of both class I 
MHC molecules.  These models were generated by a single-step amino acid substitution 
approach using the x-ray crystal structure coordinates for H-2Kb + SEV-9 (36,37) and   
H-2Db + influenza A nucleoprotein p366-374 (38) deposited in the Brookhaven Protein 
Data Bank.   
As shown in Figures 4A and 5A, the association of horse cyt c p41-49 with H-2Kb 
yields a compact peptide configuration with a clearly distinguishable protruding central 
region.  The amino terminus of horse cyt c p41-49 is anchored in the deep B pocket of the 
H-2Kb cleft through interactions with Gln42 at peptide position p2 (Figure 6 and Table 
IV).  As shown in Figure 6, Gln42 of horse cyt c p41-49 (depicted in blue) forms a single 
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hydrogen bond with Glu63 and two bonds with Asn70 located in the B pocket of H-2Kb 
(depicted in pink).  Although multiple water molecules (depicted in green) are also 
present in the B pocket, they provide no hydrogen bonding with peptide residues from 
horse cyt c p41-49. 
Conversely, horse cyt c p41-49 residues, Tyr48 and Thr49 at peptide positions p8 
and p9, anchor the carboxyl terminus in the F pocket of the H-2Kb antigen-binding cleft 
by forming complex hydrogen bond networks with water molecules and H-2Kb residues.  
As shown in Figure 7 and Table IV, Tyr48 of horse cyt c p41-49 (blue) interacts with 
Asp77 and Lys146 residues, and Thr49 of horse cyt c p41-49 form a single hydrogen bond 
with the side chain of Tyr84 located in the F pocket of H-2Kb (pink).  Two hydrogen 
bonds are also formed between Thr47 and Tyr48 of horse cyt c p41-49 and may be critical 
for maintaining the conformation of the H-2Kb/cyt c p41-49 complex.  Unlike the B 
pocket, multiple hydrogen bonds are formed between water molecules (green) found in 
the F pocket and residues Thr47 and Tyr48 of horse cyt c p41-49.  Thus, Gln42, Tyr48 and 
Thr49 serve as critical anchor residues for efficient binding of horse cyt c p41-49 to the 
cleft of H-2Kb.   
The association of horse cyt c p41-49 with H-2Db (Figures 4B and 5B) also 
reveals a bulge at the peptide center.  The carboxyl terminus is anchored to the H-2Db 
cleft largely through residues Tyr48 and Thr49 (Table IV).  The presence of Tyr48 at 
peptide position p8 results in the formation of hydrogen bonds with Gln72, Val76, Lys146 
and Trp147 of the H-2Db cleft.  The peptide residue Thr49 forms an additional bond to 
Lys146, as well to Tyr84 and Thr143 residues located in the F pocket of H-2Db (Table IV).  
The H-2Db peptide-binding cleft contains a prominent hydrophobic ridge, consisting of 
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Trp73, Trp147, Ala152 and Tyr156, that forms between the α1 and α2 helices and upon which 
the central region of horse cyt c p41-49 rests (38).  As indicated in Table IV, important 
interactions occur between residues of the H-2Db hydrophobic ridge and with the 
carboxyl terminus of horse cyt c p41-49, particularly with residues Phe46, Thr47 and Tyr48 
at peptide positions p6, p7 and p8.  It is likely that these interactions compensate for the 
absence of strong amino-terminus contacts in facilitating binding of this peptide to        
H-2Db. 
 To identify the TCR contact residues important for CTL recognition and response, 
we analyzed the solvent-accessibility of each computer-generated molecular model using 
a 1.4Å surface probe (Figure 5) (32).  The side-chain atoms of Pro44 and Phe46 at peptide 
positions p4 and p6, respectively, project outward from the H-2Kb peptide-binding cleft.  
They constitute the majority of surface-accessible contacts available for Clone B6.H-4.1c 
TCR engagement when horse cyt c p41-49 is bound to H-2Kb (Figure 5 A and C).  
Likewise, the side chain atoms of Pro44, Phe46 and Tyr48 at peptide positions p4, p6 and 
p8 represent the major contact residues available for Clone B6.H-4.1c TCR engagement 
when horse cyt c p41-49 is bound to H-2Db (Figure 5 B and D).  Thus surface-
accessibility models suggest that the TCR of Clone B6.H-4.1c utilizes conserved peptide 





 The purpose of this study is two-fold: (i) to define the structural relationship 
between two class I MHC/peptide complexes recognized by dual MHC-restricted CTLs, 
and (ii) to identify how the Clone B6.H-4.1c TCR interacts functionally with both 
MHC/peptide complexes.  We first examined the single nonamer peptide, horse cyt c 
p41-49 [G-Q-A-P-G-F-T-Y-T], with respect to how it binds and stabilizes cell-surface 
expression of H-2Kb and H-2Db class I molecules.  We then derived computer-generated 
molecular models to predict the structural relationship between the two MHC/peptide 
complexes, H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49.  With these molecular models 
we determined the common surface-accessible areas of both MHC/peptide complexes 
available for interaction with the TCR of Clone B6.H-4.1c. 
To investigate the binding characteristics of horse cyt c p41-49 to both H-2Kb and 
H-2Db clefts, we first compared its sequence to the consensus peptide-binding motifs (47) 
for H-2Kb (Table I) and H-2Db (Table II).  We showed previously (15) that the nonamer 
peptide, horse cyt c p41-49, is the optimal peptide recognized by H-2Kb- and H-2Db-
restricted CTLs.  Although this peptide contains a dominant anchor residue plus two 
weak anchor residues for binding to H-2Kb, and a single strong anchor residue plus three 
weak anchor residues for binding to H-2Db, it lacks the complete peptide-binding motif 
for either H-2Kb or H-2Db.  It is possible that this lack of a complete peptide-binding 
motif for H-2Kb or H-2Db is important for conferring a greater flexibility to the overall 
binding configurations necessary for the Clone B6.H-4.1c TCR to interact more 
efficiently with both MHC/peptide complexes. 
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By determining the minimal peptide concentration required for lysis by Clone 
B6.H-4.1c, we compared its responsiveness to H-2Kb/cyt c p41-49 and H-2Db/cyt c    
p41-49 complexes.  The minimal peptide concentrations, defined as the amount of horse 
cyt c p41-49 peptide required to yield 30% lysis of H-2Kb- or H-2Db-bearing target cells 
by Clone B6.H-4.1c at an effector-to-target ratio of 3:1, are comparable – approximately 
4 nM for H-2Kb and approximately 2 nM for H-2Db (Figure 1 and Table III). 
These minimal peptide requirements for both H-2Kb- and H-2Db-restricted 
recognition by Clone B6.H-4.1c are substantially less than that reported for other CTL 
clones.  Saito and Paterson (39) previously reported that the lytic response for the     
VSV-8-specific, H-2Kb-restricted CTL Clone 33 (48), requires approximately 10 nM of 
the VSV-8 target peptide, p52-59, to achieve a similar level of lysis.  Pease and 
coworkers (16) showed that the optimal response of the H-2Kb-restricted CTL Clone 2C 
requires approximately 100 nM of its target peptide, dEV-8, at an effector-to-target ratio 
of 2:1.  Thus the response of Clone B6.H-4.1c to both H-2Kb/cyt c p41-49 and H-2Db/cyt 
c p41-49 complexes is exquisitely more sensitive to both target MHC/peptide complexes 
than the response of other CTL clones.  
Although the response of Clone B6.H-4.1c to the two MHC/peptide complexes is 
similar, it is important to determine if differences exist in the stability of peptide binding.  
This question was addressed by peptide competition experiments (Figure 2 and Table III) 
with the competitor peptide MI B chain p7-15, which also binds efficiently to both H-2Kb 
and H-2Db (Figure 3).  The binding motif for MI B chain p7-15, which conforms closely 
to that for horse cyt c p41-49, raises the possibility that MI B chain   p7-15 binds to both 
class I MHC molecules with an affinity similar to that for horse cyt c p41-49.   
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The peptide competition experiments, summarized in Table III, demonstrated that 
significantly higher concentrations of horse cyt c p41-49 are required to yield 30% lysis 
of H-2Kb- and H-2Db-bearing targets in the presence of 10 µM insulin peptide, MI B 
chain p7-15.  The addition of MI B chain p7-15 as a competitor peptide results in a >30-
fold and >100-fold increase in the target peptide concentration required for efficient lysis 
of L + Kb and L + Db cells, respectively (Table III). 
To address possible differences in the stability of MHC/peptide complexes when 
horse cyt c p41-49 and MI B chain p7-15 are presented in the context of H-2b class I 
molecules, we performed RMA-S peptide binding studies.  As shown in Figure 3, both 
horse cyt c p41-49 and MI B chain p7-15 dissociate from H-2Kb and reach a steady state 
at 60 min when incubated at 37oC, demonstrating that the stability of H-2Kb/cyt c p41-49 
and H-2Kb/MI p7-15 complexes are comparable.  The target peptide, horse cyt c p41-49, 
also dissociates from H-2Db and reaches a steady state within 60 min at 37oC, however, 
H-2Db/MI p7-15 complexes remain stable for up to 120 min.  Thus, we conclude that the 
>30-fold and >100-fold increase in horse cyt c p41-49 concentrations noted by peptide 
competition analysis is due to the slower rate of MI B chain p7-15 dissociation from     
H-2Db. 
An alternative consideration is that the Clone B6.H-4.1c TCR might have a higher 
avidity for H-2Kb/cyt c p41-49 than H-2Db/cyt c p41-49 complexes, thus requiring fewer 
stable H-2Kb/cyt c p41-49 complexes for recognition.  As shown in Figure 1, however, 
Clone B6.H-4.1c requires comparable concentrations of horse cyt c p41-49 when 
presented in the context of H-2Kb and H-2Db for optimal lysis, ~4 nM and ~2 nM, 
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respectively.  Thus, our findings suggest that the Clone B6.H-4.1c TCR has an avidity 
that is similar for both H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes. 
Molecular models generated by interactive graphics programs provide three-
dimensional structural support for studies involving peptide binding (49-52), 
MHC/peptide complex stability (51,53) and TCR recognition (10,49,52).  QUANTA and 
CHARMm modeling software packages, described by Nell and coworkers (54) to 
determine the structure and conformation of mouse insulin monoclonal antibody, 
designated 125, were used to generate H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 
complex molecular models described in this study.  X-ray crystal structure-derived 
coordinates were obtained from the Brookhaven Protein Data Bank (PBD 1vab and 1hoc) 
and used to generate molecular models that assisted in the evaluation of the peptide 
configuration of horse cyt c p41-49 presented in the context H-2Kb and H-2Db molecules.  
Computer-generated molecular models for horse cyt c p41-49 bound to the H-2Kb 
peptide binding cleft depict a constricted peptide configuration with a clearly 
distinguishable central bulge (Figures 4 and 5).  It is important to note that although Phe46 
is predicted to serve as a dominant anchor residue for H-2Kb (55), this residue is solvent 
exposed and does not lie buried within the cleft as anticipated (Figures 4 and 5).  Instead, 
Phe46 extends distally from the antigen-binding cleft (Figures 4C and 5C) and thus fails to 
interact with the class I MHC molecule directly.  Similar findings have been reported for 
the SEV-9 peptide when bound to H-2Kb, indicating that although H-2Kb molecules 
traditionally bind octamer peptides, nonamers bind efficiently within the H-2Kb antigen-
binding cleft (6,36).  An important feature common to both horse cyt c p41-49 and   
SEV-9 peptides is the presence of an Ala-Pro-Gly sequence.  This combination of AAs, 
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particularly Pro-Gly, confer an upward protruding type II β bend configuration in the 
central core of the bound peptide.  We propose that this structural feature largely 
accounts for the efficient binding of horse cyt c p41-49 within the H-2Kb cleft (6,15,36) 
and its recognition by CTL Clone B6.H-4.1c in an H-2Kb-restricted manner. 
It appears that the stable association of horse cyt c p41-49 to H-2Kb, as with  
SEV-9, requires a clearly distinguishable peptide segment containing the internal        
Ala-Pro-Gly sequence.  The combination of Pro-Gly forms a type II β bend configuration 
in the secondary structure of the bound peptide that may be necessary for its 
accommodation within the H-2Kb antigen-binding cleft.  This model has been predicted 
previously by our lab (15) and others (6,36) and is further supported by the molecular 
model for the H-2Kb/cyt c p41-49 complex presented in this paper (Figures 4 and 5).  
Likewise, the accommodation of nonamers within the H-2Kb cleft, although traditionally 
associated with octamers, has been previously reported based on x-ray crystal structure 
(23) and biochemical analysis (6).   
Several observations in this paper demonstrate that the nonamer, horse cyt c   
p41-49, is efficiently accommodated within the H-2Kb binding cleft.  First, RMA-S 
stabilization analysis clearly demonstrates that this peptide binds H-2Kb with an 
association and dissociation rate comparable to the self peptide, MI B chain p7-15.  
Secondly, our molecular models indicate that the formation of hydrogen bond networking 
between specific H-2Kb and horse cyt c residues within both the B pocket (Figure 6) and 
the F pocket (Figure 7).  Of particular interest is the presence of water molecules within 
the F pocket of H-2Kb that may provide critical hydrogen bond networking to peptide 
residues Thr47 and Tyr48 necessary for supporting the central core of horse cyt c p41-49 
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when bound to H-2Kb (Figure 7 and Table IV).  Smith and coworkers (56), made similar 
observations for peptides bound to HLA-B53  found that water molecules located beneath 
peptides within the antigen-binding cleft act to increase the diversity of peptide sequences 
and aid in peptide stabilization. 
Computer-generated molecular models for horse cyt c p41-49 bound to H-2Db 
(Figs. 4B and 5B) reveal the presence of a crucial central peptide bulge due to the 
insertion of an Ala43-Pro44-Gly45 sequence at peptide positions p3, p4, and p5.  The 
carboxyl terminal residues, Tyr48 and Thr49 at peptide positions p8 and p9 (Table IV), 
serve to anchor the peptide into the cleft.  The H-2Db peptide binding motif (47) strong 
anchor residue, Phe46, and residues Thr47 and Tyr48 at peptide position p6, p7 and p8 are 
directly involved in MHC-peptide stability through intimate contact with the hydrophobic 
ridge of H-2Db (Table IV).  These interactions facilitate binding of horse cyt c p41-49 to 
H-2Db in the absence of strong amino-termini contacts and may explain the rapid rate of 
dissociation of this peptide from the H-2Db molecule (Figure 3).  The type II β bend 
configuration created by Pro44-Gly45 is likely required for binding of horse cyt c p41-49 
to H-2Db, thus allowing peptide residues to circumvent steric hindrance forces imposed 
by the hydrophobic ridge of H-2Db during MHC/peptide complex formation and 
stabilization. 
We also determined potential Clone B6.H-4.1c TCR contacts required for 
recognition of horse cyt c p41-49 presented by H-2Kb and H-2Db by analyzing solvent-
accessible peptide residues using a 1.4Å surface probe (55).  Pro44 and Phe46 contribute 
the majority of H-2Kb/cyt c p41-49 surface-accessible residues available for TCR 
engagement (Figures 5A and 5C).  Likewise, the solvent exposed R groups of Pro44, 
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Phe46 and to a lesser degree Tyr48 at peptide positions p4, p6 and p8 constitute the regions 
of horse cyt c p41-49 available for TCR engagement when bound to H-2Db (Figures 5B 
and 5D).  Collectively, these findings suggest that the Clone B6.H-4.1c TCR interacts 
with the centrally located solvent-accessible regions of horse cyt c p41-49 - specifically 
the Pro44 and/or Phe46 residues - when complexed to H-2Kb and H-2Db class I MHC 
molecules.  Of particular interest is the profound similarity between the orientation and 
extent of surface-accessibility of the Pro44 residue at position p4 when horse cyt c p41-49 
is bound to either H-2b class I molecules. 
We propose that the functional interaction of Clone B6.H-4.1c TCR with both   
H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes requires an intimate contact with 
the Pro44 residue at peptide position p4.  In addition, we propose that the Gly45 residue at 
peptide position p5 is critical for maintaining the type II β bend configuration.  An Ala 
substitution at this position leads to diminished peptide binding, MHC/peptide 
stabilization and recognition by Clone B6.H-4.1c.  To address these possibilities, we have 
synthesized peptide analogues of horse cyt c p41-49 containing Ala substitutions at Pro44 
or Gly45.  In the accompanying manuscript, we compared the response of Clone       
B6.H-4.1c to native horse cyt c p41-49, versus the horse cyt c p41-49 analogues, 
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Table III  
The competitor peptide, MI B chain p7-15, significantly increases the concentration 

















concentration in the 








































1 Target peptide concentrations determined as the minimal peptide concentration required  
   to yield 30% lysis by Clone B6.H-4.1c. 
2 Statistical significance determined by Student’s t-test comparison of target peptide  
   concentrations in the presence and absence of competitor peptide.   
3 Minimal peptide concentrations are given as the mean of five separate experiments for  
   target peptide concentrations and three separate experiments for peptide competition  























Hydrogen bonds formed between H-2Kb or H-2Db and horse cyt c p41-49a 
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a H-2Kb and H-2Db pockets were previously described by X-ray crystal analysis (36-38).
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FIGURES AND FIGURE LEGENDS 
 
Fig. 1  Optimum peptide concentrations1 are comparable for H-2Kb- and H-2Db-
restricted recognition of horse cyt c p41-49 by Clone B6.H-4.1c. 
L + Kb (●), L + Db (▲) and LMTK- (▼) 51Cr-labeled target cells were incubated for 20 
min in the presence of varying concentrations (2 pM to 2 µM) of target peptide, horse cyt 
c p41-49.  After target peptide incubation, the CTL Clone B6.H-4.1c was added at an 
effector-to-target ratio of 3:1 for 4 h.  Supernatants (100 µl) were collected and cytolytic 
activity was represented as the "percent specific lysis".  Spontaneous release of targets in 
the absence of CTL effectors was <10% of maximum lysis by detergent in all 
experiments.  A single representative of five separate experiments is shown. 
1 Minimal peptide concentrations were determined as the peptide concentration required 









Fig. 2 MI B chain p7-15 inhibits the response of Clone B6.H-4.1c to both                
H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes. 
L + Kb (●) and L + Db (▲) 51Cr-labeled target cells were incubated for 20 min in the 
presence of varying concentrations (2 pM to 2 µM) of target peptide, horse cyt c p41-49, 
plus the competitor peptide, MI B chain p7-15, at a constant concentration of 10 µM.  
Additionally, 51Cr-labeled L + Kb target cells were incubated with 50 nM of horse cyt c 
p41-49 ( ) or media ( ) alone, and acted as positive and negative controls for these 
experiments.  After peptide incubation, Clone B6.H-4.1c was added at an effector-to-
target ratio of 3:1 for 4 h.  Supernatants (100 µl) were collected and cytolytic activity was 
represented as the "percent specific lysis".  Spontaneous release of targets in the absence 
of CTL effectors was <10% of maximum lysis by detergent in all experiments.  A single 






Fig. 3  Horse cyt c p41-49 and MI B chain p7-15 stabilizes the class I MHC 
molecules, H-2Kb and H-2Db, with similar kinetics. 
2.5 X 106 RMA-S cells were pulsed with 10 µM concentrations of horse cyt c p41-49 
(closed), MI B chain p7-15 (open) or media (∇) for 1 h at 30oC, 5% CO2.  Cells were 
then washed to remove excess unbound peptide and incubated for 0, 30, 60, 120 and 180 
min at 37oC, 7% CO2.  At each time point, 5 X 105 cells were removed and stained for the 
presence of stable surface H-2Kb ( ) and H-2Db (∆) molecules.  Mean channel 
fluorescence was determined by flow cytometric analysis and was represented as the 
fluorescence index as described in Materials and Methods.  A single representative of 







Fig. 4 Horse cyt c p41-49 [G-Q-A-P-G-F-T-Y-T] exhibits a constricted peptide 
configuration when complexed with H-2Kb and H-2Db. 
Horse cyt c p41-49 was introduced into the antigen binding site of H-2Kb (A and C) and 
H-2Db (B and D) by single step substitution using x-ray crystal structure coordinates 
determined for H-2Kb complexed with SEV-9 (PDB 1vab) and H-2Db complexed with 
influenza A p366-374 (PDB 1hoc).  Each model is represented as a side view (A and B) 
and as viewed from above the peptide binding groove (C and D).  The class I MHC 
molecule is represented as a carbon-backbone and bound peptide is denoted by Van der 













Fig. 5 Pro44 at peptide position p4 exhibits similar solvent accessibility and 
orientation when presented by both H-2Kb and H-2Db. 
Solvent accessibility of horse cyt c p41-49 complexed with H-2Kb (A and C) and H-2Db 
(B and D) was determined for each molecular model using a 1.4Å surface probe. Each 
model is represented as a side view (A and B) and as viewed from above the peptide-
binding groove (C and D).  Horse cyt c p41-49 residues are individually colored and 
depicted as Van der Waals shells.  Likewise, solvent accessibility for each residue is 














Fig. 6 Gln42 at peptide position p2 anchors the amino terminus of horse cyt c p41-49 
in the B pocket of H-2Kb. 
Hydrogen bond interactions formed between the amino terminus of horse cyt c p41-49 
and the B pocket of H-2Kb were evaluated for potential peptide anchor residues.  Amino 
terminus residues of horse cyt c p41-49, Gly41, Gln42 and Ala43, are represented in blue, 
and H-2Kb residues in the B pocket are designated in pink.  The presence of Gln42 
provides amino terminus anchoring of horse cyt c p41-49 to H-2Kb by forming three 
hydrogen bonds with H-2Kb B pocket residues - one with the side chain of Glu63 and two 
with Asn70.  Although water molecules, depicted in green, are present in the B pocket of 



















Fig. 7 Complex hydrogen bond networks are formed in the F pocket of H-2Kb to 
facilitate carboxyl terminus anchoring of horse cyt c p41-49. 
Hydrogen bond networking in the F pocket of H-2Kb was examined to determine peptide 
anchor residues contributed by the carboxyl terminus of horse cyt c p41-49.  Carboxyl 
terminus residues of horse cyt c p41-49 are represented in blue, F pocket residues of      
H-2Kb are depicted in pink, and water molecules in the F pocket are shown in green.  The 
presence of Tyr48 contributes interactions with Lys146 and Asp77 residues in the F pocket 
of H-2Kb, and also forms two peptide-peptide bonds with Thr47 at peptide position 7.  In 
addition, Thr47 forms hydrogen bonds with water molecules found in the F pocket.  The 
peptide residue Thr49 contributes to the carboxyl terminus stabilization of horse cyt c 
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In general, a self MHC-restricted CD8+ T lymphocyte responds to a single class I 
MHC/peptide complex.  Studies from several laboratories, however, have demonstrated 
that some cloned cytotoxic T cells can respond to multiple class I MHC/peptide complex 
types.  We previously showed that CTL Clone B6.H-4.1c is specific for the horse cyt c-
derived nonamer, cyt c p41-49, presented by either H-2Kb or H-2Db class I MHC 
molecules.  We proposed that the Pro44-Gly45 dipeptide sequence serves as a critical 
contact region for the TCR of Clone B6.H-4.1c.  To address this question, we constructed 
single Ala substitution analogues of the horse cyt c peptide, p41-49, at peptide positions 
p4 and p5, designated p41-49/44A and p41-49/45A, respectively.  In this paper, we show 
that the optimal dual Kb- and Db-restricted response of Clone B6.H-4.1c is critically 
dependent on the presence of both Pro44 and Gly45 in the core region of this peptide.  
Although the p41-49/44A analogue binds as well to both H-2Kb and H-2Db as the native 
p41-49 peptide, recognition of both Kb/p41-49/44A and Db/p41-49/44A complexes by 
CTL Clone B6.H-4.1c is ablated.  The p41-49/45A analogue, when presented by either 
H-2Kb or H-2Db, can only elicit cytolysis by Clone B6.H-4.1c at significantly higher 
peptide concentrations than the native peptide.  Computer-generated molecular models 
for horse cyt c p41-49, and analogues p41-49/44A and p41-49/45A, binding to H-2Kb 
and H-2Db, demonstrate that disruption of the type II β bend formed by Pro44-Gly45 alters 





 CD8+ cytotoxic T lymphocytes (CTL) respond to short antigenic peptides 
presented in the context of a single self class I major histocompatibility complex (MHC) 
molecule (1-5).  A number of studies demonstrate, however, that certain CTLs do not 
strictly adhere to this dogma of "self MHC-restriction" (6-12).  We previously reported 
that CTL Clone B6.H-4.1c is specific for the horse cytochrome c (cyt c)-derived 
nonamer, p41-49, presented in the context of H-2Kb and H-2Db, as well as the mutant H-
2Kbm1, class I MHC molecules (9 and Frankenberry et al, manuscript submitted).  
Likewise, Pease and coworkers (11) showed that CTL Clone 2C is specific for the self 
peptide, dEV-8, in association with H-2Kb and its closely related mutant, H-2Kbm3.  In 
addition, Clone 2C also responds to a second peptide, designated p2Ca, in the context of 
either H-2Kb or H-2Ld (10). 
Our understanding of the nature of degenerate T cell recognition involves several 
components.  First, the MHC/peptide/T cell receptor (TCR) trimolecular complex 
interaction during thymic selection is somewhat promiscuous (13,14).  Developing T 
cells undergo positive selection in the thymus based on how well they interact with self 
MHC/peptide complexes (15-17).  Certain evidence supports the suggestion that thymic 
selection plays an important role in the induction of inherently degenerate T cell 
responses.  Kappler and Marrack (18) observed that a single peptide can select a wide 
range of T cells expressing various TCRs.  Thymic selection plays an important role in 
the development of inherently degenerate T cell responses, given that a single TCR is 
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confronted with a diverse pool of peptides during the positive and negative selection 
process (19).  
A second important feature of degenerate T cell recognition is the plasticity of the 
secondary structure of the TCR during its engagement with MHC/peptide complexes.  
Plasticity, in this report, refers to changes in orientation of the complementarity-
determining regions (CDR) of the TCR engaged with a MHC/peptide complex, as 
described previously (20).  We and Nathenson’s group (21) initially characterized the 
orientation of the TCR to the class I MHC/peptide distal surface by analyzing the 
cytolytic response of alloreactive CTLs to a panel of H-2Kb mutant cell lines.  This study 
demonstrated that the TCR is oriented diagonally across the distal surface of the class I 
MHC/peptide complex.  Similarly, Janeway and coworkers (22) also observed that T 
cells responding to class II MHC/peptide complexes interact in a diagonal orientation, 
with the TCR variable α (Vα) domain aligned over the peptide amino terminus and the 
TCR Vβ domain aligned over the carboxyl terminus of the peptide.  Several other studies 
describing the three-dimensional x-ray crystallographic structure for MHC/peptide/TCR 
trimolecular complexes confirm this diagonal orientation of the TCR with respect to the 
MHC/peptide complex (20,23-25). 
  The third component of degenerate T cell recognition indicates that TCR 
engagement with MHC/peptide complexes requires contact with specific peptide 
residues.  The x-ray crystal structure analysis of the H-2Kb/dEV-8/2C (25) and         
HLA-A2/Tax11-19/A6 (24) trimolecular complexes revealed that the TCR is aligned 
directly over the central peptide core region of class I MHC-bound peptides.  Joyce and 
coworkers (26) demonstrated that a H-2Kb-restricted, minor histocompatibility (H) H-4b-
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specific CTL clone recognizes only peptides within combinatorial libraries that contain 
an invariant, solvent-accessible isoleucine residue at peptide position p6.  They also 
found that the H-2Kb-restricted, herpes simplex virus (HSV)-I glycoprotein B (gB)-
specific CTL clone, Clone 2D5, recognizes only those peptides that contain glutamic acid 
at peptide position p4 (Glu4).  These observations suggest that few TCR-accessible 
peptide contact residues are necessary for antigen-specific recognition by the TCR of 
CD8+ CTL clones. 
We recently demonstrated (9) that in the horse cyt c p41-49 peptide, residues 
Pro44 and  Gly45 form a type II β bend  that contributes to formation of both H-2Kb/cyt c 
p41-49 and H-2Db/cyt c p41-49 complexes and to their recognition by the CD8+ CTL 
Clone B6.H-4.1c.  Ploegh and coworkers (27,28) showed that the Sendai virus 
nucleoprotein p324-332 (SEV-9) also binds efficiently to and stabilizes both H-2Kb and 
H-2Db molecules; the primary sequence of this peptide is [F-A-P-G-N-Y-P-A-L].  This 
nonamer stabilizes H-2Kb molecules at concentrations comparable to that of other H-2Kb-
restricted octamer peptides, including the endogenously processed vesicular stomatitis 
virus nucleoprotein peptide p52-59 (VSV-8) [R-G-Y-V-Y-Q-G-L] and the ovalbumin 
(OVA)-derived peptide, OVA257-264 [S-I-I-N-F-E-K-L] (27).  The authors propose that the 
presence of Pro and Gly residues in tandem induces certain conformational constraints 
that allow binding of the nonamer peptide to H-2Kb (27).  Thus, it is likely that the     
Pro-Gly dipeptide combination introduces a type II β bend into the peptide secondary 
structure that facilitates its binding to MHC class I molecules by allowing the peptide 
backbone to protrude out of from the antigen-binding cleft.  We propose that the dual    
H-2Kb- and H-2Db-restricted recognition of horse cyt c p41-49 by Clone B6.H-4.1c is 
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critically dependent on the prominent Pro44-Gly45-induced type II β bend found in the 
horse cyt c p41-49 peptide.  To address this possibility, we use horse cyt c p41-49 peptide 
analogues consisting of a single alanine (Ala) substitution, P44A or G45A, at peptide 
positions p4 or p5, respectively. 
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MATERIALS AND METHODS 
 
Animals   
Female C57BL/6 (B6) mice used in this study were obtained from this laboratory's 
breeding colony at West Virginia University Health Sciences Center Vivarium.  The B6 
colony was established in 1987 and has been maintained since then at the West Virginia 
University Health Sciences Center Vivarium.  All mice used in this study were between 8 
and 12 weeks of age. 
 
Target cell lines   
Transfected cell lines were derived from a thymidine kinase-negative L cell (H-2k) 
fibroblast line (designated LMTK-) and grown as adherent cultures in RPMI-1640 media 
supplemented with 10% FCS, 100 mM HEPES, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine (RP-10), as previously described (9).  These 
transfected cell lines, which include L + Kb and L + Db, were kindly provided by Drs. S. 
G. Nathenson and R. Zeff.  Appropriate H-2b class I expression was verified by flow 
cytometry in our laboratory (data not shown). 
 
Synthesis of peptides   
The peptides, horse cyt c p41-49 [G-Q-A-P-G-F-T-Y-T], analogue p41-49/44A [G-Q-A-
A-G-F-T-Y-T], analogue p41-49/45A [G-Q-A-P-A-F-T-Y-T] and mouse insulin I B 
chain (MI) p7-15 [C-G-S-H-V-E-A-L], were generously provided by Drs. J. W. Yewdell, 
J. R. Bennink and T. Schell.  Peptides were synthesized by fMoc chemistry using an 
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automated peptide synthesizer (9050 MilliGen PepSynthesizer), as previously described 
(29).  Amino acid composition and purity was determined by HPLC tracing (Waters 
600E) and the Pico Tag Amino Acid Analysis System (Waters).  Lyophilized peptides 
were solubilized in sterile 1X PBS at appropriate stock concentrations.  For the purpose 
of peptide competition studies, we used horse cyt c p41-49 and its analogue p41-49/45A 
as target peptides; the analogue p41-49/44A and MI B chain p7-15 were used as 
competitor peptides. 
 
RMA-S stabilization assays   
The method for peptide-induced stabilization of RMA-S cells has been described 
previously (30,31).  Briefly, the B6-derived, transporter associated with antigen 
processing (TAP)-deficient, murine cell line RMA-S (32,33) was grown initially in RP-
10 media in a humidified incubator at 37oC with 7% CO2.  RMA-S cells (2.5 X 106) were 
transferred to 30oC in 5% CO2 for 18-20 h to induce stable H-2Kb and H-2Db expression.  
RMA-S cells were then washed twice with 1X PBS containing 2% FCS and 0.01% 
sodium azide (PBS-2%) and incubated with 10 µM of horse cyt c p41-49, analogue p41-
49/44A, analogue p41-49/45A or MI B chain p7-15 for one hour.  Peptide-pulsed RMA-S 
cells were then washed twice with PBS-2% to remove excess unbound peptide, 
resuspended in RP-10 media, and incubated in a humidified incubator at 37oC, 7% CO2.  
RMA-S cells (5 X 105) were incubated with PE-conjugated anti-H-2Kb or anti-H-2Db 





Antibodies and flow cytometry  
Phycoerythin (PE)-conjugated anti-H-2Kb (34) and anti-H-2Db (35) mAbs were 
purchased from Caltag Laboratories® (Burlingame, CA).  Peptide-pulsed RMA-S cells (5 
X 105) were incubated for 45 minutes on ice with 20 µl of appropriate mAb (1:20) and 
washed twice with PBS-2%.  RMA-S cells (1 X 105) were analyzed for fluorescence 
intensity using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).  
The mean channel fluorescence (MCF) indicates the mean channel number of 
fluorescence, detected from 10,000 gated cells.  The fluorescence index was calculated as 
previously determined (36), using the following formula: 
 
(MCF in the presence of peptide) - (MCF in the absence of peptide) 
_________________________________________________________________________________ 
(MCF in the absence of peptide) 
 
CTL Clone B6.H-4.1c 
Maintenance of the CTL clone, Clone B6.H-4.1c, has been previously described (9).  
Briefly, 4 X 105 Clone B6.H-4.1c CTLs were incubated in a 24-well flat-bottom plate 
with 5 X 106 irradiated (2000 rads) B6 spleen cells plus 2 µM horse cyt c p41-49 
suspended in RP-10 media.  Clone B6.H-4.1c CTLs were analyzed for lytic reactivity 






51Cr-release assay   
The lytic activity of Clone B6.H-4.1c was assayed in vitro using a standard 4-h 51Cr-
release assay (21).  Briefly, 1 X 106 LMTK-, L + Kb and L + Db target cells were 
incubated in a 50 µl volume of RP-10 media plus 100 µCi sodium chromate 51 (51Cr; 
New England Nuclear, Boston, MA) per 1 X 106 cells for 60 min at 37oC, 7% CO2, 
washed in 1X HBSS and resuspended in 10 ml RP-10.  Following an additional 30 min 
incubation in a 37oC water bath, target cells were washed in 1X HBSS and resuspended 
in RP-10 media at a final concentration of 2 X 105 cells/ml.  Target cells were added in a 
volume of 50 µl/well to 96-well round-bottom microtiter plates.  Exogenous peptides to 
be tested were added at a volume of 50 µl/well with a final concentration of 2 µM and 
incubated for 20 min at 37oC, 7% CO2.  Effector CTLs, Clone B6.H-4.1c, were added at a 
volume of 100 µl/well with the following effector-to-target ratios: 30:1, 10:1, 3:1 and 1:1.  
Cells were incubated for 4 h at 37oC, 7% CO2, then the assay plates were centrifuged for 
7 min at 1200 rpm.  Supernatants (100 µl) were collected from each well and transferred 
to 6 X 50 mm tubes for determination of total 51Cr counts on an LKB Clinigamma Model 
1272 counter (LKB Instruments, Finland).  The “percent specific lysis” was determined 
as follows: 
experimental cpm - spontaneous cpm 
   ________________________________________________      X 100 
maximum cpm - spontaneous cpm 
 
 
Spontaneous release values in the absence of CTL effectors was <10% of maximum lysis 





Minimal peptide concentration determination   
Final volume peptide concentrations ranging from 2 pM to 2 µM for the native horse cyt 
c p41-49, analogue p41-49/44A or analogue p41-49/45A were added to 51Cr-labeled 
target cells and incubated for 20 min at 37oC, 7% CO2.  Clone B6.H-4.1c effector CTLs 
were added at a volume of 100 µl/well with a constant effector-to-target ratio of 3:1.  
Cells were incubated for 4-h at 37oC, 7% CO2 and the assay plates were centrifuged for 7 
min at 1200 rpm and 100 µl of supernatant was collected from each well.  Minimal 
peptide concentrations were determined as the peptide concentration required to yield 
30% lysis at an effector-to-target ratio of 3:1. 
 
Peptide competition inhibition assays  
 Competition inhibition assays have been described previously (36).  Briefly, a constant 
competitor peptide concentration was added to the target peptide concentrations ranging 
from 2 pM to 2 µM.  The target peptides (horse cyt c p41-49 or analogue p41-49/45A) 
and competitor peptides (analogue p41-49/44A or MI B chain p7-15) were added to 51Cr 
labeled target cells and incubated for 20 min at 37oC, 7% CO2.  Effector CTLs, Clone 
B6.H-4.1c, were added at a volume of 50 µl/well with a constant effector-to-target ratio 
of 3:1.  Cells were incubated for 4 h at 37oC, 7% CO2, and the assay plates were 
centrifuged for 7 min at 1200 rpm and 100 µl of supernatant was collected from each 
well.  The degree of competitor peptide inhibition was determined by a Student’s t-test 
comparison of the target peptide concentration required to yield 30% lysis at an effector-




Computer modeling   
To investigate horse cyt c 41-49, analogue p41-49/44A and analogue p41-49/45A binding 
to class I MHC molecules and T cell recognition, these peptides were introduced into the 
peptide-binding cleft of H-2Kb and H-2Db molecules.  Molecular models were generated 
using a Silicon Graphics UNIX-based computer with QUANTA/CHARMm software 
designed by Molecular Simulations, Inc.  X-ray crystal structure coordinates for the H-
2Kb complexed with the Sendai virus nucleoprotein (SEV-9) p324-332 [F-A-P-G-N-Y-P-
A-L] (37,38) and H-2Db complexed with the influenza A p366-374 [A-S-N-E-N-M-E-T-
M] (39) were obtained from the Brookhaven Protein Data Bank (PBD 1vab and 1hoc).  
QUANTA/CHARMm software was utilized to introduce horse cyt c p41-49, analogue 
p41-49/44A and analogue p41-49/45A into the parental H-2Kb and H-2Db x-ray crystal 
structure by replacing a single amino acid residue, followed by 50 cycles of 
regularization at the steepest descent and 200 cycles of the adopted basis set Newton-
Raphson (ABNR) method.  The peptide sequences were regularized after each single 
amino acid residue replacement to reduce unfavorable bonds and angles.  To minimize 
the energy configuration, the completed MHC/peptide complexes were subjected to 100 
cycles of CHARMm minimization using the ABNR method. 
 
Statistical analysis   
All statistics in this study were performed by a paired, one-tailed Student’s t-test.  





Clone B6.H-4.1c recognizes the horse cyt c p41-49 analogue p41-49/45A, but not 
analogue p41-49/44A, when presented by H-2Kb and H-2Db molecules 
The purpose of this report is to investigate the role of the type II β bend 
contributed by the dipeptide sequence, Pro44-Gly45, in Clone B6.H-4.1c recognition of   
H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.  To accomplish this aim, we 
constructed two horse cyt c p41-49 peptide analogues each containing a single Ala 
substitution, P44A or G45A, at peptide positions p4 and p5, respectively.  We used these 
analogues, designated p41-49/44A and p41-49/45A, to evaluate the responsiveness of 
Clone B6.H-4.1c to MHC/peptide complexes following disruption of the type II β bend.  
L + Kb, L + Db and LMTK- target cells were labeled with 51Cr and pre-incubated with 2 
µM concentrations of horse cyt c p41-49, analogue p41-49/44A or the analogue          
p41-49/45A prior to the addition of Clone B6.H-4.1c effector cells.  As shown in Figure 
1, Clone B6.H-4.1c recognizes analogue p41-49/45A but not analogue p41-49/44A on 
both H-2Kb or H-2Db.  Likewise, Clone B6.H-4.1c does not lyse peptide free target cells 
or the H-2k-bearing target cell line, LMTK-.  Clone B6.H-4.1c recognition of analogue 
p41-49/45A is comparable to both H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 
suggesting that the single amino acid substitution (G45A) at peptide position p5 does not 
affect responsiveness at 2 µM concentrations.  The single amino acid substitution (P44A) 
at peptide position p4 does, however, disrupt Clone B6.H-4.1c recognition.  One possible 
explanation for this lack of responsiveness by Clone B6.H-4.1c is that the horse cyt c 
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analogue, p41-49/44A, may either fail to associate with, or rapidly dissociation from,    
H-2Kb and H-2Db class I MHC molecules.  
 
Native horse cyt c p41-49 and the analogues, p41-49/44A and p41-49/45A, stabilize 
expression of class I MHC molecules, H-2Kb and H-2Db   
To determine the residues important for antigen binding to H-2Kb and H-2Db 
class I molecules, we applied the published peptide-binding motifs to the horse cyt c  
p41-49 analogues, p41-49/44A and p41-49/45A (40).  As shown in Table I, H-2Kb 
binding for both horse cyt c p41-49 analogues is predicted to involve a single dominant 
anchor, Phe46, and a weak anchor residue, Thr47, at peptide positions 6 and 7, 
respectively.  Although the weak anchor Pro44 at peptide position p4 is present in 
analogue p41-49/45A, this residue has been replaced with an Ala in analogue             
p41-49/44A, and thus its absence may adversely affect H-2Kb binding and presentation.  
Those residues that contribute to the binding of both peptide analogues to H-2Db (Table 
II) are identical to those in the native peptide; they are the single strong anchor residue, 
Phe46, and the three weak anchor residues, Glu42, Thr47 and Tyr48.  Thus, binding of the 
peptide analogues, p41-49/44A and p41-49/45A, to H-2Db is likely to be comparable to 
that of native horse cyt c p41-49.   
We also determined which MI B chain p7-15 peptide residues contribute to its 
binding to H-2Kb and H-2Db class I molecules (Table I and II).  As previously described 
(Frankenberry et al, manuscript submitted), MI B chain p7-15 also binds to both H-2Kb 
and H-2Db class I MHC molecules and is recognized by the H-2Kb- and H-2Db-specific 
CTL clones, Clone B6.MI-9c2 and Clone B6.MI-10.5.2, respectively (8).  The native MI 
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B chain p7-15 peptide contains a single dominant anchor and a single weak anchor 
residue for H-2Kb binding, as well as a single strong anchor and three weak anchor 
residues for binding to H-2Db.  Thus, both horse cyt c analogue, p41-49/44A, and MI B 
chain p7-15 appear to be capable of binding efficiently to either H-2b class I molecule. 
To determine whether the peptide analogue p41-49/44A form stable MHC/peptide 
complexes with H-2Kb and H-2Db, RMA-S stabilization assays were performed utilizing 
native horse cyt c p41-49, analogue p41-49/44A and analogue p41-49/45A.  As shown in 
Figure 2, analogue p41-49/44A stabilize H-2Kb and H-2Db molecules in a manner 
comparable to that of native horse cyt c p41-49.  Analogue p41-49/45A exhibits the 
highest binding efficiency for H-2Kb and maintains stable H-2Kb expression for up to 3 h 
when incubated at 37oC.  Analogue p41-49/45A disassociates rapidly, however, from    
H-2Db molecules and after 2 hours few stable MHC/peptide complexes are expressed at 
the cell surface.  These findings demonstrate that native horse cyt c p41-49, analogue 
p41-49/44A and analogue p41-49/45A bind to and stabilize both H-2Kb and H-2Db 
molecules and that each peptide is presented to Clone B6.H-4.1c effector CTLs.  Thus, 
the lack of responsiveness by Clone B6.H-4.1c for analogue p41-49/44A is not due to 
deficient MHC/peptide complex formation. 
 
Significantly higher analogue p41-49/45A peptide concentrations are required for 
optimal target cell lysis by Clone B6.H-4.1c   
To quantitate the lytic response of Clone B6.H-4.1c for H-2Kb and H-2Db 
molecules associated with either native horse cyt c p41-49 or the analogue p41-49/45A, 
minimal peptide concentration studies were performed.  Target cells expressing H-2Kb 
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and H-2Db molecules were labeled with 51Cr and pre-incubated with 2 pM to 2 µM 
concentrations of the target peptide native horse cyt c p41-49, analogue p41-49/44A or 
analogue p41-49/45A.  Clone B6.H-4.1c effector cells, at an effector-to-target ratio of 
3:1, were added for 4 h to determine peptide-specific lytic activity.  As described 
previously (Frankenberry et al, manuscript submitted), optimal lytic function was 
determined by the minimal peptide concentration, defined as the amount of peptide 
required to yield 30% target cell lysis by Clone B6.H-4.1c CTL effectors.  As 
demonstrated in Figures 1 and 3, the p41-49/44A analogue fails to induce a cytolytic 
response from Clone B6.H-4.1c when presented by either H-2Kb or H-2Db molecules.  
Clone B6.H-4.1c recognition of p41-49/45A requires significantly higher peptide 
concentrations than native horse cyt c p41-49 for both H-2Kb and H-2Db molecules 
(Figure 3 and Table III).  A minimal peptide concentration of ~4 nM and ~2 nM is 
required for Clone B6.H-4.1c recognition of native horse cyt c p41-49 presented by       
H-2Kb and H-2Db, respectively.  Recognition of the p41-49/45A peptide analogue bound 
to H-2Kb and H-2Db requires a minimal peptide concentration of ~125 nM and ~80 nM, 
respectively, suggesting it binds with a lower affinity than p41-49/44A to both Kb and Db. 
 
Recognition of native horse cyt c p41-49 and analogue p41-49/44A is inhibited by the 
competitor peptides, MI B chain p7-15 and p41-49/45A   
To determine the lytic capacity of the Clone B6.H-4.1c response to the H-2Kb and 
H-2Db molecules associated with native horse cyt c p41-49 or p41-49/45A, peptide 
competition experiments were performed with MI B chain p7-15 and the horse cyt c 
analogue p41-49/44A as competitor peptides.  As shown in Figure 4, target cells were co-
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incubated with native horse cyt c p41-49, ranging from 2 pM to 2 µM, plus 10 µM of 
either MI B chain p7-15 or p41-49/44A for 20 min.  Clone B6.H-4.1c effectors were then 
added at an effector-to-target ratio of 3:1 and lytic activity was determined after 4 h.  As 
shown in Figure 4 and Table III, the addition of 10 µM MI B chain p7-15 results in a 
>30-fold and >100-fold increase in the concentration of native horse cyt c p41-49 peptide 
required for optimal lysis of H-2Kb- and H-2Db-bearing target cells, respectively.  
Furthermore, the addition of 10 µM p41-49/44A as a competitor significantly increases 
the concentration of native horse cyt c p41-49 peptide required for H-2Kb- and H-2Db-
restricted lysis by approximately 6-fold and 12-fold, respectively.  Thus, the introduction 
of either competitor peptide significantly increases the concentration of native horse cyt c 
p41-49 required for optimal target cell lysis. 
To ascertain the lytic capacity of Clone B6.H-4.1c for the analogue p41-49/45A, 
target cells were co-incubated with 2 pM to 2 µM concentrations of p41-49/45A and a 
100 nM concentration of either MI B chain p7-15 or p41-49/44A for 20 minutes.  Again, 
positive and negative internal controls were included for each experiment and consisted 
of target cells pre-incubated with 50 nM of analogue p41-49/45A or media in the absence 
of competitor peptides.  As shown in Figure 5 and Table III, approximately 7-fold and 
15-fold higher concentrations of analogue p41-49/45A are required for optimal target 
lysis when H-2Kb- and H-2Db-bearing target cells were co-incubated with 100 nM MI B 
chain p7-15.  The addition of 100 nM p41-49/44A analogue results in a significant (~3-
fold) increase in the concentration of analogue p41-49/45A required for optimal lysis of 
H-2Db-bearing target cells (Figure 5 and Table III).  This competitor peptide,              
p41-49/44A, does not significantly increase the concentration of analogue p41-49/45A 
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required for H-2Kb-restricted lysis.  This may be due to enhanced stabilization of           
H-2Kb/p41-49/45A complexes when compared to analogue p41-49/44A (Figure 2). 
 
Essential TCR contacts with horse cyt c p41-49 are disrupted by the single amino acid 
substitution (Pro44→ Ala), thus ablating Clone B6.H-4.1c cytolysis   
To determine whether critical TCR-peptide contacts are disrupted following 
single amino acid substitution, (P44A) and (G45A), computer-generated molecular 
models of H-2Kb and H-2Db associated with native p41-49, p41-49/44A or p41-49/45A 
were constructed.  Each peptide was introduced into the antigen-binding cleft of the x-ray 
crystal structure for H-2Kb complexed with the SEV-9 [F-A-P-G-N-Y-P-A-L] (37,38) or 
H-2Db complexed with influenza A p366-374 [A-S-N-E-N-M-E-T-M] (39).  As depicted 
in Figure 6, peptide overlays show that the carbon backbone configuration for horse cyt c 
p41-49 and the analogue peptides bound to H-2Kb (Figure 6A and C) are comparable 
with the exception of the carboxyl terminus.  A distal carbon backbone shift is seen for 
the carboxyl terminal anchor residue, Thr49, for both p41-49/44A and p41-49/45A.  
Concomitantly, the side chain of Thr49 was rotated in the D pocket for both analogue p41-
49/44A and analogue p41-49/45A.  Individual residue side chain orientations were also 
affected by the Ala substitutions at p4 or p5.  As these peptide overlays clearly showed, 
residues Glu42, Phe46, Thr47 and Tyr48 in both the p41-49/44A and p41-49/45A analogue 
underwent conformational changes affecting R-group orientation.  The most striking 
residue side chain modification influencing available TCR-peptide contact, with the 
exception of the P44A substitution, involves Phe46 found at peptide position p6.  The 
aromatic ring of Phe46 is rotated approximately 60o for both p41-49/44A and p41-49/45A 
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compared to native horse cyt c p41-49.  As noted previously (Frankenberry et al, 
manuscript submitted), this residue constitutes the largest proportion of the surface-
accessible area available for contact by the Clone B6.H-4.1c TCR when engaged with 
native horse cyt c p41-49. 
 The carbon backbone configurations of horse cyt c p41-49 and the analogue 
peptides bound to H-2Db are comparable, with the exception of a distal shift of Ala43 in 
both p41-49/44A and p41-49/45A (Figure 6B and D).  The shift in the carbon backbone 
primarily affects the orientation of the imino ring of Pro44 found in p41-49/45A, and 
contributes to modest residue side chain modifications at Phe46, Thr47 and Tyr48 in both 
peptide analogues.  Unlike the dramatic rotation of the aromatic ring of Phe46 for both cyt 
c p41-49 analogues when bound to H-2Kb, there was a minor, but clearly distinguishable, 
change in the orientation of this aromatic ring when these peptides are bound to H-2Db.  
Computer-generated molecular models (Figure 6B and D) indicated that the distal shift of 
the imino ring of Pro44 at peptide position p4 and the change in orientation of the 
aromatic ring of Phe46 resulted in decreased surface-accessibility of TCR-peptide contact 
residues.  Thus, changes in peptide-specific sites of TCR engagement accounted for the 






 In this paper we addressed the potential role of a type II β bend, attributed to the 
presence of a Pro44-Gly45 dipeptide, in determining the dual-reactive response of CTL 
Clone B6.H-4.1c to H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.  We 
previously demonstrated that the CD8+ CTL Clone B6.H-4.1c was specific for the horse 
cyt c-derived peptide, cyt c p41-49, presented in the context of H-2Kb, H-2Db as well as 
the mutant molecule, H-2Kbm1 (9).  Recently, our observations revealed that the horse cyt 
c p41-49 dipeptide sequence, Pro44-Gly45, formed a type II β bend that facilitated binding 
to both H-2Kb and H-2Db molecules.  Ploegh and coworkers (27,28) predicted that 
nonameric peptides have the capacity to bind to H-2Kb molecules if the peptide sequence 
contains Pro-Gly residues in tandem.  They showed that the presence of a Pro-Gly 
dipeptide sequence causes a configurational restraint that facilitates binding of SEV-9 to 
H-2Kb at concentrations comparable to that for the known H-2Kb-restricted octamers, 
VSV-8 and OVA257-264 (27).   
The presence of a Pro-Gly dipeptide sequence is also important for the 
maintenance of the type II β bend of peptides derived from HIV-1 envelope glycoprotein 
gp120 (41).  In this study, the presence of secondary structure elements found in 
immunogenic peptides of 12, 24 and 40 residues in length were analyzed by nuclear 
magnetic resonance (NMR).  Although the majority of peptide residues lack a defined 
folded structure, the regions containing the conserved Pro-Gly sequence indicated a type 
II β bend (41).  Analysis of site-directed mutations in the hen lysozyme gene illustrated 
the importance of Pro-Gly sequences in maintaining the global structure and function of 
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intact proteins (42).  Disruption of the Pro-Gly induced β-sheet resulted in minor 
structural changes but contributed to a significant decrease in the activity of the lysozyme 
molecule (42).  Likewise, site-directed mutagenesis of the yeast iso-1-cyt c type II β 
bend, contributed by the conserved Pro76-Gly77 sequence, resulted in a significant 
decrease in protein function (43). 
We (9 and Frankenberry et al, manuscript submitted) recently proposed that the 
Pro44-Gly45 sequence in horse cyt c p41-49 forms a type II β bend that not only facilitates 
binding to H-2Kb and H-2Db, but also causes the peptide to protrude out of the antigen-
binding cleft, thus providing essential contacts for the Clone B6.H-4.1c TCR.  Computer-
generated molecular models of these MHC/peptide complexes suggest that Pro44 and 
Phe46 at peptide positions p4 and p6 represented the major solvent-exposed residues 
available for TCR engagement when horse cyt c p41-49 was presented in the context of 
H-2Kb and H-2Db.  Due to the close similarity in the orientation and extent of surface-
accessibility, we hypothesized that the H-2Kb- and H-2Db-restricted recognition of horse 
cyt c p41-49 by Clone B6.H-4.1c is dependent upon the solvent-exposed imino group of 
Pro44 at peptide position p4.  We obtained horse cyt c p41-49 analogues consisting of a 
single Ala substitution, (P44A) and (G45A), at peptide positions p4 and p5, respectively 
and evaluated the effect of disrupting the type II β bend on H-2Kb- and H-2Db-binding 
and Clone B6.H-4.1c recognition. 
 We first determined the cytolytic response of Clone B6.H-4.1c to analogues    
p41-49/44A and p41-49/45A, at a constant 2 µM concentration, by performing standard 
4-h 51Cr-release assays (Figure 1).  Clone B6.H-4.1c CTL effectors recognize analogue 
p41-49/45A but not p41-49/44A when presented by H-2Kb- and H-2Db-expressing target 
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cells.  This suggests that either analogue p41-49/44A fails to bind to and stabilize the 
class I H-2b molecules, or that the P44A substitution induces MHC/peptide conformation 
changes that inhibit Clone B6.H-4.1c recognition.   
Based on the peptide-binding motifs described by Rammensee and coworkers for 
H-2Kb (40), both horse cyt c p41-49 analogues contain a single dominant anchor and a 
weak anchor for binding to H-2Kb (Table I).  The p41-49/45A analogue also contains the 
weak anchor Pro44 at peptide position p4.  Both p41-49/44A and p41-49/45A contain a 
single strong anchor and three weak anchor residues described for binding to H-2Db (40) 
(Table II).  The absence of the weak anchor, Pro44, in p41-49/44A may influence H-2Kb, 
but not H-2Db, binding and presentation.  Alternatively the P44A substitution could 
disrupt the type II β bend such that p41-49/44A no longer forms MHC-peptide 
interactions necessary for stable expression of these H-2b molecules. 
We performed RMA-S stabilization assays to address the possibility that         
p41-49/44A fails to form stable MHC/peptide complexes directly.  These results show 
(Figure 2) that both p41-49/44A and p41-49/45A are bound to and stabilize H-2Kb and 
H-2Db molecules.  Native horse cyt c p41-49 and p41-49/44A exhibit similar rates of 
dissociation from both class I MHC molecules.  These results also reveal efficient 
binding of p41-49/45A to H-2Kb and enhanced MHC/peptide complex stability.  In 
additionally, we show that although analogue p41-49/45A is presented in the context of 
H-2Db, it exhibits a rapid rate of dissociation. 
To determine the cytolytic activity of Clone B6.H-4.1c for H-2Kb and H-2Db 
complexed with native horse cyt c p41-49 or p41-49/45A, peptide titration studies 
(Figure 3 and Table III) were performed.  A minimal peptide concentration of ~4 nM and 
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~2 nM is required for Clone B6.H-4.1c recognition of native horse cyt c p41-49 presented 
by H-2Kb and H-2Db, respectively.  Conversely, the Clone B6.H-4.1c lytic response to 
p41-49/45A associated with H-2Kb and H-2Db requires significantly higher 
concentrations, >30-fold and >30-fold respectively.  We also performed peptide 
competition studies, using p41-49/44A and MI B chain p7-15 as competitor peptides, to 
evaluate the efficiency of Clone B6.H-4.1c recognition for H-2Kb and H-2Db molecules 
associated with native horse cyt c p41-49 or p41-49/45A.  The introduction of either 
competitor peptide significantly increases the target peptide (native horse cyt c p41-49 or 
p41-49/45A) concentration required for optimal target cell lysis (Figures 4 and 5; Table 
III).  The non-horse cyt c related peptide, MI B chain p7-15, acts as the best peptide 
competitor, requiring higher concentrations of both target peptides for Clone B6.H-4.1c 
recognition of H-2b/peptide complexes.  It may well be that the Gly8-Pro9 sequence 
located within MI B chain p7-15 mimics, at least in part, the H-2Kb/p41-49 and             
H-2Db/p41-49 complexes. 
Clearly, these findings show that the Clone B6.H-4.1c TCR is able to distinguish 
minute changes in the MHC/peptide conformation caused by the G45A substitution, as 
well as the P44A substitution.  These findings are in agreement with several reports 
which indicates that a single amino acid substitution in the target peptide primary 
sequence can cause alterations in MHC/peptide conformation, without affecting the 
number of complexes available to the TCR, and consequently interfere with T cell 
recognition (44-47). 
Combinatorial peptide libraries were utilized by Joyce and coworkers (26) to 
show that two unique CTL clones require only one of four putative TCR contact residues 
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for target cell recognition.  We previously demonstrated that Pro44 and Phe46 at peptide 
positions p4 and p6 represent the major solvent-exposed residues available for TCR 
contact when horse cyt c p41-49 is presented in the context of H-2Kb and H-2Db 
(Frankenberry et al, manuscript submitted).  Peptide overlays (Figures 6A and 6C) of 
native horse cyt c p41-49 and both peptide analogues show a distal carbon backbone shift 
at Thr49 in the carboxyl terminus for p41-49/44A and p41-49/45A.  The aromatic ring of 
Phe46 is rotated approximately 60o for both analogues bound to H-2Kb, and a minor shift 
occurs in their carbon backbones at Ala43 when bound to H-2Db (Figure 6B and D).  
Unlike the observations for p41-49/44A and p41-49/45A bound to H-2Kb, there is a small 
but distinguishable change in the orientation of the aromatic ring of Phe46 when they bind 
to H-2Db.  In addition the imino group of Pro44, absent in analogue p41-49/44A, remains 
relatively unaltered for analogue p41-49/45A bound to H-2Kb or H-2Db.  Thus, the lack 
of responsiveness of Clone B6.H-4.1c to both H-2Kb/p41-49/44A and H-2Db/p41-49/44A 
complexes is likely due to the loss of Pro44 at peptide position p4.  Also the shift of the 
aromatic ring of Phe46 directly affects the cytolytic response of Clone B6.H-4.1c for      
H-2Kb/cyt c p41-49 and H-2Kb/p41-49/45A complexes (Figures 3 – 5 and Table III).  
Furthermore, the partial response of Clone B6.H-4.1c for p41-49/45A bound to H-2Kb 
appears to be largely due to a change in orientation of the aromatic ring of Phe46 at 
peptide position p6.  Although computer-generated molecular models suggest that few 
alterations exist in the overall configuration of p41-49/45A bound to H-2Db, the RMA-S 
stabilization experiments clearly show that this peptide dissociates rapidly from the        
H-2Db molecule.  This rapid dissociation of p41-49/45A from H-2Db corresponds more 
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closely to the decreased responsiveness of Clone B6.H-4.1c than overt changes in peptide 
configuration. 
Several investigators have described CTL clones that respond to a single peptide 
presented in the context of more than one MHC molecule (6-12).  Various explanations 
have been proposed to account for the observed degenerate T cell restriction 
demonstrated by these CTL clones.  One consideration is that TCR interactions may be 
dependent on specific peptide configurations located in the central solvent-exposed 
portions of the MHC/peptide complex.  Thus, degenerate T cell restriction may involve 
some cross-reactivity for common peptide configurations shared by multiple 
MHC/peptide complexes.  This is reinforced by studies showing that a single MHC 
molecule can present up to 104 different peptides on the cell surface and proteasomes and 
TAP transporters are highly selective for the peptides they convey into the ER (48-50).  
The results described in this paper support for this model; in that a P44A 
substitution in horse cyt c p41-49 abrogates recognition of both H-2Kb/p41-49/44A and 
H-2Db/p41-49/44A complexes.  Although removal of the centrally located, solvent-
exposed Pro44 residue at peptide position p4 does not adversely affect binding to either  
H-2Kb or H-2Db, it disrupts interactions with the TCR of Clone B6.H-4.1c that are 
essential for recognition.  The G45A substitution also contributes directly to decreased 
recognition of Clone B6.H-4.1c for H-2Kb/p41-49/45A complexes by altering the 
orientation of available TCR contact residues, thus reducing Clone B6.H-4.1c TCR 
interactions despite the presence of the imino group contributed by Pro44.  The G45A 
substitution may also indirectly contribute to the decreased CTL response to H-2Db/p41-
49/45A complexes by inducing configurational constraints that promote the rapid 
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dissociation of this peptide from H-2Db.  Overall, the findings in this paper suggest that 
the solvent-exposed R groups of both Pro44 and Phe46 are critically important for Clone 
B6.H-4.1c recognition of H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.  The 
presence of the imino group contributed by Pro44 is necessary for recognition by Clone 
B6.H-4.1c and the Gly45 residue is responsible for the proper orientation of the aromatic 




The Kb-restricted peptide-binding motif for native horse cyt c p41-49, analogue  
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The Db-restricted peptide-binding motif for native horse cyt c p41-49, analogue  
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Peptide competition assays reveal that significantly higher concentrations of native 
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p < 0.05 
 
1 Optimal peptide concentrations determined as the peptide concentration required to  
   yield 30% lysis by Clone B6H-4.1c. 
2 Statistical significance determined by Student’s t-test as described in the Materials and  
   Methods. 
3 Peptide concentrations are given as the mean of five separate experiments for optimal  
   peptide concentrations and three separate experiments for peptide competition assays,  





FIGURES AND FIGURE LEGENDS 
 
 
Fig. 1 Clone B6.H-4.1c recognizes the horse cyt c analogue, p41-49/45A, but not 
analogue p41-49/44A. 
L + Kb, L + Db and LMTK- 51Cr-labeled target cells were incubated for 20 min in the 
presence or absence (Ο) of 2 µM concentrations of target peptide, horse cyt c p41-49 (●), 
analogue p41-49/44A (■) or analogue p41-49/45A (▲).  After peptide incubation, the 
CTL Clone B6.H-4.1c was added at an effector-to-target ratio of 30:1, 10:1, 3:1 and 1:1 
and supernatants were collected 4 h later.  Supernatants (100 µl) were collected and 
cytolytic activity was represented by the "percent specific lysis".  Spontaneous release of 
targets in the absence of CTL effectors was <10% of maximum lysis by detergent in all 











Fig. 2 Native horse cyt c p41-49 and the analogues, p41-49/44A and p41-49/45A, 
stabilize H-2Kb and H-2Db molecules. 
2.5 X 106 RMA-S cells were pulsed with 10 µM concentrations of horse cyt c p41-49 
(●), analogue p41-49/44A ( ), analogue p41-49/45A (▲) or media (Ο) for 1 h at 30oC, 
5% CO2.  Cells were then washed to remove excess unbound peptide and incubated for 0, 
30, 60, 120 and 180 min at 37oC, 7% CO2.  At each time point, 5 X 105 cells were 
removed and stained for the presence of stable surface H-2Kb (A) and H-2Db (B) 
molecules.  Mean channel fluorescence was determined by flow cytometric analysis and 
was represented as the fluorescence index as described in Materials and Methods.  A 








Fig. 3 Significantly higher analogue p41-49/45A peptide concentrations1 are 
required for optimal target cell lysis by Clone B6.H-4.1c. 
  L + Kb (A), L + Db (B) and LMTK- (Ο) cells were incubated for 20 min in the presence 
of varying concentrations (2 pM to 2 µM) of target peptide, horse cyt c p41-49 (●), 
analogue p41-49/44A (■) or analogue p41-49/45A (▲).  After peptide incubation, Clone 
B6.H-4.1c was added at an effector-to-target ratio of 3:1 for 4 h.  Supernatants (100 µl) 
were collected and cytolytic activity was represented by the "percent specific lysis".  
Spontaneous release of targets in the absence of CTL effectors was <10% of maximum 
lysis by detergent in all experiments.  A single representative of five separate experiments 
is shown. 
1 Minimal peptide concentrations were determined as the peptide concentration required 






Fig. 4 Clone B6.H-4.1c responsiveness to horse cyt c p41-49 is inhibited by the 
competitor peptides, MI B chain p7-15 and analogue p41-49/44A. 
L + Kb (A) and L + Db (B) cells were incubated for 20 min in the presence of varying 
concentrations (2 pM to 2 µM) of target peptide, horse cyt c p41-49, plus the competitor 
peptides, MI B chain p7-15 (□) and analogue p41-49/44A ( ), at a constant 
concentration of 10 µM.  Additionally, 51Cr-labeled L + Kb and L + Db target cells were 
incubated with 50 nM of target peptide, horse cyt c p41-49 (●), or media (Ο) alone as 
positive and negative controls for these experiments.  After peptide incubation, Clone 
B6.H-4.1c was added at an effector-to-target ratio of 3:1 for 4 h.  Supernatants (100 µl) 
were collected and cytolytic activity was represented by the "percent specific lysis".  
Spontaneous release of targets in the absence of CTL effectors was <10% of maximum 
lysis by detergent in all experiments.  A single representative of three separate 









Fig. 5 Clone B6.H-4.1c responsiveness to analogue p41-49/45A is inhibited by the 
competitor peptides, MI B chain p7-15 and analogue p41-49/44A. 
L + Kb (A) and L + Db (B) cells were incubated for 20 min in the presence of varying 
concentrations (2 pM to 2 µM) of target peptide, analogue p41-49/45A, plus the 
competitor peptides, MI B chain p7-15 (□) and the analogue p41-49/44A ( ), at a 
constant concentration of 100 nM. Additionally, 51Cr-labeled L + Kb and L + Db target 
cells were incubated with 50 nM of target peptide, analogue p41-49/45A (▲), or media 
(Ο) alone as positive and negative controls for these experiments.  After peptide 
incubation, Clone B6.H-4.1c was added at an effector-to-target ratio of 3:1 for 4 h.  
Supernatants (100 µl) were collected and cytolytic activity was represented by the 
"percent specific lysis".  Spontaneous release of targets in the absence of CTL effectors 
was <10% of maximum lysis by detergent in all experiments.  A single representative of 









Fig. 6 Essential TCR contacts with horse cyt c p41-49 are disrupted by the single 
amino substitution (Pro44 → Ala), thus abrogating Clone B6.H-4.1c recognition. 
The target peptides, horse cyt c p41-49 (blue), analogue p41-49/44A (green) and 
analogue p41-49/45A (red), were introduced into the antigen-binding site of H-2Kb (A) 
and H-2Db (B) by single step substitution using x-ray crystal structure coordinates 
determined for H-2Kb complexed with SEV-9 (PDB 1vab) and H-2Db complexed with 
influenza A p366-374 (PDB 1hoc).  Each molecular model was represented as viewed 
from above the peptide-binding cleft (A and B) and as a side view (C and D).  The 
peptides are represented as stick figures and individually colored.  Molecular models 
were generated using a UNIX-based computer with QUANTA/CHARMm software 
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The success of clinical transplantation is largely dependent upon the development 
of immunosuppressive treatment regimens using prednisone, cyclosporine A and 
tacrolimus (also called FK506).  One concern with such therapeutic interventions is their 
adverse impact on the recipient's overall immune status due to a generalized inhibition of 
T cell responsiveness.  To circumvent this problem, we proposed to distinguish and 
remove allospecific CTLs from the T cell repertoire, based on TCR Vβ family usage.  
Using a panel of mAbs specific for 14 distinct TCR Vβ  families, accounting for >95% of 
splenic T cells, we show the expansion of CD8+ Vβ families - 8.1/8.2, 9, 10, 12, and 14 - 
in bm19 anti-C57BL/6 cultures.  Analysis of the functional reactivity of CD8+ T cells 
from these families, however, implicates only bm19 Vβ9+ and Vβ12+ CTLs as effective 
alloreactive responders against H-2Kb-expressing targets.  Thus, for bm19 CTLs 
stimulated in vitro with B6 spleen cells, Kb-specific alloreactivity resides largely, if not 
completely, within both Vβ9 and Vβ12 families.  Importantly, after removing both Vβ9 
and Vβ12 alloreactive CTLs, the remaining CTLs are still fully responsive to other       
Kb-restricted antigens, as shown by their reactivity to VSV-8 and insulin B chain p7-15 
peptides, and to unrelated H-2d alloantigens.  This study constitutes the first 
demonstration of the synergistic effects of two CTL Vβ families on alloreactivity.  
Furthermore, these findings suggest that removal of transplant-specific, alloreactive 
CTLs in vivo may be an effective means to diminish the reliance on nonspecific 




The clinical use of immunosuppressive drugs as a successful therapy to prevent 
graft rejection in transplantation is accompanied by adverse side effects on the overall 
immune status of transplant patients, with the long-term use of these drugs leading to a 
diminished overall quality of life.  Owing in part to a generalized suppression of T cell 
responsiveness in these patients, cell-mediated immunity is compromised by the very 
drugs administered to overcome the T cell mediated rejection of transplanted tissues and 
organs (1-4).  In this study, we first asked whether a single T cell receptor (TCR) Vβ 
family is responsible for the alloreactive cytotoxic T lymphocyte (CTL) response in a 
class I major histocompatibility complex (MHC) disparate mouse model.  Secondly, we 
addressed whether removing this Vβ family could lead to abrogation of the in vitro 
alloreactive CTL response, without compromising the cell-mediated immune response to 
other foreign antigens. 
Acute allograft rejection and graft-versus-host disease (GVHD) are mediated by 
alloreactive T lymphocytes, including CD8+ CTLs that respond to foreign class I MHC 
molecules on engrafted donor tissue (5-9).  Alloreactive CTLs express a membrane 
bound TCR that interacts with the complex of a small peptide bound to the antigen 
binding cleft on the distal surface of a class I MHC molecule (10,11).  The TCR is a 
disulfide-linked heterodimeric glycoprotein formed by the somatic recombination of α 
and β chain V-(D)-J segments (11,12) and is able to recognize potential foreign 
MHC/peptide complexes (13).   
 The myriad of possible TCR α and β chain combinations can theoretically 
generate a highly diverse CTL population comprised of a wide range of TCR 
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specificities.  Despite the findings of some studies describing the random use of TCR Vβ 
regions for T cells involved in alloreactive responses (14,15), considerable evidence 
indicates there is a preference for the biased usage of certain TCR Vβ families in both 
human (16-19) and murine (20-23) alloreactive T cell responses. 
 Studies by Grandea III and Bevan (24) using the MHC class I H-2Kb transgenic 
mouse mutant, H-2Kb,E65, suggest that even a single amino acid disparity in the H-2Kb 
molecule can generate a strong alloreactive CTL response.  This transgenic mouse has a 
solitary amino acid substitution at position 65 (Gln65 → Glu) located on the outward face 
of the α-helix of the α1 domain that interacts with the TCR but does not affect the 
peptide-binding groove (24).  Strong H-2Kb,E65 alloreactive CTL responses are generated 
against the wild-type Kb-expressing target cell line and against several mutant target 
cells, including H-2Kb,D65 (Gln65 → Asp), H-2Kb,R65 (Gln65 → Arg) and H-2Kb,V65   
(Gln65 → Val).  These findings suggest that cross-reactive T cells may have a higher TCR 
affinity for nonconserved amino acid changes (24).  In the present study, designed to 
assess the extent of TCR Vβ family usage among alloreactive CTLs, we selected the B6-
derived mutant mouse model, designated bm19 (25,26), that has only a single amino acid 
substitution at position 80 (Thr80 → Asn) of the H-2Kb molecule to evaluate specific 
bm19 CD8+ TCR Vβ families involved in the CTL response to H-2Kb. 
Using a similar approach, Connolly and coworkers (27) evaluated the primary Ld-
specific CTL response of the Ld-loss mutant, dm2, when stimulated with irradiated wild-
type BALB/c spleen cells.  Their results implicated Vβ8+ alloreactive CTLs as effectors 
of the Ld-specific response.  The addition of the anti-Vβ8 monoclonal antibody (mAb), 
 
 139
F23.1, to a standard 4-h 51Cr-release assay diminished the H-2Ld-specific CTL response 
by approximately 80% (27).   
We established one-way mixed lymphocyte cultures (MLC) using spleen cells 
from the mutant mouse strain B6.H-2bm19 (bm19) (26) and the parental strain, C57BL/6 
(B6).  Mice from the bm19 mutant strain differ from the B6 parental strain by a single 
amino acid substitution (Thr80 → Asn) located on the distal surface of the H-2Kb α1 helix 
(28).  In this study, we employed a panel of 14 different TCR Vβ-specific mAbs from 
Pharmingen© (Becton-Dickinson, Mountain View, CA) to distinguish alloreactive CTLs 
based on their expression of distinct Vβ regions.  We utilized flow cytometry to identify 
five distinct CD8+ Vβ families that are expanded in both short- and long-term bm19 anti-
B6 MLC.  Selective removal of preferentially expanded bm19 anti-B6 CTLs, by indirect 
panning in vitro, abrogates alloreactivity against H-2Kb-bearing target cells.  
Furthermore, depletion of these bm19 anti-B6 CTLs did not impair the antigen-specific 
response of bm19 CTLs to the immunogenic peptides, vesicular stomatitis virus 
nucleoprotein p52-59 (VSV-8) (29,30) and mouse insulin I (MI) B chain p7-15 (31), nor 
to unrelated H-2d alloantigens.  Thus, the removal of Vβ families in vivo should 
significantly prolong allograft survival.  An important advantage of this approach over 
conventional immunosuppressive drug regimens lies in its preservation of normal cell 




MATERIAL AND METHODS 
Animals 
Female B6 and bm19 mice (26) used in this study were obtained from this laboratory's 
breeding colony at West Virginia University Health Sciences Center Vivarium.  The B6 
and bm19 breeding colonies were established in 1987 and have been maintained since 
then at the West Virginia University Health Sciences Center Vivarium.  All female mice 
used in this study were 8-12 wks of age. 
 
Target cell lines 
The hybridoma cell line, SP2/0 AG.14 (SP2/0) (H-2d) (32,33), was used as a fusion 
partner for generating S.B6 and S.bm19 T cell hybridoma targets.  These hybridomas 
were generated in our laboratory, and appropriate H-2b class I expression was verified by 
flow cytometric analysis (data not shown).  The murine T lymphoma cell line, EL-4     
(H-2b) (34,35) and mastocytoma cell line, P815 (H-2d) (35,36) were used as targets for 
51Cr-release assays to measure CTL-mediated lysis.  These cell lines were grown as 
suspension cultures in RP-10 (RPMI-1640 media supplemented with 10% FCS, 100 mM 
HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine), as 




Synthesis of peptides 
Peptides, VSV-8 [R-G-Y-V-Y-Q-G-L] and MI B chain p7-15 [C-G-S-H-L-V-E-A-L], 
synthesized by fMoc chemistry using an automated peptide synthesizer (9050 MilliGen 
PepSynthesizer) as previously described (30), were generously provided by Drs. J. W. 
Yewdell and J. R. Bennink.  Amino acid composition and purity was determined by 
HPLC tracing (Waters 600E) and the Pico Tag Amino Acid Analysis System (Waters) (J. 
W. Yewdell and J. R. Bennink, personal communication).  Lyophilized peptides were 
solubilized in sterile 1X PBS at appropriate stock concentrations. 
 
Antibodies and flow cytometric analysis 
Phycoerythin (PE)-conjugated anti-CD8α mAb [designated 53-6.7] (38) and fluorescein 
isothiocyanate (FITC)-conjugated anti-Vβ2 mAb [B20.6] (39), anti-Vβ4 mAb [KT4] (40), 
anti-Vβ5.1/2 mAb [MR9-4] (41), anti-Vβ6 mAb [RR4-7] (42), anti-Vβ7 mAb [TR310] 
(43), anti-Vβ8.1/8.2 mAb [F23.1] (44), anti-Vβ8.3 mAb [1B3.3] (45), anti-Vβ9 mAb 
[MR10-2] (45), anti-Vβ10b mAb [B21.5] (39), anti-Vβ11 mAb [RR3-15] (46), anti-Vβ12 
mAb [MR11-1] (45), anti-Vβ13 mAb [MR12-3] (45), anti-Vβ14 mAb [14-2] (47), and 
anti-Vβ17a mAb [KJ23] (48) were purchased from Pharmingen (Becton Dickinson, 
Mountain View, CA).  Effector cells (5 X 105) were incubated for 45 min on ice with 20 
µl (1:100) of each of the 14 FITC-conjugated anti-TCR Vβ-specific mAb and 20 µl (1:96) 
of PE-conjugated anti-CD8α mAb, washed twice with 1X PBS and fixed in 500 µl 1% 
formalin.  Fixed cells were analyzed for fluorescence intensity using a FACScan flow 
cytometer (Becton Dickinson, Mountain View, CA).  Percent Vβ expression of 
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alloreactive CTLs was defined as 100 X (Vβn value/sum of Vβ values), as described 
previously (49). 
 
Short- and long-term alloreactive MLC 
Alloreactive CTL lines were generated as previously described (31,50) with the following 
modifications: The initial priming (1o) of bm19 anti-B6 MLC was accomplished by 
culturing 2.5 X 107 female bm19 spleen cells with 2.5 X 107 irradiated (3000 rads) 
stimulator splenocytes from female B6 mice.   1o bm19 anti-B6 MLCs were maintained 
in 10 ml RP-10 per flask for 7 days at 37oC with 7% CO2 and 95% humidity in upright 
25-cm2 tissue culture treated (T-25) flasks (Costar).  Short-term (2o) alloreactive MLC 
were established by culturing 5 X 106 effector splenocytes from 1o bm19 anti-B6 MLC 
with 2.5 X 107 irradiated splenocytes from female B6 mice on day 7.  Secondary (2o) 
bm19 anti-B6 MLC were maintained under the same conditions as described for the       
1o bm19 anti-B6 MLCs.  Subsequent long-term alloreactive MLCs were established by 
culturing 4 X 105 effector splenocytes from previous bm19 anti-B6 MLC with 5 X 106 
irradiated female B6 splenocytes on day 7.  Each long-term MLC was supplemented with 
5% interleukin-2 (IL-2)-enriched rat concanavalin A supernatant (ConA SN) and 5% 1M 
α-methyl mannoside (α-MM).  Long-term bm19 anti-B6 MLCs were maintained in a 24-
well cell culture cluster plate (Costar) at 37oC with 7% CO2 and 95% humidity. 
 
Analysis of in vitro T cell proliferation  
The proliferative capacities of 1o bm19 anti-BALB/c, bm19 anti-VSV-8 and bm19       
anti-MI B chain p7-15 CTLs, were determined on day 4 by measuring the incorporation 
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of 3H-TdR (51).  Briefly, 5 X 105 bm19 anti-BALB/c, bm19 anti-VSV-8 (29,30) and 
bm19 anti-MI B chain p7-15 (37) effector cells were incubated in 100 µl volume of RP-
10 plus 2 µCi tritiated thymidine [3H-TdR] in a 96-well U-bottom plate for 18 h.  All 
assays were performed in triplicate.  After incubation, cells were harvested using a 
Cambridge Technology, Inc. PHD Cell Harvester (Cambridge, MA), and 3H-TdR 
incorporation was measured on a Wallac 1410 Liquid Scintillation Counter (Wallac, 
Gaithersburg, MD). 
 
Analysis of in vitro CTL lytic activity  
The lytic activity of bm19 anti-B6 MLC-derived CTLs was assayed in vitro on day 5 
using a standard 4-h 51Cr-release assay, as described previously (52).  Briefly, 1 X 106 
SP2/0, S.B6 or S.bm19 target cells were incubated in 50 µl RP-10 media + 100 µCi 
sodium chromate 51 (51Cr; New England Nuclear, Boston, MA) / 106 cells for 60 min at 
37oC 7% CO2, washed in 1X HBSS and resuspended in 10 ml RP-10.  Following a 30 
min incubation at 37oC, target cells were washed in 1X HBSS and resuspended in RP-10 
media at a final concentration of 2 X 105 cells/ml.  Target cells were added in 50 µl/well 
RP-10 to 96-well round-bottom microtiter plates.  Exogenous peptides to be tested were 
added in 50 µl/well RP-10, with a final concentration of 2 µM, and incubated for 20 min 
at 37oC, 7% CO2.  In the absence of exogenous peptides, target cells were added to each 
well at a final concentration of 1 X 104 cells/200 µl.  Effector cells from bm19 anti-B6 
MLCs were added at effector-to-target ratios of 100:1, 50:1, 25:1 12.5:1, 6.3:1 and 3.1:1.  
Assay plates were incubated for 4 h at 37oC, 7% CO2 and centrifuged for 7 min at 1200 
rpm.  Supernatants (100 µl) were collected from each well and transferred to 6 X 50 mm 
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tubes for determination of total 51Cr counts on an LKB Clinigamma Model 1272 counter 
(LKB Instruments, Finland).   
The "percent specific lysis" value for 51Cr-release assay results was determined as 
follows: 
experimental cpm - spontaneous cpm 
_____________________________________________ X 100 
         maximum - spontaneous cpm 
 
Spontaneous release values of targets in the absence of CTL effectors were <10% of 
maximum lysis by detergent in all experiments.  Cytolytic activity is represented as lytic 
units (LU), where one LU is equal to the number of alloreactive CTLs (X 104) required to 
generate 30% lysis of a given target cell (53). 
 
Indirect T cell panning 
Falcon 1005 OPTILUX petri dishes were pre-coated with 10 µg/ml goat anti-mouse IgG, 
goat anti-rat IgG, or goat anti-rat IgM in 50 mM Tris buffer, pH 9.5 at a final volume of 
10 ml.  Plates were incubated overnight at 4oC, washed 3X with cold 1X PBS 
supplemented with 1% FCS (1% PBS) and stored at 4oC in 15 ml 1% PBS.  Spleen cells 
from female bm19 mice were depleted of red blood cells with 0.17M Tris-buffered 
0.16M NH4Cl at pH 7.2, washed 2X with HBSS and enriched for T cells by nylon wool 
column exclusion (54,55).  After T cell enrichment, cells were resuspended at 1 X 106 
cells/ml in 1X PBS and incubated with 1 µg/ml unconjugated mouse IgG2a anti-Vβ8.1/8.2 
[F23.1], mouse IgG1 anti-Vβ9 [MR10-2], rat IgG2a anti-Vβ10b [B21.5], mouse IgG1 anti-
Vβ12 [MR11-1], rat IgM anti-Vβ14 [14-2] and/or mouse IgG2a anti-Vβ17 [KJ23] mAb for 
30 min at 4oC.  Cells were washed 3X and resuspended in 1% PBS, and incubated on 
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appropriate pre-coated petri dishes at 4oC for 60 min with gentle shaking every 15 min.  
Non-adherent cells (Vβ-) were collected, plates were washed with 5 ml cold 1% PBS and 
adherent cells (Vβ+) were dislodged by gentle scraping with a rubber policeman.  
Recovered cells (Vβ-enriched and Vβ-depleted) were washed twice in 5 ml 1% PBS, and 
5 X 105 cells were analyzed by flow cytometry as described above, for each Vβ family 
examined.  After the cells were collected, 4 X 105 Vβ-enriched or Vβ-depleted cells were 
cultured with 5 X 106 irradiated B6 splenocytes and maintained for three wks in a 24-well 
cell culture cluster plate (Costar).  Cultures of Vβ-enriched and Vβ-depleted 3o anti-B6 
effectors were supplemented with 5% IL-2-enriched rat Con A and 5% 1M α-MM and 
evaluated on day 5 for B6-specific alloreactivity in a 4-h 51Cr-release assay. 
 
Statistical analysis 
All statistics in this study were performed by one-way analysis of variance (ANOVA).  






Short- and long-term bm19 anti-B6 MLCs exhibit strong alloreactivity for H-2Kb-bearing 
target cells. 
 We first addressed whether a single amino acid difference in the H-2Kb molecules 
expressed by B6 and bm19 mice is sufficient to induce a strong alloreactive CTL 
response by assessing the lytic capacity of bm19 splenocytes stimulated with allogeneic 
B6 splenocytes.  To determine the lytic capacity of short- and long-term MLCs generated 
against this single amino acid difference between the Kb and Kbm19 molecules           
(Thr80 → Asn) expressed on the α1 helix region by B6 and bm19 mutant strains, 
respectively, bm19 mutant (Kbm19; Asn80) splenocytes were stimulated weekly with 
irradiated B6 (Kb; Thr80) splenocytes for a period of seven weeks.  As shown in Figure 1, 
bm19 anti-B6 CTL effectors display strong H-2Kb-specific alloreactivity when tested at 
week 1 (Fig 1A), 5 (Fig 1B) and 7 (Fig 1C) after weekly stimulation.   
 
In vitro expansion of bm19 anti-B6 CTL effectors occurs among five TCR Vβ families. 
To determine whether bm19 anti-B6 CTLs exhibit preferential expansion of 
distinct CD8+ Vβ families under short- and long-term culture conditions, effector cells 
were stained with 14 FITC-conjugated Vβ-specific mAbs and counter-stained with a PE-
conjugated anti-CD8α mAb and analyzed by flow cytometry.  As shown in Figure 2, five 
CD8+ Vβ  families - Vβ8.1/8.2, 9, 10, 12 and 14 - are significantly expanded when 
compared to naïve bm19 spleen cells.  CTL effectors from the 1o bm19 anti-B6 MLC 
display preferential expansion of Vβ8.1/8.2 and Vβ12 families, but 3o bm19 anti-B6 CTLs 
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show increased expression of the Vβ8.1/8.2, Vβ9 and Vβ12.  Interestingly, only the 
Vβ8.1/8.2 and Vβ9 families are preferentially expanded in 5o bm19 anti-B6 MLCs.  All 
five CD8+ Vβ families - 8.1/8.2, 9, 10, 12 and 14 - are preferentially expressed in 7o bm19 
anti-B6 MLC (Figure 2).  The percentage of Vβ+ cells for any given family of CD8+ Vβ 
alloreactive CTLs is defined as follows: 100 X (Vβn value/sum of Vβ values) (49).  These 
findings indicate that multiple bm19 anti-B6 CD8+ TCR Vβ families underwent 
preferential expansion during short- and long-term culture conditions and may be 
involved in the Kb-specific bm19 alloreactive CTL response.   
 
Depletion of Vβ8, Vβ10, Vβ14 or Vβ17 families from naïve bm19 splenic T cells yield fully 
alloreactive 3o bm19 anti-B6 CTL effectors. 
 To determine the lytic activity of different bm19 anti-B6 TCR Vβ populations, 
naïve bm19 spleen cells were first separated into Vβ-depleted and Vβ-enriched fractions 
by indirect panning in vitro on mAb-coated petri dishes, using one of the Vβ-specific 
mAbs described above.  CD8+ T cells from each Vβ family were then stimulated in MLCs 
with irradiated B6 spleen cells, as previously described.  As shown in Figure 3, the 
selective removal or depletion of Vβ8.1/8.2, Vβ14 or Vβ17 bm19 CD8+ T cells has no 
discernible effect on the lytic response of 3o bm19 anti-B6 CTLs against the allogeneic 
target, S.B6.  Enrichment for Vβ8+, Vβ14+ or Vβ17+ bm19 CD8+ T cells, however, results 
in a dramatic reduction in the alloreactive response to S.B6 target cells.  Thus, although 
the bm19 Vβ8+ and Vβ14+ CTLs are expanded during short- and long-term bm19 anti-B6 
MLCs, they do not contribute to the alloreactive response against S.B6 target cells.   
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In these experiments, we relied on the Vβ17 family as a suitable negative control, 
since CD8+ T cells of this Vβ  family are not expanded in 1o, 3o, 5o or 7o bm19 anti-B6 
MLCs (data not shown).  Results for the Vβ10 depletion and enrichment are not shown 
here since this population of potential bm19 anti-B6 CTLs does not undergo statistically 
significant expansion until the seventh week of restimulation (Figure 2). 
 We compared the percentage of unpanned 3o bm19 anti-B6 CTL effectors to that 
of Vβ-depleted and Vβ-enriched 3o bm19 anti-B6 CD8+ T cells from the Vβ8.1/8.2, Vβ10, 
Vβ14 or Vβ17 families to determine the extent of their expansion following mAb-specific 
panning.  As shown in Table I, 3o bm19 anti-B6 CTL effectors consist of 19.4% 
Vβ8.1/8.2+ T cells in the absence of direct panning, while mAb-specific depletion reduces 
this population 5-fold (3.7%).  The depletion of CD8+ Vβ8.1/8.2+ cells also substantially 
reduces the lytic capacity to approximately 9 LU, compared to ~20 LU in unpanned       
3o bm19 anti-B6 MLCs (Table I, column D).  Enrichment for Vβ8.1/8.2 CTLs increases 
this population approximately 4-fold (77.8%) over that of unpanned 3o bm19 anti-B6 
CTLs.  Although the percentage of CD8+ Vβ8.1/8.2+ T cells is increased significantly, its 
lytic capacity is dramatically reduced compared to that of unpanned 3o bm19 anti-B6 
MLCs (approximately 0 LU versus ~20 LU). 
Also shown in Table I, depletion by panning with the Vβ10-specific mAb reduces 
the CD8+ Vβ10+ population 5-fold (1.4%), compared to approximately 8% for unpanned 
CD8+ TCR Vβ10+ T cells in the 3o bm19 anti-B6 MLC.  This Vβ10 depletion 
substantially reduces the lytic capacity to ~6 LU, compared to ~20 LU in the unpanned 3o 
bm19 anti-B6 MLCs.  Enrichment for Vβ10+ CTLs increases the CD8+ Vβ10+ population 
approximately 11-fold (92.3%) over unpanned 3o bm19 anti-B6 MLCs.  Following 
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enrichment for Vβ10+ CTLs, however, the lytic capacity of CD8+ Vβ10+-enriched CTLs is 
reduced to ~5 LU, compared to ~20 LU in unpanned 3o bm19 anti-B6 MLCs. 
In the absence of panning, 3o bm19 anti-B6 MLC effectors consists of 3.7% CD8+ 
Vβ14+ T cells (Table I), while depletion of CD8+ TCR Vβ14+ T cells by mAb-specific 
panning only reduces the CD8+ Vβ14+ population 1.5-fold (2.4%).  The lytic capacity of 
CD8+ Vβ14+ cells is moderately reduced (~8 LU) when compared to unpanned 3o bm19 
anti-B6 MLCs (~20 LU).  Enrichment for Vβ14 cells dramatically increases the CD8+ 
Vβ14+ population 22-fold (83.6%) over unpanned 3o bm19 anti-B6 MLCs and yet the 
alloreactive response for H-2Kb target cells is negligible (with a LU of ~0) compared to 
that of unpanned 3o bm19 anti-B6 MLCs (~20 LU).  Collectively, these results indicate 
that although there is a preferential expansion of the CD8+ Vβ8.1/8.2, Vβ10, and Vβ14 
families in vitro, these Vβ families are not involved in the 3o bm19 anti-B6 alloreactive 
response to H-2Kb target cells. 
 
TCR Vβ9 and Vβ12 family depletion of naïve bm19 spleen cells abrogates the alloreactive 
response of 3o bm19 anti-B6 CTLs. 
We also determined the lytic capacity of 3o bm19 anti-B6 MLCs either depleted 
or enriched for TCR Vβ9 and Vβ12 families (Figure 4A and 4B).  The selective removal 
of Vβ9 or Vβ12 families reduces the alloreactive responsiveness of 3o bm19 anti-B6 
effectors.  However, after enriching for Vβ9 or Vβ12 families the lytic capacity of these 3o 
bm19 anti-B6 CTLs is comparable (~20 LU and ~15 LU, respectively), compared to 
unpanned 3o bm19 anti-B6 MLC controls (~20 LU)  (Table II).  To determine the effect 
of depleting multiple Vβ families on the alloreactivity of 3o bm19 anti-B6 effectors, both 
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Vβ9 and Vβ12 families (Vβ9/12) were removed by mAb-specific panning and their lytic 
capacity was determined.  As shown in Figure 4C, Vβ9/12 depletion completely 
abrogates the alloreactive CTL response, in a 4h 51Cr-release assay, and Vβ9/12 
enrichment enhances the lytic capacity of 3o bm19 anti-B6 CTLs (~100 LU versus ~20) 
for the allogeneic target, S.B6.  These findings demonstrate that both Vβ9+ and Vβ12+ 
CTLs contribute synergistically to the alloreactive response of bm19 anti-B6 CD8+ 
effectors for S.B6 targets. 
To determine the relative contributions of Vβ9 and Vβ12 families to the bm19 
anti-B6 alloreactive CTL response, we analyzed TCR Vβ9-, Vβ12- and Vβ9/12-depleted 
and -enriched 3o bm19 anti-B6 cultures by two-color flow cytometry.  As shown in Table 
II, 3o bm19 anti-B6 CD8+ effectors contain approximately 7.2% Vβ9+ cells before 
panning, but after Vβ9-specific depletion this population is reduced six-fold (1.2%).  This 
depletion of Vβ9+ CTLs substantially reduces the lytic capacity of Vβ9- CD8+ cells to ~2 
LU, compared to ~20 LU in unpanned 3o bm19 anti-B6 MLCs.  By enriching for Vβ9-
expressing T cells, the CD8+ Vβ9+ population is increased 11-fold (85.1%) over unpanned 
3o bm19 anti-B6 MLCs.  Although the percentage of the CD8+, TCR Vβ9+ population is 
increased significantly by indirect panning, its lytic capacity is comparable to that of 
unpanned 3o bm19 anti-B6 cultures (~20 LU versus ~20 LU).  Thus, although 3o bm19 
anti-B6 CD8+ Vβ9+ T cells contribute to bm19 anti-B6 alloreactivity, they are most likely 
not the only Vβ+ CTLs involved.  
CD8+ T cells from the Vβ12 family constitute approximately 6.4% of unpanned 3o 
bm19 anti-B6 CTLs (Table II).  Depletion and enrichment for Vβ12+ T cells by panning 
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results in a 4-fold decrease (3.4%) and a 4–fold increase (78%), respectively, in the CD8+ 
Vβ12+ population, compared to unpanned 3o bm19 anti-B6 CTLs (16.5%).  The selective 
removal of CD8+ Vβ12+ T cells causes a 74% reduction (~7 LU versus ~20 LU) in the 
lytic capacity of 3o bm19 anti-B6 effectors, which mirrors the decrease in Vβ12+ CTLs 
following depletion by panning.  In addition, a 4-fold enrichment of CD8+ Vβ12+ cells 
not only fails to enhance the lytic capacity of 3o bm19 anti-B6 effectors, it reduces the 
LU value (~15 LU versus ~20 LU).  These findings indicate that 3o bm19 anti-B6 CD8+ 
TCR Vβ12+ population contributed to B6-specific allorecognition, as demonstrated by the 
reduction in lytic capacity following TCR Vβ12+ depletion, but presumably require 
additional CTLs from other Vβ families for maximum lytic activity. 
Taken together, the data indicate that both Vβ9+ and Vβ12+ bm19 CTLs are 
necessary to achieve optimal Kb-specific alloreactivity in vitro.  Furthermore, under these 
conditions other CD8+ Vβ families are not involved in mediating this alloreactivity.  To 
confirm this conclusion, we examined Vβ9/12-enriched and -depleted CTLs for their 
alloreactivity against B6.  Panning to remove both Vβ9 and Vβ12 (Table II) reduces the 
CD8+ Vβ9/12+ fraction from 23.1% in unpanned 3o bm19 anti-B6 MLC to approximately 
1.7% and completely abrogates the alloreactivity of 3o bm19 anti-B6 CTLs.  Conversely, 
enrichment for CD8+ Vβ9/12+ CTLs results in a 3.5-fold (85.8%) increase in the 
percentage of CD8+ Vβ9/12+ CTLs compared to unpanned 3o bm19 anti-B6 MLC CD8+ 
Vβ9/12+ T cells (23.1%).  The lytic capacity of TCR Vβ9/12+-enriched CTLs from the 3o 
bm19 anti-B6 MLC is enhanced approximately 5-fold (~100 LU) compared to that of 
unpanned cultures.  Thus, these results confirm that the selective removal of both Vβ9+ 
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and Vβ12+ families from the 3o bm19 anti-B6 MLCs completely abrogates the B6-
directed alloreactivity of 3o bm19 anti-B6 CTLs.  
 
Antigen-specific and unrelated allospecific proliferation and function remain intact 
following the selective removal of TCR Vβ9/12+ CD8+ T cells. 
 Having shown that Vβ9/12+ T cell depletion from 3o bm19 anti-B6 cultures 
completely remove Kb-specific in vitro alloreactivity, it is equally important that the 
remaining CD8+ T cells are undiminished in their functional capacity to recognize and 
respond to antigens unrelated to the H-2Kb alloantigen.  To address this concern, we 
selectively removed CD8+ Vβ9/12+ T cells from naïve bm19 spleens by panning and 
stimulated the remaining CD8+ Vβ9/12- T cells with either irradiated BALB/c splenocytes 
(unrelated alloantigen) or irradiated bm19 splenocytes pulsed with VSV-8 peptide 
(foreign peptide) or the MI B chain p7-15 (self-peptide).  The proliferative capacity of 
Vβ9/12- 1o bm19 anti-BALB/c, bm19 anti-VSV-8, and bm19 anti-MI B chain p7-15 
CTLs was determined on day four by measuring the 18-h incorporation of 2 µCi 3H-TdR.  
As shown in Figure 5A, the selective removal of CD8+ Vβ9/12 T cells does not interfere 
with alloreactive or antigen-specific proliferation. 
 To assess the alloreactive cytolytic activity of Vβ9/12-depleted bm19 spleen cells 
stimulated with the unrelated H-2d alloantigen, we compared the in vitro functional 
reactivity of Vβ9/12- and normal 1o bm19 anti-BALB/c CTLs by 51Cr-release assay.  As 
shown in Figure 5B, Vβ9/12- 1o bm19 anti-BALB/c CTLs lyse P815 (H-2d), but not EL-4 
(H-2b), target cells as efficiently as the normal bm19 anti-BALB/c CTLs.  This confirms 
that the cytolytic activity against unrelated H-2d alloantigen is unaffected by removing 
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Vβ9/12+ T cells from bm19 anti-B6 MLCs.  We also examine whether the antigen-
specific cytolytic response of bm19 spleen cells depleted of Vβ9/12+ T cells for the viral 
peptide, VSV-8, or the MI B chain p7-15 self-peptide is altered.  Target cells expressing 
Kbm19 were labeled with 51Cr and pulsed with 2 µM VSV-8, MI B chain p7-15 or media 
alone and were incubated for 4 h with Vβ9/12- or normal 1o bm19 anti-VSV-8 or bm19 
anti-MI B chain p7-15 CTLs.  As shown in Figure 5C, Vβ9/12- 1o bm19 anti-VSV-8 
CTLs respond as efficiently as normal bm19 anti-VSV CTLs to VSV-8 in a Kbm19-
restricted manner.  This is also the case for the Vβ9/12- 1o bm19 anti-MI B chain p7-15 
response, as shown in Figure 5D.  Thus, these findings confirm that under these in vitro 
conditions, the Vβ9/12- CD8+ T cells are unimpaired in their capacity to respond 





Despite continuing advances and refinements in immunosuppressive drug 
therapies, the inherent T cell inhibitory properties of these treatment modalities 
predispose the transplant recipient to an increased risk for various infections (56,57).   In 
a study by Walker and coworkers (2) it was noted that, depending upon the extent of 
immunosuppressive treatment, 52 - 86% of renal transplant patients experienced one or 
more episodes of infection during the first 6 months post transplantation.  Approximately 
65 percent of renal transplant patients develop infection during the first 6 months post 
transplantation, leading to death in 3.8 percent of those individuals (1).   
Transplant recipients are also predisposed to higher rates of malignancy compared 
to the general population (56).  Vital organ transplants, such as cardiac, liver and lung 
allografts, require intense immunosuppression and have a higher incidence of 
malignancies compared to renal allograft recipients (3,4,58).  The most common types of 
cancer noted after organ transplantation include skin carcinomas (particularly squamous-
cell, basal-cell, Kaposi’s sarcoma and melanoma), but the occurrence of lymphomas, 
meningiomas, bronchogenic carcinomas and carcinomas of the breast, esophagus, colon 
and cervix have also been demonstrated (2,59).   
 To alleviate these immunosuppression-associated problems in transplant patients, 
a number of investigators (18 - 20) have sought to distinguish transplant-specific, 
alloreactive T cells in the T cell repertoire.  In so doing, it may be possible to devise a 
feasible approach to selectively eliminate these T cells, without disturbing the intricate 
balance of antigen-specific T cell reactivity required for controlling the immune response 
to various pathogens and tumors.  In this study we address the in vitro requirements for 
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identifying and eliminating allograft-specific CTLs without compromising the in vitro 
CTL response to other foreign antigens.     
As noted in the introduction, a recent study by Grandea and Bevan (24) involving 
the MHC class I H-2Kb transgenic mouse mutant, H-2Kb,E65, demonstrate that activation 
of an alloreactive CTL response can be initiated by as little as a single amino acid 
disparity in the H-2Kb molecule.  The transgenic mouse mutant, H-2Kb,E65, has a single 
H-2Kb amino acid substitution at position 65 (Gln65 → Glu), located on the outward face 
of the α-helix of the α1 domain and interacts with the TCR but does not affect the 
peptide-binding groove.  This study supports the earlier finding by Bevan and Hunig (60) 
that distinct allogeneic differences, involving only a few amino acid changes in the class I 
MHC molecule, elicite a stronger alloreactivity than those that are more disparate.  Their 
work also suggests that alloreactive CTLs may have higher TCR avidities for 
nonconservative amino acid changes within a closely related class I MHC-peptide 
complex (24).     
The bm19 mutant mouse strain, the model used in the current study, differs by a 
single amino acid change at position 80 (Thr80 → Asn) in the H-2Kb molecule of the B6 
parental strain (25).  It is unclear whether the basis for the bm19 anti-B6 alloreactive CTL 
response is due to direct or indirect allorecognition, or both.  But in either case, we 
clearly demonstrate that CTLs from both the Vβ9 and Vβ12 TCR families are key 
participants in the immune effector response.  Interestingly, it is possible that one of these 
TCR Vβ families (Vβ9 or Vβ12) recognizes the distinct amino acid change (Thr80) on the 
α-helix, via direct allorecognition, while the second TCR Vβ family may respond through 
indirect allorecognition, reacting to a change in MHC/peptide three-dimensional 
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structure, due to either: (1) the altered binding configuration of a self-peptide that differs 
between Kb and Kbm19, or (2) a Kbm19-bound peptide derived from the allogeneic H-2Kb 
molecule.   
Studies are presently being planned to determine whether one or both of the bm19 
anti-B6 Vβ9 and Vβ12 families, identified as alloreactive CTL effectors in this paper, 
might utilize indirect recognition to respond to allogeneic Kb differences.  In these 
studies, peptides from H-2Kbm19 molecules stimulated with B6 spleen cells will be eluted 
from the H-2Kbm19/peptide complex and sequenced by reverse-phase HPLC and tandem 
mass spectrometry to determine peptide composition.  This process has been documented 
in the identification of peptides associated with human bladder tumor cell lines (61), 
insulin-dependent diabetes mellitus (62) and GVHD in allogeneic bone marrow 
transplantation in mice (63).  The peptide sequence analysis will be used to determine 
whether the Kbm19-bound peptide contains the native Thr80 residue found in the wild-type 
Kb sequence.  If so, subsequent in vitro CTL analysis, using peptide-pulsed H-2Kbm19-
expressing target cells, will be performed to evaluate the cytolytic responsiveness of 
alloreactive Vβ9+ and Vβ12+ CTLs.  In addition to traditional CTL analysis with these 
peptide-pulsed target cells, MHC/peptide tetramers (64,65) will be employed to 
determine whether CTLs of either or both Vβ9 and Vβ12 families respond via indirect 
allorecognition; and, if so, what proportion of these CTLs respond accordingly.  One 
advantage to using Kbm19/peptide tetramers is that the three-dimensional structure can be 
discerned with the aid of X-ray crystal structure analysis and computer-generated 
modeling approaches.  In this case, the orientation and interaction of CTLs from a given 
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Vβ family (Vβ9 or Vβ12) with the Kbm19/peptide complex could also be examined in 
greater detail.   
As previously noted, Connolly and co-workers implicate TCR Vβ8+ CTLs in the 
Ld-specific response of the Ld-loss mutant dm2 when stimulated with irradiated wild-type 
BALB/c spleen cells.  Removal of Vβ8+ CTLs, using the anti-Vβ8 monoclonal antibody, 
F23.1, diminishes the H-2Ld-specific CTL response by approximately 80% (27).  
Although in vivo depletion of Vβ8+ T cells prolongs the mean survival of Ld-disparate 
skin grafts by two-fold it has no effect on rejection of H-2Dk-disparate skin grafts 
(27,66); thus indicating the allospecific effect of Vβ8+ T cell depletion on allograft 
rejection.    
 In the current study, we show that two distinct Vβ families work synergistically in 
the in vitro alloreactive response of bm19 anti-B6 CTL effectors.  In a companion paper 
(Frankenberry et al., submitted) we extend these studies to examine the effect of in vivo 
Vβ9/12+ T cell depletion in bm19 mice on their ability to reject B6 skin allografts.  
Furthermore, we compare these Vβ9/12+ T cell-depleted bm19 mice with normal bm19 
mice in their ability to mount an antigen-specific response leading to the clearance of a 
Listeria monocytogenes infection.   
In summary, we identify CD8+ T cells from both Vβ9 and Vβ12 families as the 
critical alloreactive CTL effectors in the in vitro response of long- and short-term bm19 
anti-B6 CTLs against allogeneic Kb-expressing targets.  Furthermore, depletion of both 
CTL Vβ families completely abrogates the Kb-directed allospecific response, without 
inhibiting to other unrelated allogeneic molecules or peptide antigens.  This is the first 
study, to our knowledge, to identify the synergistic effect of multiple CD8+ Vβ families as 
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critical effectors in the response against an allogeneic target.  In addition, we show that 
although the CD8+ Vβ families, Vβ8.1/8.2, 10 and 14, underwent significantly expansion 
upon in vitro stimulation with B6 spleen cells, they are not actively involved in the bm19 
anti-B6 alloreactive CTL response.  We also show that the selective removal of both TCR 
Vβ9/12 families abrogates the in vitro response of bm19 anti-B6 effectors toward B6-
specific target cells, but does not inhibit unrelated allo- or antigen-specific host 
responses. 
The removal of select CTL populations that mediate one specific alloreactive 
response without compromising unrelated allospecific or antigen-specific responses is a 
novel and exciting discovery.  It suggests a unique approach to confronting the daunting 
complications of transplant immunology.  Rather than broadly depressing the 
responsiveness of the entire T cell compartment with non-selective immunosuppressive 
agents or immunomodulating mAbs, it should be possible to remove only those T cells 





Table I    
Percent CD8+ TCR Vβ+ cells and lytic unit values for 3o bm19 anti-B6 CTLs 
 













10.8 ± 1.5 
 
19.4 ± 1.6 
 
77.8 ± 7.3 
 
0 
Vβ8.1/8.2-   3.7 ± 2.5 ~9 
     
Vβ10+ 4.6 ± 2.0 8.1 ± 0.8 92.3 ± 4.2 ~5 
Vβ10-   1.4 ± 0.1 ~6 
     
Vβ14+ 7.2 ± 2.1 3.7 ± 0.5 83.6 ± 5.3 0 
Vβ14-   2.4 ± 1.5 ~8 
     
Vβ17+ 20.4 ± 3.3 9.0 ± 4.4 78.7 ± 3.0 0 
Vβ17-   6.0 ± 1.7 ~7 
     
3o bm19 anti-B6 - - - ~20 
1Percentage ± SD CD8+ TCR Vβ+ families detected in naïve bm19 spleens by flow 
cytometry. 
2Percentage ± SD 3o bm19 anti-B6 CD8+ TCR Vβ+ families in the absence of panning. 
3Percentage ± SD 3o bm19 anti-B6 CD8+ TCR Vβ+ families following panning for TCR 
Vβ8.1/8.2, Vβ10, Vβ14 or Vβ17 on day 0. 
4Values are representative of the cytolytic capacity of 3o bm19 anti-B6 MLC of three 







Table II    
Percent CD8+ TCR Vβ+ cells and lytic unit values for 3o bm19 anti-B6 CTLs 
 













5.3 ± 0.6 
 
7.2 ± 1.8 
 
85.1 ± 1.8 
 
~20 
Vβ9-   1.2 ± 0.1 ~2 
     
Vβ12+ 6.4 ± 0.5 16.5 ± 2.5 78.2 ± 7.8 ~15 
Vβ12-   3.4 ± 2.6 ~7 
     
Vβ9/12+ 11.7 ± 0.7 23.1 ± 1.4 85.8 ± 0.5 ~100 
Vβ9/12-   1.7 ± 0.4 0 
     
3o bm19 anti-B6 - - - ~20 
1Percentage ± SD naïve CD8+ TCR Vβ+ families detected in naïve bm19 spleens by flow 
cytometry. 
2Percentage ± SD 3o bm19 anti-B6 CD8+ TCR Vβ+ families in the absence of panning. 
3Percentage ± SD 3o bm19 anti-B6 CD8+ TCR Vβ+ families following panning for TCR 
Vβ9, Vβ12 and Vβ9/12 on day 0. 
4Values are representative of the cytolytic capacity of 3o bm19 anti-B6 MLC of three 






FIGURES AND FIGURE LEGENDS 
 
Fig. 1  Short- and long-term bm19 anti-B6 MLCs exhibit strong alloreactivity for  
H-2Kb-bearing target cells. 
1o (A), 5o (B), and 7o (C) bm19 anti-B6 CTL effectors were incubated with 1 X 104 51Cr-
labeled SP2/0 (●), S.B6 ( ) and S.bm19 (∇) target cells for 4 h in order to determine 
their lytic reactivity.  Following this incubation, 100 µl samples of supernatants were 
collected and the number of radioactive counts was determined; cytolytic activity was 
represented as "percent specific lysis".  Spontaneous 51Cr release values from targets in 
the absence of CTL effectors were <10% of maximum in all experiments.  The results 






Fig. 2 In vitro expansion1 of bm19 anti-B6 CTL effectors occurs among five Vβ 
families. 
Naïve bm19 spleen cells (solid bars), 1o (horizontal bars), 3o (hatched bars) 5o (open 
bars), and 7o (diagonal bars) bm19 anti-B6 CTLs were evaluated for the expression of 
distinct TCR Vβ families by flow cytometric analysis.  Samples of 5 X 105 cells were 
incubated for 45 min on ice with 20 µl (1:100) of one of 14 FITC-conjugated Vβ-specific 
mAbs and counter-stained with 20 µl (1:96) of PE-conjugated anti-CD8α mAb, washed 
twice with PBS and fixed in 500 µl 1% formalin.  Fixed cells were analyzed by flow 
cytometry for CD8+, Vβ+ T cell populations and were expressed as (Vβn value/sum of Vβ 
values) X 100.  Asterisks represent statistically significant expansion of bm19 anti-B6 
TCR Vβ+ families, as compared to naïve spleen cell populations, and were determined by 
one-way analysis of variance (ANOVA) performed in five separate experiments.  1Only 









Fig. 3  Depletion of Vβ8, Vβ14 or Vβ17 families from naïve bm19 splenic T cells 
yields fully alloreactive 3o bm19 anti-B6 CTL effectors. 
TCR Vβ8+ (A), Vβ14+ (B), and Vβ17+ (C) T cells from naïve bm19 spleens were depleted 
and/or enriched by indirect panning, stimulated with irradiated B6 splenocytes and 
maintained for three wk, as described in the Materials and Methods section.  3o bm19 
anti-B6 CTL from depleted and/or enriched cultures were incubated with 1 X 104 SP2/0 
(●), S.B6 ( ) and S.bm19 (∇) 51Cr-labeled target cells for 4 h.  Supernatants (100 µl) 
were collected and cytolytic activity was represented as the "percent specific lysis".  
Spontaneous release of targets in the absence of CTL effectors was <10% of maximum 
lysis by detergent in all experiments.  A single representative of three separate 
experiments is shown. 
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Fig. 4 TCR Vβ9 and Vβ12 family depletion of naïve bm19 spleen cells abrogates the 
alloreactive response of 3o bm19 anti-B6 CTLs. 
TCR Vβ9+ (A), Vβ12+ (B), and Vβ9/12+ (C) T cells from naïve bm19 spleens were 
depleted and/or enriched by indirect panning, stimulated with irradiated B6 splenocytes 
and maintained for three wk, as described in the Materials and Methods section.  3o bm19 
anti-B6 CTL from depleted and/or enriched cultures were incubated with 1 X 104 SP2/0 
(●), S.B6 ( ) and S.bm19 (∇) 51Cr-labeled target cells for 4 h.  Supernatants (100 µl) 
were collected and cytolytic activity was represented as the "percent specific lysis".  
Spontaneous release of targets in the absence of CTL effectors was <10% of maximum 
lysis by detergent in all experiments.  A single representative of three separate 






Fig. 5 Antigen-specific and unrelated allospecific proliferation and function remain 
intact following the selective removal of TCR Vβ9/12+ T cells. 
A. TCR Vβ9/12+ T cells from naïve bm19 spleen cells were depleted by indirect 
panning.  The remaining T cell fractions were stimulated with irradiated BALB/c 
splenocytes (open bars), irradiated bm19 splenocytes pulsed with 2 µM VSV-8 (solid 
bars), or irradiated bm19 splenocytes pulsed with 2 µM MI B chain p7-15 (hashed 
bars).  To determine the proliferative capacity of TCR Vβ9/12- bm19 anti-BALB/c, 
bm19 anti-VSV-8, and bm19 anti-MI B chain p7-15 CTL, 1 X 105 cells from each 
culture were transferred on day four to a 96-well plate and incubated for 18 h with 2 
µCi of 3H-TdR. 
B. 1o bm19 anti-BALB/c CTL (filled symbols) and TCR Vβ9/12- 1o bm19 anti-BALB/c 
CTL (open symbols) were incubated with P815 (Ο) or EL-4 ( ) 51Cr-labeled target 
cells for 4 h.  Supernatants (100 µl) were collected and cytolytic activity was 
represented as the "percent specific lysis".  A single representative of three separate 
experiments is shown. 
C. 1o bm19 anti-VSV-8 CTL (filled symbols) and TCR Vβ9/12- 1o bm19 anti-VSV-8 
CTL (open symbols) were incubated with 51Cr-labeled S.bm19 target cells in the 
presence (Ο) or absence ( ) of 2 µM VSV-8 for 4 h.  Supernatants (100 µl) were 
collected and cytolytic activity was represented as the "percent specific lysis".  A 
single representative of three separate experiments is shown. 
D. 1o bm19 anti-MI B chain p7-15 CTL (filled symbols) and TCR Vβ9/12- 1o bm19 anti-
MI B chain p7-15 CTL (open symbols) were incubated with 51Cr-labeled S.bm19 
target cells in the presence (Ο) or absence ( ) of 2 µM MI B chain p7-15 for 4 h.  
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Supernatants (100 µl) were collected and cytolytic activity was represented as the 
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The clinical application of immunosuppressive drug therapy in transplantation 
medicine has resulted in the progressive development of successful allograft survival for 
a highly diverse set of organ and tissue transplants.  These agents, however, are 
nonspecific and affect the overall immune status of transplant recipients, causing 
generalized inhibition of T cell responsiveness, thus leaving these patients susceptible to 
higher rates of opportunistic infection and malignancy.  Since CD8+ T cells play an 
integral role in transplant rejection, we propose that the identification and elimination of 
TCR Vβ+ CTLs actively involved in the alloreactive response will result in the 
maintenance of the graft recipients immune system.  We have previously identified two 
distinct TCR Vβ families - Vβ9 and Vβ12 - as critical effectors in the alloreactive 
response of bm19 anti-B6 MLCs that act synergistically in the recognition of H-2Kb-
bearing targets.  Interestingly, the in vitro depletion of Vβ9+ and Vβ12+ T cells from the 
bm19 T cell repertoire does not impair antigen-specific responsiveness to the 
immunogenic peptides, VSV-8 and MI p7-15.  In the present study, we show that the in 
vivo depletion of both TCR Vβ families significantly prolong B6 skin allograft survival 
when transplanted onto bm19 mice.  We also demonstrate that bm19 mice are capable of 
mounting a cell-mediated immune response against L. monocytogenes after the in vivo 
removal of TCR Vβ9/12+ CTLs.  These findings suggest that the selective depletion of 
allograft-specific Vβ+ CTLs can prolong graft survival without disrupting the host 





 The administration of immunosuppressive drugs is the major therapeutic option 
for the prevention of allograft rejection and is largely responsible for the success of 
clinical transplantation.  These agents, however, also adversely affect the overall immune 
status of transplant patients, leaving these patients susceptible to opportunistic infections 
and malignancies (1-4).  Despite current advances in immunosuppressive therapies, these 
treatment modalities predispose the transplant recipient to infection (5,6).  It has been 
noted that, depending upon the intensity of immunosuppression, 52 to 86 percent of renal 
transplant patients experienced one or more episodes of infection during the first 6 
months post transplantation (2).  The rates of infection, mortality and overall morbidity 
remain comparable in hepatic, cardiac, lung and pancreatic islet transplant recipients 
despite the therapeutic use of immunosuppressive agents (7-10). 
 The number of patients with end-stage renal disease has increased by 7 to 8 
percent per year in the United States (11).  The limited number of kidneys available for 
transplantation, reported as between 6200 living and 8500 cadaveric donors (11,12), 
precludes the only currently available treatment modality for these patients (13).  With 
the use of immunosuppressive agents, such as cyclosporine A, tacrolimus, 
corticosteroids, and more recently muromonab-CD3 (OKT3) and mycophenolate mofetil, 
the one-year survival rate of renal grafts has increased from 88.8 to 93.9 percent with 
living donors and 75.7 to 87.7 percent with cadaveric donors from 1988 to 1996 (11). 
 In addition to traditional immunosuppressive medications, extensive research has 
been focused on developing immunomodulatory agents aimed at blocking interleukin-2 
receptor (IL-2R) engagement.  Daclizumab (Zenapax), basiliximab, Simulect, anti-Tac 
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and BT563 are humanized mAb specific for cluster of differentiation 25 (CD25), the    
IL-2R α chain induced by antigenic stimulation (14,15).  These agents have been shown 
to reduce allograft rejection in renal transplantation recipients by 49 percent at six months 
post transplantation when added to cyclosporine A, prednisolone and mycophenolate 
mofetil or azathioprine regimen (14).  This treatment modality, however, did not reduce 
the incidence of malignancies or risk of infection for renal transplant recipients.  
Likewise, daclizumab, in conjunction with cyclosporine A, corticosteroids and 
mycophenolate mofetil, was effective in preventing alloreactivity and acute rejection in 
cardiac transplantation during a 3 month trial (15).  Unfortunately, IL-2R mAb diminish 
the total number of all activated T-cells regardless of whether these cells have been 
activated by antigen-specific or allogeneic stimulation, thus predisposing the transplant 
recipient to higher rates of infectious and malignant illnesses. 
 Several other immunomodulatory agents have been studied as adjuvants to 
traditional immunosuppresion.  Alemtuzumab (Campath-1H) when combined with 
tacrolimus is reported to prevent acute rejection in human intestinal transplantation (16).  
Campath-1H is a humanized mAb directed against the CD52 antigen, a pan T, B, NK cell 
and monocyte marker.  Likewise, FTY720 has been shown to reduce intestinal allograft 
rejection in rats (17).  FTY720 reduces the total number of circulating lymphocytes and 
increases lymphocyte homing to lymphoid tissues, including mesenteric lymph nodes and 
Peyer’s patches (18), and reduces the total CD3+ cell number in skin allografts (19).  
Koppi and collaborators (20) investigated the effects of blocking CMRF-44, a dendritic 
cell (DC)-associated differentiation-activation antigen, on allogeneic bone marrow 
transplantation (BMT) and solid organ transplantation.  They determined that 89 percent 
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of activated DCs are depleted by CMRF-44-dependent complement-mediated lysis and 
subsequently reduce T helper type 1 and type 2 responses (20). 
 Unfortunately, all of the immunosuppressive agents mentioned above act in a 
nonselective manner and therefore reduce the overall immune status of the patient.  We 
employ a unique in vitro murine model system to distinguish allospecific CTL effectors 
from the remaining splenic T cell repertoire in bm19 mutant mice stimulated with 
allogeneic B6 spleen cells, based on their Vβ expression (Frankenberry et al., submitted).  
Thus, by identifying and eliminating only those Vβ+ CTLs actively involved in the 
alloreactive response, we can maintain the majority of the patient’s immune system. 
The bm19 mutant differs from the parental B6 strain by a single amino acid 
change in the class I H-2Kb, resulting in a Thr80 → Asn substitution.  As previously 
demonstrated in vitro (Frankenberry et al, submitted), although five distinct Vβ families 
(Vβ8.1/8.2, Vβ9, Vβ10, Vβ12 and Vβ14) show increased expansion when bm19 
splenocytes are stimulated with irradiated splenocytes from the parental B6 strain, only 
Vβ9+ and Vβ12+ CTL effectors show cytolytic activity against allogeneic Kb-expressing 
target cells.  Furthermore, depletion of both Vβ9+ and Vβ12+ CD8+ T cells results in a 
dramatic reduction in the lytic responsiveness of bm19 anti-B6 alloreactive CTL 
effectors.  Similarly, enrichment for Vβ9+ and Vβ12+ CTLs significantly increases their 
lytic activity against H-2Kb-expressing targets (Frankenberry et al, submitted).  Thus 
these experiments strongly implicate CD8+ T cells from both Vβ9 and Vβ12 families as 
critical alloreactive effectors in this bm19 anti-B6 model.  Importantly, we also find that 
depletion of Vβ9+ and Vβ12+ CD8+ T cells from the bm19 T cell repertoire does not 
impair the antigen-specific responsiveness of bm19 CTLs to the immunogenic peptides, 
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vesicular stomatitis virus nucleoprotein p52-59 (VSV-8) (21,22) and mouse insulin I (MI) 
B chain p7-15 (23).  These findings suggest that removal of both TCR Vβ families in vivo 
should significantly prolong B6 skin allograft survival when transplanted onto bm19 
mice. 
To address whether CD8+ T cells from the Vβ9 and Vβ12 families are the primary 
alloreactive CTL effectors involved in the rejection of B6 skin allografts, we administer 
intraperitoneal (i.p.) monoclonal antibody (mAb) injections of 500 µg anti-
Hemagglutinin A (HemA) isotype control (24), 500 µg anti-TCR Vβ9 [MR10-2] (25) or 
750 µg anti-TCR Vβ12 [MR11-1] (25) mAb in 200 µL sterile PBS on days -3, 0, +3 and 
+21 of skin graft placement and determine B6 skin allograft survival.  In this paper, we 
show that in vivo depletion of either Vβ9+ or Vβ12+ T cell populations from naïve bm19 
mice prolongs the survival of B6 skin allografts, and the simultaneous depletion of both 
Vβ9 and Vβ12+ T cells further enhances B6 skin allograft survival, when compared to 
saline and isotype controls.  Furthermore, although depletion of the Vβ9 and Vβ12 
families removes more than 10% of the CD8+ T lymphocyte repertoire, these bm19 mice 







MATERIALS AND METHODS 
 
Animals 
Female C57BL/6 (B6) and B6.C-H-2bm19 (bm19) (26) mice used in this study were 
obtained from this laboratory's breeding colony at West Virginia University Health 
Sciences Center Vivarium.  The B6 breeding colony was established in 1987 and has 
been maintained since then at West Virginia University Health Sciences Center 
Vivarium.  All female mice used in this study were 8-12 weeks of age. 
 
Antibodies and flow cytometry 
Phycoerythin (PE)-conjugated anti-CD8α [53-6.7] (27) and fluorescein isothiocyanate 
(FITC)-conjugated anti-Vβ9 [MR10-2] (25), and Vβ12 [MR11-1] (25) mAbs were 
purchased from Pharmingen (Becton Dickinson, Mountain View, CA).  Harvested 
splenocytes, 5 X 105, were incubated for 45 min on ice with 20 µl (1:100) FITC-
conjugated anti-TCR Vβ-specific mAb and 20 µl (1:96) of PE-conjugated anti-CD8α 
mAb.  The cells were then washed twice with 1X PBS and fixed in 500 µl 1% formalin.  
Fixed cells were analyzed for fluorescence intensity using a FACScan flow cytometer 
(Becton Dickinson, Mountain View, CA).  The percentage expression of cells of a given 
Vβ family among CD8+ alloreactive CTLs is defined as 100 X (Vβn value/sum of Vβ 






In vivo depletion of Vβ-specific TCR families 
T cells from the Vβ9 and/or Vβ12 families were depleted in vivo as previously described 
by Connolly and coworkers (29) with the following modifications:  Female bm19 mice 
were injected i.p. with 500 µg anti-HemA isotype control (24), 500 µg anti-Vβ9    
[MR10-2] (25) or 750 µg anti-Vβ12 [MR11-1] (25) mAb in 200 µL sterile PBS on days -
3, 0, +3 and +21 of skin graft placement.  The isotype control, anti-HemA, was kindly 
provided by Dr. Elliott (24).  Five bm19 mice from each experimental or control group 
were sacrificed on days +3, +7, +14, +21, +24, +28 and +35, and spleens were removed, 
processed and evaluated by flow cytometry to determine the percentage of Vβ9+ and 
Vβ12+ CD8+ T lymphocytes. 
 
Skin allograft transplantation 
Preparation of skin allografts and recipient mice was performed as described by 
Billingham and Steinmuller (30,31) with the following modifications:  On day 0, 
recipient female bm19 mice were weighed and anesthetized by i.m. injection with a 
combination of xylazine (5 mg/kg) and ketamine (95 mg/kg).  Anesthetized mice were 
shaved on the dorsal surface from the shoulder blades to the hind limbs using mouse 
sheers; the surface was moistened with sterilized water and allowed to air dry.  The 
shaved area was then treated with a depilatory agent to remove any remaining hair and 
subsequently removed with sterilized water and gauze padding.  The graft area was 
cleaned with betadine and allowed to air dry.   
Skin sections (8 mm) from the right and left flank were isolated using a circular 
biopsy punch; tissues were placed in sterile PBS and any remaining connective tissue was 
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removed using forceps.  Donor grafts (8 mm) obtained from female B6 or bm19 mice 
were placed directly on the graft area at an 180o orientation opposite to normal hair 
growth.  Each bm19 recipient received an allograft (B6) and a control graft (bm19).  
Graft sites were secured using a 3/4-inch double surgical tape bandage wrap.  Engrafted 
mice were placed in a micro-isolator cage on a slide warmer set at 37o C until their 
recovery from the anesthetic (approximately 15-30 minutes).  Protective bandage wraps 
were removed on day +7, and triple antibiotic cream was applied to the graft sites to 
prevent potential infection.  Grafts were visually monitored daily for signs of rejection, 
and caliper measurements were used to quantitate the extent of viability for each skin 
graft. 
 
Listeria monocytogenes infection 
Female bm19 mice (n=8 per group) were injected (i.p.) with 1 X PBS, 500 µg anti-HemA 
mAb, or 500 µg of anti-Vβ9 mAb [MR10-2] and 750 µg of anti-Vβ12 [MR11-1] on days -
3, 0, and +3 of skin engraftment.  L. monocytogenes (1 X 106 CFU) was injected i.p. on 
day +3.  Livers and spleens were harvested on day +6 and +10 of infection, homogenized 
on a Brinkmann homogenizer and plated in triplicate on brain-heart infusion (BHI) media 
with an Autoplate 4000 (Spiral Biotech, Norwood, MA).  Cultures were incubated for 18 
h and counted using a CASBA 4 (Spiral Biotech, Norwood, MA) colony counter. 
Statistical analysis 
All statistics in this study were performed using the paired two-tailed student’s T-test, 





Depletion of Vβ9+ T cells in vivo significantly enhances the survival of B6 skin allografts 
transplanted onto bm19 mice. 
 To determine the effect of bm19 Vβ9+ CTLs on the rejection of B6 skin allografts, 
we selectively depleted Vβ9+ T lymphocytes from the bm19 T repertoire by administering 
three successive i.p. injections of 500 µg Vβ9-specific mAb [MR10-2] on day -3, 0 and 
+3 of B6 skin allograft placement.  As shown in Table I, the Vβ9+ T cell population is 
significantly reduced from 5.5% to 0.09% on day +3.  Although the bm19 Vβ9+ 
population remains below 1% throughout the duration of these studies, we noted a slight 
trend toward the recovery of Vβ9+ CTLs by day +21, expanding from 0.35% to 0.6% of 
total CD8+ T cells.  Thus, we administered an additional i.p. injection of 500 µg anti-Vβ9 
mAb [MR10-2] on day +21, and the CD8+ Vβ9+ T cell pool is subsequently reduced to 
0.3% by day +24.  Conversely, treatment with an IgG1 isotype control, the anti-HemA 
mAb, has no significant effect on Vβ9+ CTLs in bm19 mice.  All bm19 control mice 
reject the B6 skin allograft by day +13 and thus do not require a fourth injection on day 
+21. 
 All experimental bm19 mice that receive B6 allografts without Vβ mAb treatment 
completely reject the B6 skin allograft within 13 days post transplantation, and control 
bm19 mice that receive syngeneic bm19 skin grafts fully accept the transplanted tissue 
(Figure 1).  All bm19 mice treated with the Vβ9-specific mAb [MR 10-2] on days -3, 0, 
+3 and +21 displays a significant delay in graft rejection.  Although the B6 skin allograft 
exhibits a steady declined in size after 15 days it is maintained for 31 days (p < 0.05).  
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Similar to the saline control group, bm19 mice injected with the IgG1 isotype control, 
anti-HemA mAb, reject their B6 skin allografts by day +13.   
 
Depletion of Vβ12+ CTLs in vivo significantly enhances the survival of B6 skin allografts 
transplanted onto bm19 mice. 
 Having observed that Vβ9+ T cell-depleted bm19 mice show a >2-fold increase in 
B6 skin allograft survival, we addressed whether depletion of Vβ12+ T cells might have a 
similar effect on the ability of bm19 mice to reject B6 skin allografts.  Thus, bm19 Vβ12+ 
T cells were selectively depleted in vivo by administering four 500 µg i.p. injections of 
the Vβ12-specific mAb [MR11-1] on days -3, 0, +3 and +21 of engraftment.  As shown in 
Table I, the untreated and anti-HemA mAb treated Vβ12+ populations in bm19 mice 
contribute between 6.0% and 6.5% of the total CD8+ cell repertoire.  The Vβ12+ T cells 
are significantly depleted following anti-Vβ12 mAb treatment, with an initial decrease to 
0.03%.  As described above for the Vβ9-depleted bm19 mice, we recognized that the 
TCR Vβ12 family could potentially recover during the experiment and administered a 
fourth injection (i.p.) of anti-Vβ12 mAb on day +21 to circumvent this possible 
complication.  The TCR Vβ12+ T cell population remains below 1% throughout the 
duration of these experiments and peaks on day +35, well after the B6 graft is completely 
rejected.  As noted previously, the IgG1 isotype control, anti-HemA-specific mAb, has no 
significant effect on the CD8+ TCR Vβ12 effectors in bm19 mice.  Again, all bm19 mice 
treated with anti-HemA-specific mAb reject the B6 skin allograft by day +13 and thus 
does not require a fourth injection on day +21. 
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 Saline control bm19 mice that received bm19 skin grafts accept the newly 
transplanted tissue, but those that received B6 allografts promptly reject them within 13 
days (Figure 1).  Likewise, isotype control bm19 mice reject the B6 allografts by day 
+13.  The experimental group of bm19 mice, treated with four 500 µg i.p. injections of 
the Vβ12-specific mAb [11-1], show significantly increased B6 allograft survival 
compared those in the saline control group (p < 0.05).  Thus, Vβ12-depleted bm19 mice 
do not completely reject their B6 skin allografts until day +22, thereby prolonging graft 
survival >1.5-fold.  Similar to the Vβ9-depleted bm19 mice, the B6 skin allografts in 
Vβ12-depleted bm19 mice gradually diminish in size throughout the rejection process. 
 
The depletion of T cells from both Vβ9 and Vβ12 families in vivo further increases the 
survival of B6 allografts in bm19 mice. 
 Given that in vivo depletion of T cells from either the Vβ9 or Vβ12 family results 
in significant enhancement of B6 allograft survival in bm19 mice, we addressed whether 
the combined depletion of T cells from both families would further enhance B6 allograft 
survival.  To achieve depletion of both Vβ9+ and Vβ12+ T cells, bm19 mice were given 
four (i.p.) injections with the combination of 500 µg Vβ9-specific mAb [10-2] + 750 µg 
Vβ12-specific mAb [11-1], on days -3, 0, +3 and +21.  Interestingly, we found that the 
volume of anti-Vβ12 mAb required to deplete the Vβ12+ T cell population, to levels 
comparable to previous experiments, had to be increased to 750 µg.  As shown in Table I, 
the initial Vβ9/12 population in untreated bm19 mice contribute approximately 11.7% of 
the total CD8+ TCR Vβ CTL available.  The number of TCR Vβ9/12+ T cells is 
significantly decreased following treatment with anti-Vβ9/12 mAb (0.12%), and remains 
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below 1% throughout the duration of these experiments.  As noted above, the IgG1 
isotype control, anti-HemA-specific mAb, has no effect on the TCR Vβ9/12 populations 
in bm19 mice (data not shown). 
 Saline treated bm19 mice that received B6 allografts promptly reject the skin 
graft within 13 days, while the saline treated bm19 mice that received bm19 skin grafts 
accept the newly transplanted tissue (Figure 1).  As noted previously, the isotype control 
(anti-HemA treated) bm19 mice reject the B6 allograft on day +13.  Treating bm19 mice 
with both anti-Vβ9 and anti-Vβ12 mAb significantly prolongs B6 skin graft survival as 
compared to saline and anti-HemA treated bm19 mice (p <0.001).  The B6 allograft on 
TCR Vβ9/12 depleted mice gradually decreases in size and is completely rejected by day 
+36 post transplantation.  Thus, the selective depletion of both TCR Vβ9 and Vβ12 CTLs 
acts in a synergistic manner, prolonging B6 skin allograft survival by >2.5-fold. 
 
The selective removal of TCR Vβ9/12+ T cells in vivo does not affect the cell-mediated 
immune response. 
 Having determined that the in vivo depletion of both TCR Vβ9 and Vβ12 
significantly prolonged the B6 skin allograft survival, we sought to determine whether 
the absence of these T cell families would substantially alter the immunological function 
of these bm19 mice.  TCR Vβ9/12 depleted bm19 mice were evaluated for their ability to 
clear a systemic L. monocytogenes infection.  Female bm19 mice were injected (i.p.) with 
1 X PBS, 500 µg of anti-HemA mAb, or 500 µg of anti-Vβ9 mAb and 750 µg of anti-
Vβ12 mAb on days -3, 0 and +3.  On day +3, 4 h after the third mAb injection, 1 X 106 
CFU of L. monocytogenes was injected (i.p.).  The spleens and livers of L. 
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monocytogenes infected bm19 mice were harvested on day +6 and +10.  The organs were 
homogenized and plated in triplicate on BHI media petri dishes.  Cultures were incubated 
for 18 h and colony counts were determined to evaluate organ clearance.  As shown in 
Figure 2, TCR Vβ9/12 depleted bm19 mice are capable of mounting a cell-mediated 
immune response against L. monocytogenes in a manner that is comparable to both saline 
and isotype treated controls.  These findings indicate that despite removing two distinct 
TCR Vβ families from these bm19 mice, which account for approximately 12% of the T 






 In this paper, we clearly show that the in vivo depletion of either TCR Vβ9+ or 
Vβ12+ T cell populations from naïve bm19 mice prolongs the survival of B6 skin 
allografts.  We report that B6 skin allografts transplanted onto bm19 mice remain intact 
for 31 days, 18 days longer than saline or isotype controls, when TCR Vβ9+ cells have 
been removed.  Likewise, depletion of TCR Vβ12+ cells prolongs B6 skin allograft 
survival to 22 days, 9 days beyond saline or isotype controls.  When TCR Vβ9+ and 
Vβ12+ families are removed simultaneously there is a dramatic increase in B6 skin 
allograft survival, extending graft viability to 36 days post transplantation, a >2.5-fold 
increase in B6 allograft survival.  These results demonstrate that both TCR Vβ families 
(Vβ9/12) are not only key players in the B6 allograft recognition and rejection by bm19 
CTLs, but most interestingly, Vβ9/12 act in a synergistic manner. 
 Our initial study (Frankenberry et al, submitted for publication) demonstrates that 
although five distinct TCR Vβ families, Vβ8.1/8.2, Vβ9, Vβ10, Vβ12 and Vβ14, exhibit 
preferential expansion when bm19 splenocytes were stimulated in vitro with the 
irradiated splenocytes from the parental B6 strain, only CD8+ TCR Vβ9 and Vβ12 CTL 
effectors showed cytolytic activity against H-2Kb-bearing target cells.  It is possible that 
the remaining TCR Vβ families, Vβ8.1/8.2, Vβ10, and Vβ14, are directly responsible for 
the B6 skin allograft rejection seen in this study, despite minimal cytolytic activity in 
vitro.  To address this possibility, future studies of B6 skin allograft survival, when 
transplanted onto female bm19 mice, will include two-color flow cytometry analysis of 
both CD4+ and CD8+ TCR Vβ splenocytes at specific time points (days +10, +15, +20, 
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+25 and +30) to evaluate the in vivo expansion of TCR Vβ+ cells that may be actively 
involved in transplant rejection.  In addition, B6 skin allografts, at time points throughout 
the acute rejection phase, will be removed, encased in paraffin wax, sectioned and 
analyzed by two-color flow cytometric staining.  Thus allowing for direct identification 
of those CD4+ or CD8+ T cells infiltrating the allograft. 
 An alternative explanation for the delayed rejection of the B6 skin allografts can 
be explained by indirect allorecognition of the H-2Kb single amino acid difference (Asn80 
→ Thr) when presented in the context of recipient-derived antigen-presenting cells 
(APCs).  It has been documented that donor-derived extracellular antigens are 
internalized by recipient APCs and subsequently processed and presented in the antigen-
binding cleft of both major histocompatibility complex (MHC) class I and class II 
molecules, thus allowing for presentation to either CD4+ or CD8+ T cells (32,33).  Unlike 
the direct pathway, which employs a high proportion of T cells recognizing the allogeneic 
MHC molecule (1 out of 200), the proportion of T cells involved in the indirect pathway 
is comparable to the recognition of nominal antigens (1 out of 100,000) (34).  That 
indirect allorecognition plays a role in the rejection of B6 skin allografts is possible, 
owing to the observation that the allogeneic peptides presented via the indirect pathway 
can be derived from donor MHC class I, MHC class II or minor histocompatibility 
antigens (34).  Indirect allorecognition in our bm19 mouse model would be further 
restricted to peptides derived from the donor class I H-2Kb single amino acid difference 
(Asn80 → Thr); since this is the only disparity between the bm19 mouse and the parental 
strain B6.  Thus the combination of these observations, lower numbers of T cells 
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involved in the indirect pathway and the restriction of peptide sequences derived from the 
donor H-2Kb molecule, could explain the delay in B6 skin allograft rejection. 
 The role of direct versus indirect allorecognition in transplant immunology has 
been extensively studied and is dependent on several factors; the tissue/organ being 
transplanted, the experimental model and the phase of rejection (35).  For example, donor 
MHC class I is necessary for pancreatic islet cell rejection, but not heart rejection (36,37).  
The acute rejection phase in murine skin allograft experiments is dominated by direct 
allorecognition, with 90% of the recipient T cells recognizing the donor MHC molecule 
and 10% of recipient T cells responding to donor-derived MHC peptide presented by 
donor APCs (38).  However, studies involving MHC class I-deficient mice that reject 
skin allografts from MHC class II-deficient mice have demonstrated that CD4+ T cells 
were capable of recognizing donor-derived antigens presented in the context of recipient 
MHC class II on APCs through indirect allorecognition (39).  Both of these observations 
occur in the early phase of acute rejection and it has been speculated that the blockade of 
the dominant mechanism of allograft rejection, the direct pathway, may allow the indirect 
pathway to contribute more prominently in the activation of allospecific T cells (40). 
 In our bm19 anti-B6 skin allograft survival model, we selectively depleted the 
TCR Vβ9+ and Vβ12+ T cell populations by successive injections (i.p.) of mAbs specific 
for each TCR Vβ family.  One drawback to this model is that we deplete both CD8+ and 
CD4+ T cells bearing the Vβ9 and Vβ12 TCR.  It is possible that engagement of the TCR-
specific mAb without complimentary engagement of the CD4 co-receptor inactivated 
CD4+ TCR Vβ9+ and Vβ12+ T cells and influence the activation of less dominant 
alloreactive CD8+ CTLs, CD4+ TH cells or APCs.  It has been shown that patients treated 
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with T cell depleting therapy exhibited decreased CD4+ T cell lymphoproliferative 
responses and reduced induction of early activation markers, CD69, CD25 and HLA-DR, 
after in vitro stimulation (41).  This group also demonstrates that CD4+ T cell depleted 
populations have decreased IL-2 production and that attempts to increase T cell 
proliferation and CD69 cell surface expression by adding exogenous IL-2 fail (41).  
Therefore, depletion of CD4+ TCR Vβ9+ and Vβ12+ cells in vivo may result in 
defective/decreased TH cell IL-2 production for activated CD8+ T cells.   
Likewise, the interaction between CD28 on T cells and B7.1 and B7.2 on APCs 
provides co-stimulatory signaling to T cells that initiate cytokine production and cell 
proliferation (42).  Resting APCs express low levels of B7.1 and B7.2 on the cell surface 
and require stimulation via IL-2, interleukin-4 (IL-4), lipopolysaccaride or signaling 
through the MHC class II molecule for up-regulation (43,44).  IL-4-depleted mice 
challenged with allogeneic skin grafts demonstrated prolonged graft survival and a 
reduction in IL-2, IL-4 and interferon-γ (IFN-γ) production (45).  The authors suggest 
that the lack of IL-4 leaves T cells unactivated but functional, a phenomenon seen when 
B7 molecule interactions are prevented (46).  Thus, depleting CD4+ (TH2) cells in vivo 
could have disrupted the production of IL-4 and IL-2, both important stimuli for APC up-
regulation of B7.1 and B7.2, and consequently caused a reduction in CTL activation and 
function. 
An important finding in this paper is that the selective in vivo depletion of two 
distinct TCR Vβ families, which account for approximately 12% of the available T cell 
repertoire, does not inhibit L. monocytogenes organ clearance in these bm19 mice, 
suggesting that the cell-mediated immune system is still intact and functional.  Although 
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it has been established that TCR γδ-bearing T cells contribute to the host defense during 
the early stage of L. monocytogenes infection (47,48), recent studies implicate perforin-
dependent cytolysis and IFN-γ production from CD8+ T cells as active components of the 
protective immunity against L. monocytogenes (49,50).  Interestingly, Harty and co-
workers (50) demonstrate that in perforin-deficient mice there is a 5-fold reduction in the 
per-cell protective capacity of L. monocytogenes antigen specific memory CD8+ T cells 
and that this deficiency in antilisterial immunity can be overcome by increasing the 
number of memory CD8+ T cells through repeated vaccinations.  Although the Vβ9/12+ T 
cell populations are depleted in this study, the remaining CD8+ T cells are capable of 
mounting an immunological response that is comparable to that of controls. 
This is the first paper, to our knowledge, that addresses 1) the synergistic 
involvement of two distinct TCR Vβ families in transplant immunology, 2) the enhanced 
survival of allogeneic B6 skin grafts following the in vivo depletion of multiple TCR Vβ 
families and 3) the ability of bm19 mice to mount a cell-mediated immune response 
against L. monocytogenes after the selective in vivo removal of Vβ9/12+ CTLs.  These 
observations are important to our understanding of transplant immunology and further 
our knowledge in devising methods by which we can alleviate the use of nonspecific 
immunosuppressive agents in the post transplantation setting.  Theoretically, we can 
decrease patient morbidity, increase patient quality of life and decrease hospitalization 
time, secondary to opportunistic infections and carcinoma development, by selectively 
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5.3 ± 0.62 
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0.88 ± 0.10 
Individual bm19 female mice were given three i.p. injections (day –3, 0 and +3) of 500µg 
TCR Vβ9-specific mAb (MR10-2), 500µg TCR Vβ12-specific mAb (MR11-1), 500µg 
TCR Vβ9- and 750µg TCR Vβ12-specific mAb or 500µg anti-HemA mAb.  All mAb are 
IgG1, thus the anti-HemA mAb serves as the isotype control for TCR Vβ12-specific 
mAb. 
 
Values are represented as the percent CD8+ TCR Vβ+ lymphocytes ± SD from five 
separate bm19 female mice. 
 




FIGURES AND FIGURE LEGENDS 
 
Fig. 1 Depletion of Vβ9+, Vβ12+ and Vβ9/12+ T cells in vivo significantly enhances the 
survival of B6 skin allografts transplanted onto bm19 mice. 
Female bm19 mice (n=8 per group) were injected (i.p.) with 500 µg of anti-TCR Vβ9 
mAb [MR10-2] (Ο), 500 µg of anti-TCR Vβ12 mAb [MR11-1] ( ), 500 µg of anti-TCR 
Vβ9 mAb [MR10-2] and 750 µg of anti-TCR Vβ12 [MR11-1] (∇) or 500 µg anti-HemA 
mAb (■) on days -3, 0, +3, and +21.  8mm skin samples from B6 and bm19 donors were 
transferred to bm19 recipients on day 0 as described in the Materials and Methods 
section.  Saline treated female bm19 mice receiving only B6 grafts (▼) acted as our 
positive control while saline treated female bm19 mice receiving only bm19 grafts (●) 
acted as our negative control.  Graft survival was determined by visual inspection and 
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Fig. 2 The selective removal of TCR Vβ9/12+ T cells in vivo does not affect the cell-
mediated immune response. 
Female bm19 mice (n=8 per group) were injected (i.p.) with 1 X PBS (A), 500 µg      
anti-HemA mAb (B), or 500 µg of anti-TCR Vβ9 mAb [MR10-2] and 750 µg of         
anti-TCR Vβ12 [MR11-1] (C) on days -3, 0, and +3.  L. monocytogenes (1 X 106 CFU) 
was injected (i.p.) on day +3.  Livers (∆) and spleens (Ο) were harvested on day +6 
(filled symbols) and +10 (open symbols), homogenized on a Brinkmann Homogenizer 
and plated in triplicate on BHI media petri dishes by an Autoplate 4000 (Spiral Biotech, 
Norwood, MA).  Cultures were incubated for 18 h and counted using a CASBA 4 (Spiral 
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 This dissertation has been divided into two sections, Part I includes the antigen-
specific response of Clone B6.H-4.1c to the horse cyt c peptide sequence, p41-49, in the 
context of two separate class I MHC molecules, H-2Kb and H-2Db, and Part II involves 
the allospecific recognition of the parental strain, B6, class I MHC/peptide complex by 
the H-2Kbm19 mutant mouse. 
 
Part I - Chapters 2 and 3 
 
The concept of  “self MHC restriction” requires that a CD8+ CTL respond to a 
short peptide of 8-10 AA residues, presented in the context of a single self class I MHC 
molecule (1-5).  More recently, this tenet of immunology has been reevaluated by the 
discovery of several peptides that not only bind to multiple class I MHC molecules, but 
are recognized by CTL clones (6-14).   
To further characterize the dual-restricted recognition of CTL clones, we analyzed 
the ability of horse cyt c p41-49 [G-Q-A-P-G-F-T-Y-T] to bind and stabilize both H-2Kb 
and H-2Db molecules and assessed the cytolytic reactivity of Clone B6.H-4.1c for         
H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes.  In Chapter 2, we show that 
horse cyt c p41-49 is recognized by Clone B6.H-4.1c when presented in the context of 
both Kb and Db and requires comparable peptide concentrations, ~4 nM and ~2 nM 
respectively, to elicit cytolysis.  Although horse cyt c p41-49 lacks the complete peptide-
binding motif for either H-2Kb or H-2Db, this peptide does contain a dominant anchor 
residue plus two weak anchor residues for Kb-binding and a single strong anchor residue 
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plus three weak anchor residues for Db-binding, and stabilizes both class I MHC 
molecules (15).  Furthermore, H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49 complexes 
reach a steady state at 60 min when RMA-S cells were incubated at 37oC, demonstrating 
that horse cyt c p41-49 is presented in the context of both class I molecules.  We also 
show that the introduction of a competitor peptide, MI B chain p7-15, cause significant 
increases (>30-fold for H-2Kb and >100-fold for H-2Db) in the horse cyt c p41-49 peptide 
concentration required for Clone B6.H-4.1c recognition.   
Computer-generated molecular models for horse cyt c p41-49 bound to the H-Kb 
and H-2Db were constructed to determine peptide configuration and reveal that the 
central peptide region bulged distally, away from the peptide-binding groove, for both 
MHC/peptide complexes.  These models also demonstrate that the combination of    
Pro44-Gly45 confer a type II β bend in the peptide configuration that may be required not 
only for Kb- and Db-binding, as previously predicted (16-18), but also Clone B6.H-4.1c 
recognition.  Our molecular models facilitate the examination of MHC-peptide 
interactions and show that cyt c p41-49 utilizes peptide residues Gln42, Pro44, Tyr48 and 
Thr49 bind to H-2Kb (Pro42, Phe46 and Thr47 are predicted anchor residues for H-2Kb) and 
Gly41, Gln42, Tyr48 and Thr49 bind to H-2Db (Gln42, Phe46, Thr47 and Tyr48 are predicted 
anchor residues for H-2Db).  To evaluate potential H-2Kb/cyt c p41-49 and H-2Db/cyt c 
p41-49 residues that interact with the TCR of Clone B6.H-4.1c, our models were 
analyzed for solvent-accessible residues using a 1.4Å probe (19).  The solvent exposed 
R-groups of Pro44 and Phe46 contribute the majority of H-2Kb/cyt c p41-49 surface-
accessible contact residues.  Similarly, the solvent exposed R-groups of Pro44 and Phe46, 
with minor contributions by the R-group of Tyr48 contribute the potential H-2Db/cyt c 
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p41-49 surface-accessible contact residues.  Based on these observations, we hypothesize 
that the Pro44-Gly45 peptide sequence is critical for both horse cyt c p41-49 stabilization 
of both H-2Kb and H-2Db and the dual-restricted recognition of Clone B6.H-4.1c. 
To address the above proposal, we synthesized peptide analogues of horse cyt c 
p41-49 that contain single Ala substitutions at Pro44 or Gly45, designated p41-49/44A and 
p41-49/45A, and determined Kb- and Db-stabilization and assessed the cytolytic activity 
of Clone B6.H-4.1c for both analogues.  In Chapter 3, we show that Clone B6.H-4.1c 
CTLs recognizes analogue p41-49/45A, but not analogue p41-49/44A, when presented by 
Kb- and Db-expressing target cells.  RMA-S stabilization analysis reveals that both 
analogues p41-49/44A and p41-49/45A stabilize H-2Kb and H-2Db molecules, but     
p41-49/45A exhibits increased H-2Kb steady states and rapidly dissociates from H-2Db 
when compared to native horse cyt c peptide.  We demonstrate that Clone B6.H-4.1c 
recognition of H-2Kb/p41-49/45A and H-2Db/p41-49/45A requires significantly higher 
concentrations, >30-fold and >30-fold, respectively.  We also show that the introduction 
of a competitor peptide, MI B chain p7-15 or analogue p41-49/44A, causes significant 
increases in the native horse cyt c p41-49 and analogue p41-49/45A peptide 
concentration required for optimal target cell lysis.  These peptide competition assays 
clearly reveal that the TCR of Clone B6.H-4.1c is capable of distinguishing minute 
changes in the MHC/peptide conformation caused by the G45A and P44A substitution.  
To better define peptide configuration changes that disrupt Clone B6.H-4.1c recognition, 
we constructed H-2Kb and H-2Db molecular models with native horse cyt c p41-49, 
analogue p41-49/44A and analogue p41-49/45A presented in the peptide-binding groove.  
These models for H-2Kb demonstrate C-terminus carbon backbone shifts at Thr49 and 
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rotation of the aromatic ring of Phe46 for both analogue p41-49/44A and analogue p41-
49/45A.  The H-2Db molecular models show only minor carbon backbone shifts and 
small but distinguishable rotation of the Phe46 aromatic ring compared to native horse cyt 
c p41-49.  These observations indicate that the absence of Pro44 and the rotation of the 
aromatic ring of Phe46 directly affects the cytolytic response of Clone B6.H-4.1c for      
H-2b/cyt c p41-49 and H-2b/p41-49/45A complexes.  In addition, the rapid dissociation of 
p41-49/45A may also decrease the responsiveness of Clone B6.H-4.1c.  Our conclusions 
from the studies outlined in Chapters 2 and 3, are that the solvent-exposed R groups of 
both Pro44 and Phe46 are important for Clone B6.H-4.1c recognition of H-2Kb/cyt c     
p41-49 and H-2Db/cyt c p41-49 complexes.  We propose that the imino group of Pro44 is 
necessary for recognition by Clone B6.H-4.1c and the orientation of the Phe46 aromatic 
ring, caused by Gly45, is essential for full CTL responsiveness. 
To address this hypothesis, future studies are directed at single Ala substitution of 
Phe46 at peptide position, p6.  Although our molecular models show that cyt c p41-49 
utilizes peptide residues Gln42, Pro44, Tyr48 and Thr49 to bind to H-2Kb and Gly41, Gln42, 
Tyr48 and Thr49 to bind to H-2Db, although Phe46 is predicted to be an anchor residue for 
both class I H-2b molecules.  The loss of the aromatic side chain, contributed by Phe46, 
may prohibit both Kb- and Db-binding or may disrupt Clone B6.H-4.1c recognition of 
these MHC/peptide complexes, as seen with the p41-49/44A analogue.  As noted in 
Chapter 3, several other investigators have reported that the substitution of a single AA in 
the peptide sequence alter the MHC/peptide conformation, without affecting the number 
of complexes available to the TCR, and influence CTL recognition (20-23). 
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In addition to standard RMA-S stabilization analysis, combinatorial peptide 
libraries, peptide competition assays and computer-generated molecular models that 
examine native peptides and their analogues, the crystal structures of the trimolecular 
complexes, H-2Kb/cyt c p41-49 and H-2Db/cyt c p41-49, with the TCR of Clone      
B6.H-4.1c, would provide invaluable insight into the TCR/MHC/peptide interaction.  The 
generation of these crystal structures would provide direct analysis of the interactions 
between the native cyt c p41-49 peptide and the TCR.  In this manner we could identify, 
and prove or disprove our hypothesis, the peptide residues essential for Clone B6.H-4.1c 
recognition.  Likewise, crystal structures of the H-2Kb/p41-49/45A and                        
H-2Db/p41-49/45A with the TCR of Clone B6.H-4.1c would provide comparative 
analysis and insight into the flexibility of TCR interactions. 
The demonstration that the horse cyt c peptide is presented efficiently to cloned 
CTLs by the H-2Kb, H-2Db and H-2Kbm1 molecules (18) prompted the analysis of horse 
cyt c p41-49 recognition by Clone B6.H-4.1c when presented in the context of the H-2Kb 
mutant strains, H-2Kbm19 and H-2Kbm11 (24,25).  The H-2Kbm11 mutant strain varies from 
the parental strain, B6, by an AA substitution on the α1 helix at position 77, Asp77 → Ser, 
and an AA substitution on the α1 helix at position 80, Thr80 → Asn (24,25).  Similarly, 
the H-2Kbm19 mutant strain varies from the parental strain, B6, by an AA substitution on 
the α1 helix at position 80, Thr80 → Asn (24,25).  Initial 51Cr-release analysis reveal that 
H-2Kbm19/cyt c p41-49 and H-2Kbm11/cyt c p41-49 complexes are recognized by Clone 
B6.H-4.1c (data not shown).  Although we have not determined the stability of these 
MHC/peptide complexes or whether the minimal peptide concentrations required for lysis 
are comparable with H-2Kb/cyt c p41-49, the demonstration that a cloned CTL can 
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recognize the same peptide in the context of five disparate class I MHC molecules is 
indeed a novel finding. 
 
Part II - Chapters 4 and 5 
 
 Acute allograft rejection and graft-versus-host disease (GVHD) are mediated by 
alloreactive T lymphocytes that respond to foreign class I MHC molecules on the 
engrafted donor tissue (26-30).  Studies by Grandea II and Bevan (31) using the class I 
H-2Kb transgenic mouse mutant, H-2Kb,E65 (Gln65 → Glu), show that a single AA 
disparity in the H-2Kb molecule generated a strong CTL response.  These H-2Kb,E65 
alloreactive CTLs exhibit cytolytic activity against the wild-type Kb-expressing target cell 
line and several mutant target cells, including H-2Kb,D65 (Gln65 → Asp), H-2Kb,R65    
(Gln65 → Arg) and H-2Kb,V65 (Gln65 → Val).  These findings suggest that cross-reactive 
CTLs may have a higher affinity for nonconserved AA changes (31).  Connolly and 
coworkers (32,33) evaluated the Ld-specific CTL response of the Ld-loss mutant, dm2, 
and implicate the TCR Vβ8+ alloreactive CTLs as effectors of the Ld-specific response.  
They show that by adding the anti-Vβ8 mAb, F23.1, to 51Cr-release assays the H-2Ld-
specific CTL response is diminished by approximately 80% (32,33).  They also 
demonstrate that the depletion of Vβ8+ CTLs in vivo prolongs the survival of Ld-disparate 
skin grafts by two-fold, indicating that the CD8+ Vβ8+ effectors contribute to the 
allospecific response (32,33). 
 In this dissertation, we have selected the B6-derived mutant mouse strain, bm19 
(24,25), that has a single AA substitution at position 80 (Thr80 → Asn) of the H-2Kb 
molecule, and evaluated specific bm19 CD8+ TCR Vβ families involved in the 
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alloreactive response to H-2Kb.  As shown in Chapter 4, we initially identify five distinct 
CD8+ Vβ families - Vβ8.1/8.2, 9,10,12 and 14 - that preferentially expand in both short- 
and long-term bm19 anti-B6 MLCs.  We show that although the Vβ8.1/8.2, 10 and 14 
families exhibit preferential expansion in vitro, enrichment for these CD8+ Vβ families 
fails to increase the cytolytic activity of 3o bm19 anti-B6 CTLs, and reduces the lytic unit 
(LU) value dramatically (~0 LU, ~5 LU and ~0 LU versus ~20 LU for untreated bm19 
anti-B6 effectors).  Depleting the Vβ8.1/8.2, 10 and 14 families also causes minimal 
reductions in the cytolytic activity of 3o bm19 anti-B6 CTLs, but these tertiary MLCs 
retain H-2Kb-specific alloreactivity comparable to untreated bm19 anti-B6 CTLs.  The 
selective removal of Vβ9+ or Vβ12+ families reduces the alloreactive responsiveness of 3o 
bm19 anti-B6 effectors (~2 and ~7 LU, respectively), while enrichment for Vβ9+ or Vβ12+ 
families causes a minimal reduction in the cytolytic activity of 3o bm19 anti-B6 CTLs 
(~20 LU and ~15 LU, respectively).  By depleting both the Vβ9+ and Vβ12+ (Vβ9/12+) 
CTL effectors we abrogate the alloreactive response to H-2Kb while enriching for both 
the CD8+ Vβ9/12+ T cells enhances the lytic capacity of 3o bm19 anti-B6 CTLs (~100 LU 
versus ~20 LU) for the allogeneic target, S.B6.  These observations demonstrate that 
Vβ9+ and Vβ12+ effectors contribute synergistically to the alloreactive response against 
Kb-expressing target cells.  Chapter 4 also documents the preservation of both antigen- 
and allospecific recognition in vitro despite the selective depletion of CD8+ Vβ9/12+ T 
cells, approximately 12% of the bm19 T cell repertoire.  We show that the removal of the 
Vβ9/12+ families has no effect on bm19 anti-B6 proliferation or recognition of the VSV-8 
peptide (viral), the MI B chain p7-15 peptide (self) or to the unrelated H-2d alloantigen.  
Based on these findings, we hypothesize that the in vivo depletion of Vβ9/12+ T cells 
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would prevent B6 skin allograft rejection without compromising the entire immune 
system. 
 To address the above proposal, we selectively depleted the Vβ9+, Vβ12+, and 
Vβ9/12+ T cells from female bm19 mice and evaluated the B6 skin allograft survival.  In 
Chapter 5, we demonstrate that selectively removing the Vβ9+ T cell population prolongs 
B6 skin graft survival by 18 days when compared to the saline and isotype controls (31 
days versus 13 days).  Likewise, the in vivo depletion of Vβ12+ T cells prolongs B6 skin 
allograft survival by 9 days beyond control mice (22 days versus 13 days).  Most 
importantly, the depletion of both TCR Vβ9/12+ families simultaneously extends B6 skin 
graft survival to 36 days, a >2.5-fold increase in survival, thus supporting the in vitro 
evidence that both TCR Vβ families act synergistically in the alloreactive response to    
H-2Kb.  To show that the immune status of bm19 mice is intact, despite removing 
approximately 12% of the bm19 T cell repertoire, we infected Vβ9/12- bm19 mice with L. 
monocytogenes.  Organ clearance is comparable in both saline control bm19 mice and 
those that are depleted of TCR Vβ9/12+ T cells, thus indicating that the host immune 
system was functional.  This dissertation is the first to demonstrate that alloreactive CTLs 
can act synergistically in their response to alloantigen and that selectively removing these 
CTLs can prolong allograft survival without compromising the host immune system.  The 
findings in Chapters 4 and 5 suggest that although allograft survival is prolonged, other 
factors are involved in the final rejection of the B6 skin allograft.  Therefore, we propose 
that those TCR Vβ families (Vβ8.1/8.2, 10 and 14) that exhibit preferential in vitro 
expansion, but demonstrate minimal cytolytic activity, are responsible for the ultimate 
rejection of B6 skin allografts in our model system. 
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 To determine whether the TCR Vβ8.1/8.2, 10 and 14 families are actively 
involved in bm19 anti-B6 rejection of B6 skin allografts, future studies will include two-
color flow cytometric analysis of both CD4+ and CD8+ TCR Vβ splenocytes, inguinal and 
brachial lymph nodes (LN) at designated time points (i.e., days +10, +15, +20, +25 and 
+30) to evaluate the in vivo expansion of Vβ+ T cells following B6 skin transplantation.  
In addition, histological assessment of the B6 allograft with two-color staining will 
identify the CD4+ and CD8+ T cells infiltrating the transplant at the same time points as 
spleen and LN evaluations.  This approach will allow both a direct and indirect 
characterization of the T cell populations active in the alloreactive response against Kb-
expressing cells. 
 It is also possible that a TCR Vβ family, not detected by preferential in vitro 
expansion, is induced in vivo by the indirect allorecognition pathway.  Although this 
would require that recipient APCs present a peptide, derived from the donor class I       
H-2Kb, containing the single AA disparity (Asn80 → Thr), it has been reported that 
donor-derived extracellular antigens are internalized by recipient APCs, processed and 
presented in the context of both class I and class II MHCs (34,35).  Thus it is possible 
that the single AA disparity (Asn80 → Thr) of H-2Kb could be presented to either CD4+ 
or CD8+ T cells.  The proposed studies (above) would identify both CD4+ and CD8+ T 
cell expansion induced by either the direct or indirect allorecognition pathway, but would 
not differentiate between the two. 
 The demonstration, by Sheil and coworkers (36), that the H-2Kb-restricted CTL 
response to VSV-infected Kb-expressing target cells is partially cross-reactive to the 
uninfected H-2Kbm8 mutant target cells and the observations described in Chapters 4 and 
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5 prompted studies investigating the cross-reactive response of bm19 anti-B6 CTLs 
against the H-2Kb mutant strain, bm11.  Preliminary analysis of the cytolytic activity of 
bm19 anti-B6 MLCs demonstrate that these bm19 CTLs exhibit cross-reactivity to the 
closely related Kbm11-expressing target cells (data not shown).  Although these studies are 
preliminary, it is tempting to speculate that the TCR Vβ families (Vβ8.1/8.2, 10 and 14) 
that exhibited preferential in vitro expansion are involved in the cross-reactive response 
of bm19 anti-B6 effectors against S.bm11 targets.  Future studies, involving Vβ8.1/8.2, 
10 and 14 depletion and enrichment for each Vβ family both in vitro and in vivo, may 
reveal that while TCR Vβ9/12+ CTLs are critical for recognition of H-2Kb, the remaining 
Vβ families participate in cross-reactive recognition of H-2Kbm11. 
 
Leaps of Faith 
 
  This dissertation is designed to bridge two seemingly different topics in 
immunology, antigen- and allospecific recognition.  As described above, several CTL 
clones display dual-restricted recognition of a single peptide in the context of several 
class I MHC molecules.  In the case of Clone B6.H-4.1c, recognition of horse cyt c     
p41-49 occurs in the context of H-2Kb, H-2Kbm1, H-2Kbm11, H-2Kbm19 and H-2Db and 
recognition of the analogue p41-49/45A occurs on H-2Kb- and H-2Db-expressing targets.  
Likewise, although the peptide bound to H-2Kb is unknown, the alloreactive response of 
bm19 anti-B6 CTLs exhibit cross-reactivity against the closely related mutant, Kbm11.   
  Wilson and coworkers (37,38) reported that the CTL clone, Clone 2C, recognizes 
the peptide dEV8 when presented by H-2Kb and H-2Kbm3 and also responds to SIYR 
when in the context of H-2Kb.  The primary basis for the dual-recognition observed for 
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Clone B6.H-4.1c and Clone 2C may be that the MHC/peptide/TCR interaction has a high 
rate of degeneracy (or cross-reactivity).  Studies analyzing the 2C, KB5-C20 and LC13 
TCRs reveal conformational differences between unliganded and liganded TCRs (38-40).  
The CDR3 region demonstrates the main focus of conformational reorganization, with 
minimal change within the CDR1 and CDR2 loops.  The variability of the Vα-Vβ pairing 
and the flexibility of the CDR3 facilitates conformational changes in the TCR to 
accommodate the restrained MHC/peptide complex conformation (41,42).  Reiser and 
coworkers (40) demonstrate that some CDR3s can adopt at least two discrete 
conformational states, but only one of these states is able to bind to the MHC/peptide 
complex.  Malissen and coworkers (43) performed a comparative analysis for CTL 
BM3.3 TCR in complex with two distinct peptides, pBMI and VSV-8, bound to H-2Kb.  
Their results show that an Asn, at peptide position p6, of pBMI and a Gln, at peptide 
position p4, of VSV-8 constitute the critical contact positions for BM3.3 recognition.  
The cross-reactivity of the BM3.3 TCR is largely due to the flexibility of the CDR3, 
which facilitates contact with VSV-8 by the CDR3α loop, thus compensating for the loss 
of CDR3β contacts (involved in the recognition of pBMI).  This study demonstrates how 
the flexibility of the CDR3 region may facilitate recognition despite variations in the 
available residue contacts.  Likewise, Wilson and coworkers (44) demonstrate that in the 
alloreactive CTL Clone 2C the CDR3β interactions occur with the C-terminal half of the 
H-2Ld bound peptide, suggesting that the TCR contact with peptide strongly affects, in 
large part, the alloreactive response.  Thus, the flexibility of the CDR3 region may 
account the cross-reactivity that is seen in both antigen-specific and allospecific CTLs 
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